Functional changes of the vasculature in HIV/AIDS patients on Haart and Haart Naïve HIV participants by Awotedu, Kofoworola Olajire
  
 
FUNCTIONAL CHANGES OF THE VASCULATURE IN HIV/AIDS 
PATIENTS ON HAART AND HAART NAÏVE HIV PARTICIPANTS 
 
by 
 
KOFOWOROLA    OLAJIRE   AWOTEDU 
A thesis  submitted in fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY(Ph.D) 
(Health Sciences, Physiology) 
 
at 
 
WALTER SISULU UNIVERSITY 
 
SUPERVISOR: PROFESSOR B. LONGO 
CO-SUPERVISOR: PROFESSOR E.UMAPATHY 
 
 
SEPTEMBER  2013 
 
 
 
 
 i 
ABSTRACT 
The present study sought  to explore the functional changes that occur in the 
vasculature of HIV positive participants of African origin in Mthatha district of South 
africa which might lead to increased risk in their cardiovascular system. Available 
literature shows that arterial stiffness plays an important role in cardiovascular 
events such as stroke, vasculitis and myocardial infarction. Measurement of (aortic 
pulse wave velocity; PWV) provides some of the strongest evidence concerning the 
prognostic significance of large artery stiffening. This study was aimed at  
investigating the relationship between anthropometry, age, E-Selectin level, cytokine 
levels, haemodynamic variables, blood counts and blood lipid profile with pulse wave 
velocity. Some traditional cardiovascular risk factors such as alcohol, and smoking 
were also taken into account. 
 
This was a cross-sectional study comprising of 169 participants (62 males and 107 
females). 63 were HIV negative (group A), 54 HIV positive on treatment (group B), 
and 52 were HIV positive not on treatment (group C). Pulse wave velocity (PWV) 
was assessed using the Sphygmocor Vx.  Statistically, ANOVA was used for variables 
with normal distribution and non parametric tests were used for variables with 
skewed distribution. 
 
Notable significant differences were seen in the means of the following variables  
across all the 3 groups. The mean PWV value for group C (7.21±2.17) was greater  
 
ii 
 
than that for group B (6.84± 1.17) which in turn was more than group A 
(6.38±1.67); P=0.037. In participants who are HIV negative, In univariate analysis 
PWV correlated significantly with the following: Augmentation index; AIx (75): 
(r=0.850,p=0.004): Systolic aortic blood pressure; Spa: (r=0.635, p<.000); diastolic 
blood pressure; dbp: (r=0.436, p<0.000); aortic pulse pressure; Ppa: (r=0.472, 
p=0.000); Mean arterial pressure; MP: (r=0.446 p=<0.00) and age (r=0.606, 
p<0.000).  
 
In participants who are on HAART the following variables were positively correlated 
with PWV: Ppa: (r=0.338,p=0.012), MP: (r=0.400,p=0.400), monocytes 
(r=0.320,p=0.047).  Neutrophils: (r=0.341,p=0.034), CD4: (r=-0.446,p=0.009).  In 
participants who are HAART naïve and HIV positive the following correlated with 
PWV Spa: (r=0.369, p=0.012), MP: (r=0.400, r=0.003) Ppa: (r=0.338,p=0.012), 
waist to hip ratio: (r=0.319, p=0.037), platelets: (r=0.037, p=0.019), triglycerides: 
(r=0.490, p=0.002).  
 
With multiple linear regression Spa, age and triglycerides as the only independent 
and significant determinants of PWV among HIV negatives R2= 56.9% (adjusted 
R2=54.7%), model adjusted for gender, anthropometric parameters, HDL-C, TC, 
LDL-C, haematologic data, haemodynamic data, cytokines, smoking and alcohol. 
Only MP and waist circumference were identified as the most important and 
significant independent determinants of PWV in HIV positive participants not on 
treatment.  
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Age, MP, HDL-C, and triglycerides were identified as the significant independent 
determinants of the variations of PWV in HIV positive participants on HAART. R2 =57 
%(adjusted R2 =53.5%). Model adjusted for gender, anthropometric data, smoking, 
alcohol, cytokines, adhesion molecules, total cholesterol, LDL-C. Haematological 
data, CD4 count, and other haemodynamic parameters. 
 
For Aix(75) In HIV negatives the multiple linear regression model identified age 
(positive correlation), height (negative correlation), CD4 (positive correlation) and 
MP (positive correlation) as the independent and significant determinants of AIx (75) 
among HIV negatives. Spa and Age were independently and significantly associated 
with the variations of Aix(75) among HIV positives not on HAART. On the other hand 
height was negatively and significantly associated with Aix(75) amongst HIV 
positives not on HAART. After excluding confounding factors, height (negative 
correlation) age (positive correlation), MP (positive correlation, HDL-C (negative 
correlation), platelets (positive correlation) alcohol intake (excessive consummation 
associated with positive correlation) and TNFα (negative correlation) were identified 
as the independent and significant variables associated with increase in AIx(75) 
among HIV positive participants on HAART. 
 
Conclusion: This study showed that HIV infected patients with or without 
antiretroviral therapy have increase arterial stiffness which is associated with an 
increased cardiovascular risk. The sphygmocor is an accurate, non invassive  and 
useful tool in the evaluation of arterial stiffness and its use in clinical practice should 
be encouraged. PWV and the augmentation index (AIx) are the two major non-
iv 
 
invasive methods of assessing arterial stiffness. Life style modification should be 
incorporated into the management of HIV patients so as the continuous monitoring 
of their haematological and lipid profile. 
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RESEARCH OUTLINE 
The Thesis is divided into six chapters. 
 
CHAPTER 1   
This is the chapter that contains the introduction, background of the study and statement of 
the problem. Included in this section is the main research question, sub research questions, 
research objectives, and rationale of the study.  
 
CHAPTER 2  
This chapter contains the literature review. The body of the chapter is made up of health 
burden of the HIV/AIDS  disease,  deals with the structure, life cycle of HIV, and types of 
HIV. Types and classes of antiretroviral drugs are mentioned. The strucure of the major types 
of blood vessels are indicated and illustrated with pictures. Arterial stiffness and 
inflammation are reviewed. Arterial stiffness in relation to lipids, cytokines and adhesion 
molecules are also reviewed. Arterial stiffness was also related to immunity. 
 
CHAPTER 3 
This deals with the method and data analysis. It comprises the study design, study population, 
calculation of sample size, administration of questionnairres, methods for measuring total 
cholestrol (TC), low densiy lipoprotein cholesterol (LDL-C),High density lipoprotein 
cholesterol (HDL-C), and triglycerides (TG). Also included are methods for measuring 
cytokines, E-selectin and arterial stiffness using the Sphygmocor.  
CHAPTER 4 
This contains the results. These were illustrated with the aid of graphs, box plots, regression 
plots and tables where appropriate. 
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CHAPTER 5 
This chapter  deals with the discussion. It discusses the composition of the participants. The 
effect of  HIV on arterial stiffness in the participants, role of HIV in atherosclerosis, influence 
of cardiovascular risk factors on arterial wall, arterial stiffness and anthropometry, arterial 
stiffness and aging, arterial stiffness and blood pressure. This chapter also included the 
limitations and perspectives. 
 
CHAPTER 6 
This chapter incorporates the conclusion. 
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CHAPTER 1. 
INTRODUCTION 
1.1.The Human immunodeficiency virus/AIDS 
Human immunodeficiency virus (HIV)/AIDS is one of the greatest medical challenges facing 
the African continent today.  The impact of the HIV epidemic on the cardiovascular system in 
Africans has  received little attention in the world literature. 
 
In 2010, 27 million people were infected with HIV, the number has now risen to an  
estimated 34 million people globally. This includes millions who have developed Acquired 
immunodeficiency sydrome (AIDS), (UNAIDS 2011).   
 
HIV-infected patients have higher rates of atherosclerosis than HIV-seronegative persons 
(Hsue et al. 2004, Triant et al. 2007). Factors that may contribute to this risk, include direct 
antiretroviral drug toxicity (Nolan et al. 2007), virus-induced endothelial injury, and chronic 
inflammation (Ghandi et al. 2006). It had been deduced that both traditional and 
nontraditional risk factors contribute to atherosclerotic disease in HIV-infected patients (Lo et 
al. 2010).  
 
Endothelial dysfunction, an early marker of atherosclerosis with prediction for cardiovascular 
events could be the link between HIV infection and atherosclerosis (Mundel 2007). The 
pathogenesis of endothelial dysfunction which is a surrogate of atherosclerosis in HIV-1 
infection is also undergoing investigation. Several mechanisms have been postulated and  
include the following: HIV-induced endothelial cell injury, activation of endothelial cells by 
pro-inflammatory cytokines and mediators, and toxicity from ART which may itself have 
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direct and indirect actions. Hence the effect of these substances on the blood vessels of HIV 
participants will be studied. 
 
In this environment where the first line drugs still being used in public hospitals are the 
nucleosides and non nucleosides, it is still unclear if metabolic complications consequent  on 
the use of these drugs have significant effects on the vasculature. It is also not clear if these 
cardiovascular complications are due to the human immunodeficiency virus, effects of  
HAART, or the effects of some other factors like cytokines and lipaedemia. It is to answer 
these questions that this study  seeks to determine the effect of HIV, its treatment and other 
cardiovascular risk factors on the vasculature.  
 
1.2. STATEMENT OF THE PROBLEM 
HIV infection is associated with increase in risks for cardiovascular disease (Wilkinson & 
Cockcroft 2007). Some of the risk factors are low levels of HDL cholesterol and elevated 
levels of triglycerides. Patients with hypercholesterolaemia have a higher central pulse 
pressure and stiffer blood vessels than matched controls, despite having similar peripheral 
blood pressures (Wilkinson & Cockcroft 2007). It has also been reported that the risk for 
myocardial nfarction is 70% to 80% higher among people with HIV compared with those 
who are HIV negative (Lo et al. 2010).  
 
Some researchers  (Carr et al. 2008, Obel et al. 2007 ) found that aortic stiffness is increased 
in HIV treatment-naive patients free from cardiovascular disease and without major 
atherosclerotic risk factors. These findings suggest HIV infection as a potentially relevant 
contributor to atherosclerosis and for the increased cardiovascular risk observed among HIV-
infected individuals regardless of antiretroviral treatment (Carr et al. 2008, Obel et al. 2007). 
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1.3. AIM 
The aim of the study was to evaluate the level of vascular dysfunction and the magnitude of 
its determinants as cardiovascular risks in antiretroviral therapy naïve HIV positive 
participants, HIV positive participants on antiretroviral therapy, compared with HIV 
seronegative participants in black Africans of Mthatha district of old Transkei in South 
Africa. 
 
1.5. MAIN RESEARCH QUESTION  
Does HIV infection increase cardiovascular risk in black Africans ? 
 
1.4.1. Subresearch questions 
They are raised as follows: 
 does HIV infection affect the vasculature thereby giving rise to endothelial 
dysfunction with consequent arterial stiffness which may lead to increased 
cardiovascular risks? 
 
 does HAART affect the vasculature giving rise to endothelial dysfunction with 
consequent arterial stiffness leading to increased cardiovascular risk in HIV positive 
participants on first line antiretroviral in the public clinics in Mthatha district of 
Eastern Cape Province? 
 
 do cytokines, adhesion molecules, and dyslipidemia contribute to arterial stiffness in 
antiretroviral naïve HIV participants and participants on first line antiretroviral in the 
public clinics in Mthatha district of Eastern Cape Province? 
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1.5. RESEARCH OBJECTIVES 
In order to answer the research questions the following objectives were defined: 
 
 to assess cardiovascular risk factors such as smoking, body mass index, blood 
pressure, in antiretroviral therapy naive, HIV positive participants on treatment and 
HIV negative participants; 
 
 to determine cardiovascular risk by assessing the functional changes of the 
vasculature (arterial stiffness) using SphygmoCor Vx (a non invasive method);  
 
 to measure the lipid profiles among antiretroviral therapy naïve HIV positive 
participants, HIV positive participants on antiretroviral therapy, and HIV seronegative 
participants; 
 
 to measure some cytokines such as, TNFα and IL-6 in antiretroviral therapy naïve 
HIV positive participants , HIV positive participants on antiretroviral therapy, and 
HIV seronegative participants; 
 
 to measure adhesion molecules such as E- selectin in antiretroviral therapy naïve 
HIV positive participants, HIV positive participants and HIV seronegative 
participants. 
 
1.6. Rationale and significance of study 
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The five countries with the highest prevalence rates of HIV infection in the world are situated 
in Southern Africa.  South Africa in 2011 had an estimated 5.6 million people living with 
HIV and has more cases of HIV/AIDS than any other country (UNAIDS 2012). The impact 
of this on the country might  worsen if more people are infected. Highly active antiretroviral 
therapy (HAART) has greatly reduced the risk of early death from opportunistic infections 
and extended the lifespan of people infected with HIV.  Many complications and organ 
damage in the HIV infected population have thus emerged.  
 
 
 
 
 
 
CHAPTER 2: LITERATURE REVIEW.  
 
2.1.The Human Immunodeficiency virus and acquired immunodeficiency syndrome 
This is a condition in humans in which the immune system begins to fail, leading to life 
threatening opportunistic infections (Quinn 2011). HIV primarily infects vital cells in the 
human immune system such as the helper T cells. These are cluster of differentiation 4 
lymphocytes expressed on the surface of T helper cells (specifically CD4
+
 T cells), 
macrophages, and dendritic cells. HIV infection leads to low levels of CD4
+
 T cells through 
three main mechanisms: firstly, direct  killing of infected cells by the virus, secondly, by the 
virus increasing rates of apoptosis of infected cells ; and thirdly, killing of infected CD4
+
 T 
cells by cluster of differentiation 8 (CD8) cytotoxic lymphocytes that recognize infected 
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cells. When CD4
+
 T cell number declines below a critical level, cell mediated immunity is 
impaired. 
 
Viruses such as HIV cannot grow or reproduce on their own, they need to infect the cells of a 
living organism in order to replicate. The human immune system usually finds and kills 
viruses fairly quickly, but the HIV attacks the immune system itself. HIV infection is 
basically divided into  four stages: incubation period, acute infection, latency stage and 
AIDS. Previous names for the virus include human T lymphocyte virus-111 (HTLV-111), 
lymphadenopathy associated virus (LAV) and AIDS associated retrovirus (Coffin et al. 1986, 
and Sowadsky et al. 1999). 
HIV is a highly variable virus which mutates very readily. The major routes of transmission 
are: unprotected sexual intercourse, contaminated needles, blood products during transfusion, 
breast milk, and transmission from an infected mother to her baby at birth (Joint United 
Nations Programme on HIV/AIDS 2008). Within these body fluids, the virus is present as 
both free virus particles and virus within infected immune cells. 
 
2.1.1. Types and subtypes of HIV 
There are two types of HIV: HIV-1 and HIV-2. Both types are transmitted by sexual contact, 
through blood, and from mother to child, and they appear to cause clinically indistinguishable 
AIDS. However, it seems that HIV-2 is less easily transmitted, and the period between initial 
infection and illness is longer in the case of HIV-2 (Plantier et al. 2009). Worldwide, the 
predominant virus is HIV-1, and generally when people refer to HIV without specifying the 
type of virus they will be referring to HIV-1. The relatively uncommon HIV-2 type is 
concentrated in West Africa and is rarely found elsewhere (WHO 2011). It is known that 
there are many different strains of HIV, even within the body of a single infected person. 
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Based on genetic similarities, the numerous virus strains may be classified into types, groups 
and subtypes.  
 
As shown in Figure 1, the strains of HIV-1 can be classified into four groups: the "major" 
group M, the "outlier" group O and two new groups, N and P. These four groups may 
represent four separate introductions of simian immunodeficiency virus into humans ( Gao et 
al 1998). 
Group O subgroup appears to be restricted to West-Central Africa and group N - a strain 
discovered in 1998 in Cameroon - is extremely rare. 
 
 
Figure 1. Types and subtypes of HIV. 
Copied from  Wainberg M A (2004, 3rd June) 'HIV-1 subtype distribution and the problem of 
drug resistance' AIDS 18(S3). 
 
In 2009 a new strain closely relating to gorilla simian immunodeficiency virus was 
discovered in a Cameroonian woman  (WHO 2011). It was designated HIV-1 group P. More 
than 90 per cent of HIV-1 infections belong to HIV-1 group M. Within group M there are 
known to be at least nine genetically distinct subtypes  of HIV-1. These are subtypes A, B, C, 
D, F, G, H, J and K. (Gao et al. 1998). Occasionally, two viruses of different subtypes can 
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meet in the cell of an infected person and mix together their genetic material to create a new 
hybrid virus (a process similar to sexual reproduction, and sometimes called "viral sex").  
 
Many of these new strains do not survive for long, but those that infect more than one person 
are known as "circulating recombinant forms" (CRFs). For example, the HIV Circulating 
Recombinant Forms (CRF A/B) is a mixture of subtypes A and B. The classification of HIV 
strains into subtypes and CRFs is a complex issue and the definitions are subject to change as 
new discoveries are made. Some scientists talk about subtypes A1, A2, A3, F1 and F2 instead 
of A and F, though others regard the former as sub-subtypes (Gao et al.1998). 
 
2.1.2. Health burden of HIV/AIDS 
HIV infection in humans is now a pandemic. The UNAIDS global report estimated that the 
number of people living with HIV/AIDS by the end of 2009 was 33 million. By 2008, the 
global funding for HIV/AIDS had climbed to $15.6 billion (Kates et al. 2009) and by 2009, 
WHO estimated that 5.2 million were on ART in low and middle income countries (WHO, 
2010). As of January 2006, the Joint United Nations Programme on HIV/AIDS (UNAIDS 
2006) and the World Health Organization (WHO) estimated that AIDS has killed more than 
25 million people since it was first recognized in December 1, 1981. 
 
It is estimated that 0.06% of the world‘s population was infected with HIV in 2008 (Joint 
United Programme on AIDS 2008). AIDS has decreased life expectancies by 20 years, and 
the high rates of HIV infection in adolescents and women of reproductive age have resulted 
in community destruction, family dissolution, and economic losses in many sub-Saharan 
African countries. AIDS prevention programme has been actively pursued, and there are  
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significant ongoing researches focused on the development of an HIV vaccine and effective 
antiretroviral drugs. 
 
Africa disproportionately bears the burden of the HIV/AIDS pandemic.  Although only 11% 
of the world's population lives in Africa, approximately 67% of those living with HIV/AIDS 
are in Africa. In Africa, there were 22.4 million people living with HIV and 1.9 million new 
HIV infections in 2008.  An estimated 14 million children in Africa have been orphaned as a 
result of HIV/AIDS (WHO/UNAIDS/UNICEF 2011). 
 
In 2008 prevalence rate in adults aged 15-49 years was 17.8%, average life expectancy was 
48.3 years. It is  6.5 years less than it would have been without the disease.  The number of 
adults aged 15 years and above  living with HIV was 5,300,000. Women aged 15 years and 
above living with HIV was 3,300,000. Children aged 0 to 14 years living with HIV was 
330,000. Almost 1,000 AIDS deaths occur every day in South Africa (UNAIDS 2008 report 
on the global AIDS epidemics). Hospitals are struggling to cope with the number of patients 
with HIV related diseases that they have to care for. In South Africa, parallel private and 
public systems exist. The public system serves the vast majority of the population, but is 
chronically underfunded and understaffed. The wealthiest 20% of the population uses the 
private system and are far better served. In 2005, South Africa spent 8.7% of GDP on health 
care, or US$437 per capita. Of that, approximately 42% was government expenditure (WHO 
2008). About 79% of doctors work in the private sector (Atagbua 2010). 
 
In 2006 a leading researcher estimated that HIV positive patients would soon account for 60-
70% of medical expenditure in South African hospitals (Inter Press Service News Agency 
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May,2006). Schools have fewer teachers because of the AIDS epidemic. In 2006 it was 
estimated that 21% of teachers in South Africa were living with HIV (UNAIDS/WHO 2006). 
 
The meagre healthcare budgets in most African countries are not sufficient to cope with the 
added burden imposed by the HIV pandemic. In an environment where most people are 
dependent on government for healthcare, the impact of AIDS has been crippling. In some 
countries up to 16% of healthcare workers are HIV positive, and it is estimated that between 
19% and 53% of all government health employee deaths are AIDS related (Benatar 2004). 
 
Clinic visits and hospital admissions have increased. The result has been the reversal of 
progress in socioeconomic development, healthcare, and improvement in life expectancy. It is 
difficult to overstate the suffering that HIV has caused in South Africa, with statistics 
showing that almost one in five adults are infected. For each person living with HIV, the 
impact is not only on their lives but also on their families, friends and wider communities. 
 
New HIV infections were reduced by 21% since 1997, and deaths from AIDS-related 
illnesses also decreased by 21% since 2005. The favourable report that emerged from 
UNAIDS in November 2011 showed a downward trend in HIV/AIDS which gave some light 
and hope to the people of Africa. There have seen a massive scale up in access to HIV 
treatment which has had a dramatic effect on the lives of people everywhere. According to 
UNAIDS and WHO estimates, 47% (6.6 million) of the estimated 14.2 million people 
eligible for treatment in low and middle income countries were accessing lifesaving 
antiretroviral therapy in 2010 which is an increase of 1.35 million since 2009. The 2011 
UNAIDS World AIDS Day report also highlighted that there are early signs that HIV 
treatment is having a significant impact on reducing the number of new HIV infections. 
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Decrease in AIDS-associated mortality coincided with the introduction of highly active 
antiretroviral therapy (HAART), including protease inhibitors. This suggests that survival 
following HIV infection increased from 10–12 years to more than 25 years (Greener 2002).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 shows that  an estimated 5.3 million people are infected in South Africa and 3.7 
million in Nigeria in 2003. North Africa seem to have the lowest number of infections in the 
continent. 
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Figure  2. Map of HIV/AIDS in Africa.  Source: (CIA World Factbook).   
The darker portion of the map shows the area where HIV infection is highest in the continent. 
 
2.1.3. The structure of the HIV  
Figure 3. is that of the human immunodeficiency virus. It is roughly spherical with a diameter 
of about 120nm, which is 60 times smaller than a red blood cell, yet large for a virus. It is 
composed of two copies of positive single stranded RNA that code for the virus‘s nine genes 
enclosed by a conical capsid composed of 2000 copies of the viral protein. The single strand 
RNA is tightly bound to nucleocapsid proteins, p7 (Nielsen et al. 2005).  . 
15 
 
 
Figure  3. The structure of the Human immunodeficiency virus. Source: (National 
Institute of Allergy and Infectious Diseases, 2009). 
 
HIV particles surround themselves with a coat of fatty material known as the viral envelope 
(or membrane). Projecting from the viral envelope are around 72 little spikes, which are 
formed from the proteins gp 120 and gp 41. Just below the viral envelope is a layer called the 
matrix, which is made from the protein p17 (Nielsen et al. 2005).  The viral core (or capsid) 
is usually bullet-shaped and is made from the protein p24. Inside the core are three enzymes 
required for HIV replication called reverse transcriptase, integrase and protease. Also held 
within the core is HIV's genetic material, which consists of two identical strands of 
ribonucleic acid (RNA). Almost all organisms, including most viruses, store their genetic 
materials on long strands of DNA. Retroviruses are the exception because their genes are 
composed of only RNA.  
 
RNA has a very similar structure to deoxyribose nucleic acid (DNA). However, small 
differences between the two molecules mean that HIV's replication process is a bit more 
complicated than that of most other viruses. HIV has just nine genes (compared to more than 
500 genes in a bacterium, and around 20,000-25,000 in a human). Three of the HIV genes, 
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called gag, pol and env, contain information needed to make structural proteins for new virus 
particles. The other six genes, known as tat, rev, nef, vif, vpr and vpu, code for proteins that 
control the ability of HIV to infect a cell, produce new copies of virus, or cause disease. At 
either end of each strand of RNA is a sequence called the long terminal repeat, which helps to 
control HIV replication (Nielsen et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
2.1.4.   The life cycle of HIV 
HIV can only replicate inside human cells. The process typically begins when a virus particle 
bumps into a cell that carries on its surface a special protein called CD4. The life cycle of 
HIV can be as short as about 1.5 days from viral entry into a cell, through replication, 
assembly and release of additional viruses, to infection of other cells. HIV enters 
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macrophages and CD4
+ 
T cells by the adsorption of glycoproteins on its surface to receptors 
on the target cell, followed by fusion of the viral envelope with the cell membrane and the 
release of the HIV capsid into the cell. The spikes on the surface of the virus particle sticks to 
the CD4
+
 receptor on the cell and allows the viral envelope to fuse with the cell membrane 
(Figure 4). The contents of the HIV particle are then released into the cell, leaving the 
envelope behind. Once inside the cell, the HIV enzyme reverse transcriptase converts the 
viral RNA into DNA, which is compatible with human genetic material. 
  
Figure 4. The life cycle of the HIV. Sources:  NIH Health Topics and "Biology of HIV" 
(Nielsen et al. 2005). 
 
 
2.1.4.1. Transportation of the DNA into the cell  
This  DNA is transported to the cell's nucleus, where it is spliced into the human DNA by the 
HIV enzyme integrase. Once integrated, the HIV DNA is known as provirus. HIV provirus 
may lie dormant within a cell for a long time.  When the cell becomes activated, it treats HIV 
genes in much the same way as human genes. First it converts them into messenger RNA 
(using human enzymes). Then the messenger RNA is transported outside the nucleus, and is 
used as a blueprint for producing new HIV proteins and enzymes (Nielsen et al. 2005). 
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2.1.4.2.  The release of new viral particles 
Among the strands of messenger RNA produced by the cell are complete copies of HIV 
genetic material. These gather together with newly made HIV proteins and enzymes to form 
new viral particles. The HIV particles are then released or 'bud' from the cell (Figure 5).  
   
Figure 5. showing  HIV budding from an infected cell. Sources:  NIH Health Topics and 
"Biology of HIV"(Nielsen et al. 2005). 
The enzyme protease plays a vital role at this stage of the HIV life cycle by chopping up long 
strands of protein into smaller pieces, which are used to construct mature viral cores.  The 
newly matured HIV particles are ready to infect another cell and begin the replication process 
all over again. 
 
In this way the virus quickly spreads through the human body.  Once a person is 
infected, they can pass HIV on to others through their body fluids. HIV differs from 
many viruses in that it has very high genetic variability. This diversity is as a result of 
its fast replication cycle with the generation of 109 to 1010 virions every day coupled 
with a high mutation rate. This complex scenario, leads to the generation of many 
variants of HIV in a single cell infected patient in the course of one day (National 
Institute of Allergy and Infectious Diseases (NIAID) (2009). 
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2.1.5. Events in HIV infection 
Untreated HIV disease is characterized by a gradual deterioration of immune function. Most 
notably, the T cells that contain CD4 proteins (represented as CD4
+
 T cells) are disabled and 
killed during the typical course of infection. These cells, sometimes called 'T-helper cells', 
play a central role in the immune response, signaling other cells in the immune system to 
perform their special functions.  A healthy, uninfected person usually has 800 to 1,200 CD4
+
 
T cells per cubic millimeter (mm
3
) of blood. During HIV infection, the number of these cells 
in a person's blood progressively declines. When the CD4
+
 T cell count falls below 200/mm
3
, 
a person becomes particularly vulnerable to the opportunistic infections and cancers that 
typify AIDS, the end stage of HIV disease (CDC, 1994). 
 
Most scientists think that HIV causes AIDS by inducing the death of CD4+ T cells or 
interfering with their normal function, and by triggering other events that weaken a 
person's immune function. For example, the network of signaling molecules that 
normally regulates a person‟s immune response is disrupted during HIV disease, 
impairing a person's ability to fight other infections. The HIV-mediated destruction of 
the lymph nodes and related immunologic organs also plays a major role in causing 
the immunosuppression seen in people with AIDS.   
 
2.1.6.  The acute phase of primary infection in HIV 
Once the virus enters the body, it infects a large number of CD4+ cells and replicates 
rapidly. During this acute phase of primary infection the blood contains many viral 
particles that spread throughout the body seeding various organs especially the 
lymphoid organs. Two to four weeks after exposure to the virus, some people may 
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suffer flu-like symptoms related to the acute infection. Their immune system fights 
back with killer T cells (CD8+ T cells) and B-cell-produced antibodies, which 
dramatically reduce HIV levels (CDC, 1994). 
 
A person's CD4+ T cell count may rebound somewhat and even approach its original 
level. A person may then remain free of HIV-related symptoms for years despite 
continuous replication of HIV in the lymphoid organs that had been seeded during 
the acute phase of infection. One reason that HIV is unique is the fact that despite 
the body‟s aggressive immune responses, which are sufficient to clear most viral 
infections, some of the HIV invariably escapes. This is due in large part to the high 
rate of mutations that occur during the process of HIV replication. In addition, early 
in the course of HIV infection, people may lose HIV-specific CD4+ T cell responses 
that normally slow the replication of viruses. Such responses include the secretion of 
interferons and other antiviral factors, and the orchestration of CD8+ T cells. Finally, 
the virus may hide within the chromosomes of an infected cell and be shielded from 
surveillance by the immune system. Such cells can be considered as a latent 
reservoir of the virus. The antiviral agents currently in our therapeutic arsenal attack 
are not effective against hidden, inactive viral DNA (so-called provirus). New 
strategies to purge this latent reservoir of HIV have become one of the major goals 
for current research efforts (CDC 2009).  
 
2.1.7.  Variation in disease progression in HIV/AIDS 
Among people enrolled in large epidemiologic studies in Western countries, the 
median time from infection with HIV to the development of AIDS-related symptoms 
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has been estimated to be 10 to 12 years without the use of antiretroviral therapy. 
Researchers, however, have observed a wide variation in disease progression. 
Approximately 10 per cent of HIV-infected people in some of these studies have 
progressed to AIDS within the first 2 to 3 years following infection, while up to 5 per 
cent of individuals in the studies have stable CD4+ T cell counts and no symptoms 
even after 12 or more years. Factors such as age or genetic differences among 
individuals, the level of virulence of an individual strain of virus, and co-infection 
with other microbes may influence the rate and severity of disease progression. 
Drugs that fight the infections associated with AIDS have improved and prolonged 
the lives of HIV-infected people by preventing or treating conditions such as 
Pneumocystis jirorecii pneumonia, cytomegalovirus disease, and diseases caused by 
a number of fungi. 
 
Recent research has shown that most infecting strains of HIV use a co-receptor 
molecule called chemokine receptor 5 (CCR5), in addition to the CD4 molecule, to 
enter certain of its target cells (Lederman et al 2006). HIV-infected people with a 
specific mutation in one of their two copies of the gene for this receptor may have a 
slower disease course than people with two normal copies of the gene. Rare 
individuals with two mutant copies of the CCR5 gene appear, in most cases, to be 
completely protected from HIV infection (Anderson & Sansom 2007). Mutations in 
the gene for other HIV co-receptors also may influence the rate of disease 
progression. Numerous studies show that people with high levels of HIV in their 
bloodstream are more likely to develop new AIDS-related symptoms or die than 
those with lower levels of virus (Quinn 2011). In the multicenter AIDS cohort study 
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(MACS), investigators showed that the level of HIV in an untreated person‟s plasma 
6 months to a year after infection (the so-called viral "set point") is highly predictive 
of the rate of disease progression; that is, patients with high levels of virus are much 
more likely to get sick faster than those with low levels of virus. The MACS and other 
studies have provided the rationale for providing aggressive antiretroviral therapy to 
HIV-infected people, as well as for routinely using newly available blood tests to 
measure viral load when initiating, monitoring, and modifying anti-HIV therapy.  
 
2.1.8. HAART and progression to AIDS 
Potent combinations of three or more anti-HIV drugs known as highly active 
antiretroviral therapy, or HAART, can reduce a person‟s viral burden to very low 
levels and in many cases delay the progression of HIV disease for prolonged periods. 
Before the introduction of HAART therapy, 85 per cent of patients survived an 
average of less than 3 years following AIDS diagnosis. Antiretroviral regimens, 
however, have yet to completely and permanently suppress the virus in HIV-infected 
people. 
 
Recent studies have shown that, in addition to the latent HIV reservoir, HIV persists 
in a replication-competent form in resting CD4+ T cells even in people receiving 
aggressive antiretroviral therapy who have no readily detectable HIV in their blood. 
Investigators around the world are working to develop the next generation of anti-
HIV drugs that can stop HIV, even in these biological scenarios. A treatment goal, 
along with reduction of viral burden, is the reconstitution of the person's immune 
system, which may have become sufficiently damaged that it cannot replenish itself.  
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2.1.9. HIV progresson and cytokines 
Various strategies for assisting the immune system are being tested in clinical trials. 
Although HIV-infected people often show an extended period of clinical latency with 
little evidence of disease, the virus is never truly completely latent. Researchers have 
shown that even early in the disease, HIV actively replicates within the lymph nodes 
and related organs, the virus become trapped in networks of specialized cells. These 
cells are called follicular dendritic cells (FDCs). FDCs are located in hot spots of 
immune activity in lymphoid tissue called germinal centres. FDCs trap invading 
pathogens until B cells come along to start an immune response. Over a period of 
years significant amounts of virus accumulate in the lymphoid tissue, both within 
infected cells and bound to FDCs. Numerous CD4+ T cells are probably activated  by 
immune system cells within the lymphoid tissue in the germinal centres by 
increasing production of cytokines such as tumour necrosis factor (TNFα) and 
interleukin 6 (IL-6). Activating the CD4 cells allows uninfected cells to be more easily 
infected and increases replication of HIV in already infected cells (National Institute 
of Allergy and Disease, 2009). While greater quantities of certain cytokines such as 
TNFα and IL-6 are secreted during HIV infection, other cytokines with key roles in 
the regulation of normal immune function may be secreted in decreased amounts 
(National institute of Allergy and Disease, 2009). For example, CD4+ T cells may lose 
their capacity to produce Interleukin 2 (IL-2), a cytokine that enhances the growth 
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of other thymus dependent cells (T cells) and helps to stimulate other cells' response 
to invaders (National institute of Allergy and Disease, 2009). Infected cells also have 
low levels of receptors for IL-2, which may reduce their ability to respond to signals 
from other cells. Ultimately, with chronic cell activation and secretion of 
inflammatory cytokines, the fine and complex inner structure of the lymph node 
breaks down and is replaced by scar tissue. With the breakdown in structure, cells in 
the lymph node cannot communicate and the immune system cannot function 
properly. Investigators also have reported recently that this scarring reduces the 
ability of the immune system to replenish itself following antiretroviral therapy that 
reduces the viral burden (National institute of Allergy and Disease, 2009).  
 
2.1.10. CD8 + T Cells and HIV progression 
CD8+ T cells are critically important in the immune response to HIV. These cells 
attack and kill infected cells that are producing the virus. Thus, vaccine efforts are 
directed toward eliciting or enhancing these killer T cells, as well as eliciting 
antibodies that will neutralize the infectivity of HIV. CD8+ T cells also appear to 
secrete soluble factors that suppress HIV replication (National institute of Allergy and 
Disease, 2009). 
 
Several molecules, including  “regulated upon activation normal T cell expressed 
(RANTES),  and presumably secreted” molecules, macrophage Inflammatory Protein-
1 alpha, (MIP-1alpha), macrophage Inflammatory Protein-1 beta, (MIP-1beta), and 
macrophage derived chemokine (MDC) appear to block HIV replication by occupying 
the co-receptors necessary for many strains of HIV to enter their target cells. There 
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may be other immune system molecules - including the so-called CD8 antiviral factor 
(CAF), the defensins (type of antimicrobials), and others yet undiscovered - that can 
suppress HIV replication to some degree (National Institute of Allergy and Infectious 
Disease, 2012).  
 
2.1.11. Mutation, Cell death in  HIV progression  
HIV replicates rapidly and  several billion new virus particles may be produced every 
day. In addition, the HIV reverse transcriptase enzyme makes many mistakes while 
making DNA copies from HIV RNA. As a consequence, many variants or strains of 
HIV develop in a person, some of which may escape destruction by antibodies or 
killer T cells. Additionally, different strains of HIV can recombine to produce a wide 
range of variants (Nielsen et al. 2005). During the course of HIV disease, viral 
strains emerge in an infected person that differs widely in their ability to infect and 
kill different cell types, as well as in their rate of replication. Scientists are 
investigating why strains of HIV from people with advanced disease appear to be 
more virulent and infect more cell types than strains obtained earlier from the same 
person. 
 
Researchers around the world are studying how HIV destroys or disables CD4+ T 
cells, and many think that a number of mechanisms may occur simultaneously in an 
HIV-infected person. Data suggest that billions of CD4+ T cells may be destroyed 
every day, eventually overwhelming the immune system‟s capacity to regenerate. 
Infected CD4+ T cells may be killed directly when large amounts of virus are 
produced and bud out from the cell surface, disrupting the cell membrane, or when 
26 
 
viral proteins and nucleic acids collect inside the cell, interfering with cellular 
machinery. Infected CD4+ T cells may be killed when the regulation of cell function 
is distorted by HIV proteins, probably leading to cell suicide by a process known as 
programmed cell death or apoptosis (National Institute of Allergy and Disease, 
2009). Recent reports indicate that apoptosis occurs to a greater extent in HIV-
infected people, both in their bloodstream and lymph nodes. Apoptosis is closely 
associated with the aberrant cellular activation seen in HIV disease. Uninfected cells 
also may undergo apoptosis. 
 
Investigators have shown in cell cultures that the HIV envelope alone or bound to 
antibodies sends an inappropriate signal to CD4+ T cells causing them to undergo 
apoptosis, even if not infected by HIV (NIAID 2009). Uninfected cells may die in an 
innocent bystander scenario: HIV particles may bind to the cell surface, giving them 
the appearance of an infected cell and marking them for destruction by killer T cells. 
This process is called antibody-dependent cellular cytotoxicity. Killer T cells also may 
mistakenly destroy uninfected cells that have consumed HIV particles and that 
display HIV fragments on their surfaces. HIV envelope proteins bear some 
resemblance to certain molecules that may appear on CD4+ T cells, the body‟s 
immune responses may mistakenly damage such cells as well. 
 
2.1.12. Cell activation and HIV progression 
Researchers have shown in cell cultures that CD4+ T cells can be turned off by 
activation signals from HIV that leaves them unable to respond to further immune 
stimulation (National Institute of Allergy and Disease, 2009). This inactivated state is 
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known as anergy. Studies suggest that HIV also destroys precursor cells that mature 
to have special immune functions, as well as the microenvironment of the bone 
marrow and the thymus needed for developing such cells (NIAID 2009). These 
organs probably lose the ability to regenerate, further compounding the suppression 
of the immune system. Although monocytes and macrophages can be infected by 
HIV, they appear to be relatively resistant to being killed by the virus (Kopperstaner 
et al. 2012). These cells, however, travel throughout the body and carry HIV to 
various organs, including the brain, which may serve as a hiding place or 'reservoir' 
for the virus that may be relatively resistant to most anti-HIV drugs.  
 
2.1.13. The normal immune response 
During a normal immune response, many parts of the immune system are mobilized to fight 
an invader. CD4
+
 T cells, for instance, may quickly multiply and increase their cytokine 
secretion, thereby signalling other cells to perform their special functions. Scavenger cells 
called macrophages may double in size and develop numerous organelles, including 
lysosomes that contain digestive enzymes used to process ingested pathogens. Once the 
immune system clears the foreign antigen, it returns to a relative state of quiescence. 
 
2.1.14. Chronic cell activation and disease progression 
HIV disease for most of its course is characterized by immune system hyperactivation, which 
has negative consequences. HIV replication and spread are much more efficient in activated 
CD4
+
 cells ( NIAID 2009). Chronic immune system activation during HIV disease also may 
result in a massive stimulation of B cells, impairing the ability of these cells to make 
antibodies against other pathogens. Chronic immune activation also can result in apoptosis, 
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and an increased production of cytokines that not only may increase HIV replication but also 
have other deleterious effects. 
 
Increased levels of TNF-alpha, for example, may be at least partly responsible for the severe 
weight loss or wasting syndrome seen in many HIV-infected people (National Institute of 
Health, 2001). The persistence of HIV and HIV replication plays an important role in the 
chronic state of immune activation seen in HIV-infected people. In addition, it has been 
shown that infections with other organisms activate immune cells and increase production of 
the virus in HIV-infected people (NIAID 2009). Chronic immune activation due to persistent 
infections or the cumulative effects of multiple episodes of immune activation and bursts of 
virus production, likely contribute to the progression of HIV disease. 
 
2.1.15. Concept of cardiovascular risk and HIV 
Ischaemic cardiovascular events increasingly occur in those patients infected  for many years 
with HIV and are attributed either to the infection itself or to the use of HAART.   In the 
context of declining rates of HIV-related death, proportions of HIV infected patients dying of 
other causes have increased. For example, a death certificate study in New York City showed 
that the proportion of deaths among HIV-infected patients due to non–HIV-related causes 
increased from 19.8% to 26.3% between 1999 and 2006, reflecting mortality resulting from 
cardiovascular disease (CVD), substance abuse, and non–AIDS-defining cancers (Sackoff et 
al. 2006). Among individuals aged 55 years or older, CVD was the leading cause of death. 
Numerous studies have indicated increased risk of myocardial infarction (MI) in HIV 
populations, with HIV infection considered at least a partial CVD risk factor in these studies 
(Triant et al. 2007). Triant et al (2007) found a 75% increase in risk of MI admissions in 
HIV-infected patients. 
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At the 9th Retrovirus conference in February 2002 different conflicting datas were presented  
about HAART and cardiovacular risk factors. In the research work presented by Holmberg et 
al (2002) they followed 5,676 HIV positive people at nine clinics, HIV Out Patient clinics 
(the HOPS cohort) from Centres for Disease Control and prevention (CDC) from 1993 to 
2001. Slightly more than half the group used protease inhibitor (PI) -based regimens. 
Thirteen of 3,013 (0.43%) participants taking protease inhibitors (PIs) suffered myocardial 
infarctions during the study period, compared with two out of 2,663 (.075%) participants not 
using PIs (Holmberg et al. 2002). Bozzette et al (2002) claimed that there seems to be a slight 
decline in heart disease and strokes since the advent of HAART. They examined the medical 
records of 36,766 HIV positive patients at U.S. Veterans administration medical centers over 
eight-year period. During this time there were 1,800 hospital admissions and 500 deaths due 
to cardiovascular or cerebrovascular disease. They found out that since 1997, rates of hospital 
admissions and deaths due to heart attack or stroke have fallen compared to the rates prior to 
the availability of PIs.  Over the course of the study period, heart attack and stroke admission 
and mortality rates declined by 10-20%. The researchers concluded that their findings did not 
support an association between PI, NRTI, or non-nucleoside reverse transcriptase inhibitor 
(NNRTI) use and excess cardiovascular or cerebrovascular problems. However, the results of 
the study by Bozzette et al (2002)  may reflect the fact that by 1997 health-care providers 
were prescribing statins and other lipid-lowering therapies for HIV positive people with high 
blood lipid levels.  
 
A smaller study by Klein et al (2002) also did not detect an increase in cardiovascular events 
among 4,159 HIV positive men in the Kaiser health-care system (Kaiser health-care system is 
an  integrated managed care consortium, based in Oakland, California, United States, founded 
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in 1945 by industrialist Henry J. Kaiser and physician Sidney Garfield)  since the 
introduction of PIs.  
 
Arterial stiffness is an independent predictor of all-cause and cardiovascular mortality in 
hypertensive patients. Atherosclerotic changes within the arterial wall are known to increase 
arterial stiffness and alter wave reflection (Laurent et
 
al. 2006).
 
 Increased arterial wave 
reflection is associated with coronary artery disease and is an independent predictor of 
adverse coronary events (London et al. 2001). This has however not been well studied in the 
setting of HIV infection.  This study will therefore  involve looking into arterial stiffness 
which  will be a surrogate of atherosclerosis in HIV positive participants on treatment and 
drug naïve HIV positive participants. 
Some studies found HIV infection and HAART treatment are associated with increased 
arterial stiffness and increased heart rate. These vascular alterations are possible causes of the 
increased cardiovascular risk observed in HIV infected patients (Papita et al. 2011). Arterial 
stiffness and pulse pressure were found to be important determinants of cardiovascular risk. 
The two leading causes of death in the developed world, myocardial infarction and stroke, are 
both  direct consequences of atherosclerosis. 
 
In a study by Dube et al (2008), it was stated that HIV-related cardiovascular disease is an 
under recognized and unappreciated cause of symptomatic illness and a predictor of all cause 
mortality in late stage HIV infection (Dube at al. 2008). A high degree of suspicion and early 
screening may allow appropriate intervention and improved quality of life in those affected. It 
might be therefore imperative if HIV patients both on treatment and those who are treatment 
naïve be screened and evaluated for their vascular functions. It will also be  worthy of note to 
know the effects of cytokines and adhesion molecules on arterial stiffness. The natural course 
31 
 
of the HIV virus itself will be looked into, including the mechanism by which the virus 
increases cardiovascular morbidity and mortality. 
 
In 2008 the DAD (Data collection on adverse events on anti HIV Drugs) study group 
reported ways of decreasing cardiovascular risks in HIV. They reported that having HIV is 
associated with increases in two important risk factors for cardiac disease. These are; low 
levels of HDL- cholesterol and elevated levels of triglycerides. These scientists (DAD study 
group, 2008) noted that many HIV infected patients have abnormal levels of cholesterol, 
insulin resistance, diabetes, excess abdominal weight and other risk factors which may be 
side effects of antiretroviral medications. These disturbances in lipid and glucose metabolism 
may contribute to the excess cardiovascular disease morbidity and mortality observed in HIV 
infected individuals (Francisci et al. 2009).  
 
Antiretroviral therapy has greatly reduced the risk of early death from opportunistic 
infections and extended the lifespan of people infected with the HIV. This has led to many 
complications and organ damage in the HIV infected population. Grunfeld  et al (1992) 
mentioned that in the era before HAART the only metabolic abnormality noted in AIDS was 
the hypertriglyceridaemia associated with a wasting syndrome. This he attributed to high 
levels of cytokines accompanying chronic infection. Since the advent of effective 
antiretroviral therapy, infection with the human immunodeficiency virus has been 
transformed in the western world to a chronic disease associated with a variety of metabolic 
complications (Gkrania-Klotsas & Klotsas 2007). HAART has allowed for prolonged 
survival even in patients at an advanced stage of AIDS, with their life expectancy increased 
by more than 10 years.  The association between the use of HAART and an increased risk in 
metabolic syndrome and cardiovascular disease remains unclear (Mondy et al. 2008). Large 
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international studies have also implicated the HIV itself and anti-retroviral therapy (ART) as 
potential mediators of this increased risk of CVD. There were whole lots of contradicting 
findings on cardiovascular risk factors in HIV positive patients on treatment and drug naïve 
participants (Monteiro et al. 2012, Saves et al. 2003 ). 
 
The few studies evaluating the prevalence of traditional cardiovascular risk factors among 
HIV positive patients in sub-Saharan Africa suggest that rates are significantly lower than in 
developed countries but some of this difference may be attributed to under detection based on 
low clinical suspicion and small sample sizes.  
 
Inflammation contributes to the pathogenesis of cardiovascular disease. TNFα in particular is 
a key mediator of inflammation and vascular dysfunction and progression of atherosclerotic 
disease (Haddy et al. 2003).  Zhang (2008) showed that inflammatory cytokines like TNFα, 
IL-6, P selectin, Von Willebrand factor may all increase in chronic HIV infection. He cited 
inflammatory cytokines as important protagonists in formation of atherosclerotic plaque, 
eliciting their effects throughout the atherosclerotic vessel. These studies, however, have not 
included patients from sub-Saharan Africa.  
 
2.1.16. Cardiovascular risk factors and HIV in Africa 
Africa is home to the majority of the world‘s HIV infected population (UNAIDS 2004) and 
yet very few of recent reviews on the cardiovascular manifestation of HIV have examined the 
African experience (Barbaro 2002). Although the link between heart disease and HIV 
positive status has been proven in first world countries, there is difficulty in ascertaining the 
root cause because many people are already on HIV treatment.  
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Estimates from outside Africa are that the incidence of HIV-associated vasculitis is less than 
1% (Johnson et al 2003). Ntsheke & Hakim (2005) reported that large-vessel vasculopathy 
involving the aorta or its major branches is increasingly being recognized in young African 
subjects with mean age of 31 years.  It was reported that these young Africans had no 
evidence of atherosclerosis, syphilis or other causes of vasculitis. The large vessel 
vasculopathy occurred at a relatively early stage of HIV disease (median CD4 count 
370x10
6
/L).  
 
Concurrently, the epidemiology and demography of sub-Saharan Africa is shifting towards 
older populations with a higher proportion of CVD due to chronic, non-communicable 
diseases. Despite these facts, the region is under-represented in studies examining the 
relationship between HIV and CVD risk factors. Africa is important due to the exceedingly 
high prevalence of HIV in this region. Furthermore, global efforts in sub-Saharan Africa 
aimed solely at HIV care may be missing a critical opportunity to improve overall 
cardiovascular health if chronic CVD risk factors is highly prevalent. The majority of the 
articles in Africa examined aspects of pericardial disease in HIV infected African subjects. 
The remainder described the prevalence of clinical spectrum and unusual features of cardiac 
disease in HIV infected subjects. Mutimura (2008) in Kigali, Rwanda suggested an increasing 
incidence of HIV-associated cardio metabolic syndrome (CMS), in developing countries 
especially in urban settings. Predictions indicate that the greatest increase in the prevalence of 
diabetes will occur in Africa over the next two decades due to lifestyle changes. This, 
coupled with increased access to HAART, may exponentially increase the prevalence of 
CMS in developing countries, where HIV infection is prevalent.  
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Appropriate evaluation and intervention programmes need to be implemented in the 
developing world, especially sub-Saharan Africa, to curtail HIV-related CMS. This should 
include routine cardiovascular risk assessments, management of HIV infection with more 
―metabolically friendly‖ HAART, and encouragement of lifestyle modifications, particularly 
smoking cessation, weight management, regular exercise, and adherence to a healthy diet. 
 
2.1.17. Clinical staging of HIV/AIDS by WHO 
The World Health Organization (WHO) has developed case definitions for HIV surveillance 
and clinical staging and immunological classification of HIV-related disease in adults and 
children. This system uses standardized clinical parameters to direct medical decision making 
for patients with HIV/AIDS and can be used based solely on patient clinical features, thus 
accommodating facilities with no or limited access to laboratory testing.  
 
The WHO Clinical Staging system has been shown to be a practical and accurate way to 
manage HIV-infected patients, with international studies showing agreement between clinical 
manifestations included in the WHO staging system and laboratory markers including CD4 
cell count and total lymphocyte count. With the progression of the HIV/AIDS epidemic, 
consideration of the entire spectrum of infection is necessary. Several discrete clinical phases 
can be recognized which correlate with the degree of immunodeficiency that arises with 
progression of HIV infection.  
 
The revised WHO HIV/AIDS Clinical Staging System is intended for baseline assessment of 
patients and for use in provision of ongoing care (WHO 2005). It provides guidance, 
including when to start, switch, or stop prophylactic medications, antiretrovirals, and other 
interventions. It assists clinicians in the assessment of a patient‘s current clinical status; 
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encourages clinical providers to offer diagnostic HIV testing to patients who exhibit clinical 
symptoms and  signs suggestive of HIV infection; classifies disease in a progressive sequence 
from least to most severe. It is designed to be used with reference to current and previous 
clinical events, making it useful for surveillance purposes.  
 
2.1.18. The  Clinical Stages of HIV/AIDS defining their illnesses 
The WHO system for adults, sorts patients into one of four hierarchical clinical stages 
ranging from stage 1 (asymptomatic) to stage 4 (AIDS). Patients are assigned to a particular 
stage when they demonstrate at least one clinical condition in that stage‘s criteria. Patients 
remain at a higher stage after they recover from the clinical condition which placed them in 
that stage.  
 
2.1.18.1. Stage 1 
Patients who are asymptomatic or have persistent generalized lymphadenopathy 
(lymphadenopathy of at least two sites (not including inguinal) for longer than 6 months are 
categorized as being in stage 1, where they may remain for several years.  
 
2.1.18.2. Stage 2 
Clinical findings included in stage 2 (mildly symptomatic stage) are unexplained weight loss 
of less than 10 per cent of total body weight and recurrent respiratory infections (such as 
sinusitis, bronchitis, otitis media, and pharyngitis), as well as a range of dermatological 
conditions including herpes zoster flares, angular cheilitis, recurrent oral ulcerations, papular 
pruritic eruptions, seborrhoeic dermatitis, and fungal nail infections.  
 
2.1.18.3. Stage 3 
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Those manifestations encompassed by the WHO clinical stage 3 (the moderately 
symptomatic stage) category are weight loss of greater than 10 per cent of total body weight, 
prolonged (more than 1 month), unexplained diarrhoea, pulmonary tuberculosis, and severe 
systemic bacterial infections including pneumonia, pyelonephritis, empyema, pyomyositis, 
meningitis, bone and joint infections, and bactereamia. Mucocutaneous conditions, including 
recurrent oral candidiasis, oral hairy leukoplakia, and acute necrotizing ulcerative stomatitis, 
gingivitis, or periodontitis, may also occur at this stage.  
2.1.18.4. Stage 4 
The WHO clinical stage 4 (the severely symptomatic stage) designation includes all of the 
AIDS-defining illnesses. Clinical manifestations for stage 4 disease that allow presumptive 
diagnosis of AIDS to be made based on clinical findings alone are HIV wasting syndrome, 
pneumocystis pneumonia (PCP), recurrent severe or radiological bacterial pneumonia, 
extrapulmonary tuberculosis, HIV encephalopathy, central nervous system (CNS) 
toxoplasmosis, chronic (more than 1 month) or orolabial herpes simplex infection, 
esophageal candidiasis, and Kaposi‘s sarcoma.  
 
A modified version of the WHO Clinical Staging System is available for infants and children 
under 15 years. According to the WHO, advanced HIV/AIDS disease is defined for 
surveillance purposes as any clinical stage-3 or stage-4 disease or any clinical stage with a 
CD4 count less than 350 per cubic mm, and this information can be used to calculate the 
burden of disease and the demand for antiretroviral therapy. WHO recommends definitive 
initiation of antiretroviral therapy in adults and adolescents in clinical stage 4, consideration 
of therapy initiation for those in clinical stage 3, and antiretroviral use for those in clinical 
stage 1 or 2 only if the CD4 count is less than 250 per cubic mm. 
 
37 
 
For patients taking antiretroviral therapy for more than 24 weeks, new or recurrent clinical 
staging events can be a guide to decision-making. Prior to 24 weeks of antiretroviral 
treatment, clinical events are largely influenced by immune reconstitution or treatment 
toxicity and may not accurately reflect immune deterioration.  
 
2.2. Antiretrovirals 
Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily 
HIV. This is the main type of treatment for HIV or AIDS. It is not a cure, but it can stop 
people from becoming ill for many years. The treatment consists of drugs that are taken every 
day for the rest of a person‘s life. The aim of antiretroviral treatment is to keep the amount of 
the virus in the body at a low level. This stops any weakening of the immune system and 
allows it to recover from any damage that HIV might have caused already.  
The drugs are often referred to as:  
 Antiretrovirals;  
 ARVs;  
 anti-HIV or anti-AIDS drugs.  
Taking two or more antiretroviral drugs at a time is called combination therapy. Taking a 
combination of three or more anti-HIV drugs is sometimes referred to as Highly Active 
Antiretroviral Therapy (HAART). If only one drug was taken, HIV would quickly become 
resistant to it and the drug would stop being effective. Taking two or more antiretrovirals at 
the same time vastly reduces the rate at which resistance would develop, making treatment 
more effective in the long term. There are different classes of antiretroviral drugs that act at 
different stages of the HIV Cycle. 
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The key goal of HIV treatment is to slow HIV replication as much as possible and enable 
recovery of the immune system. Antiretroviral drugs are the mainstay of HIV treatment: each 
antiretroviral drug class targets a different step in the viral life-cycle. These include, but are 
not limited to: 
 
 Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NRTIs); 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs); 
 Protease inhibitors; 
 Integrase inhibitors; 
 Fusion inhibitors; 
 CCR5 inhibitors. 
There are a number of other candidate drugs in clinical trials, including one in a class called 
'maturation inhibitors', as well as innovations in immune-based strategies (Thaczuk 2012). 
 
The standard of care for anyone on antiretroviral treatment is highly active antiretroviral 
therapy (HAART), using drugs with at least two different mechanisms of action (for 
example, two NRTIs plus either an NNRTI or a protease inhibitor). Over time, HIV can 
develop mutations that make it resistant to drugs. By targeting multiple steps in the viral life-
cycle simultaneously, the emergence of resistance can be slowed or prevented (Collin &Van 
Lint 2009). 
 
Researchers have also explored other approaches for treating HIV, such as inhibiting cellular 
factors the virus needs for its replication, gene therapy that protects cells from infection, and 
removal of cells that are already infected (Allers et al. 2011). Many of these approaches are 
experimental and some remain purely theoretical. But there is evidence that complementary 
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therapies such as nutrient supplements (used in conjunction with antiretroviral therapy) can 
improve the overall health of people with HIV (Thaczuk 2012). New studies are showing that 
even at CD4 cell counts between 350 and 500 cells/mm
3
, there is a greater risk of morbidity 
and mortality from non-AIDS illnesses (Zolopa et al. 2009). 
 
While viral load suppression is considered an indicator of effective therapy, the ultimate goal 
of treatment is to preserve immune function, increase disease-free survival, and reduce 
mortality (Borrow et al. 2010). 
 
2.2.1. Classes of drugs 
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTI), inhibit reverse 
transcription by being incorporated into the newly synthesized viral DNA and preventing its 
further elongation.  
 
Non nucleoside reverse transcriptase inhibitors (NNRTI), inhibit reverse transcriptase 
directly by binding to the enzyme and interfering with its function. 
 
Protease inhibitors (PIs), target viral assembly by inhibiting the activity of protease, an 
enzyme used by HIV to cleave nascent proteins for final assembly of new virons. 
 
Integrase inhibitors, inhibit the enzyme integrase, which is responsible for integration of 
viral DNA into the DNA of the infected cell. There are several integrase inhibitors currently 
under clinical trial, and raltegravir became the first to receive FDA approval in October 2007. 
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Entry inhibitors (or fusion inhibitors), interfere with binding, fusion and entry of HIV -1 to 
the host cell by blocking one of several targets. 
 
Maturation inhibitors, inhibit the last step in gag processing in which the viral capsid 
polyprotein is cleaved, thereby blocking the conversion of the polyprotein into the mature 
capsid protein. Because these viral particles have a defective core, the virions released consist 
mainly of non infectious particles. 
 
CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 
receptor. The C-C motif chemokine receptor CCR5 is involved in the process by which HIV, 
enters cells. Hence antagonists of this receptor are entry inhibitors and have potential 
therapeutic applications in the treatment of HIV infections (Ledermann et al. 2006). 
 
NRTIs and NNRTIs are available in most countries. Fusion/entry inhibitors and   integrase 
inhibitors are usually only available in resource-rich countries. Protease inhibitors are 
generally less suitable for starting treatment in resource-limited settings due to the cost, 
number of pills which need to be taken, and the particular side effects caused by protease 
drugs. The most common drug combination given to those beginning treatment consists of 
two NRTIs combined with either an NNRTI or a "boosted" protease inhibitor. An example of 
a common antiretroviral combination is the two NRTI‘s zidovudine and lamivudine, 
combined with the NNRTI efavirenz. Some antiretroviral drugs have been combined into one 
pill, which is known as a ‗fixed dose combination‘. This reduces the number of pills to be 
taken each day. Most people living with HIV in the developing world still have very limited 
access to antiretroviral treatment and often only receive treatment for the diseases that occur 
as a result of a weakened immune system. At the beginning of treatment, the combination of 
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drugs that a person is given is called first line therapy. If after a while HIV becomes resistant 
to this combination, or if side effects are particularly bad, then a change to second line 
therapy is usually recommended. 
 
According  to WHO and UNAIDS recommendations, the South African guidelines endorse 
the use of NRTI‘S and NNRTI‘s as first line therapy. For the initiation of ARV therapy, 2 
NRTIs and an NNRTI (one drug from category 1 and one from category 11 and one from 
category IV) may be prescribed. If the viral load is >55,000 a third NRTI (category 111) may 
be considered as part of a triple NRTI regimen.  
 
Table 1. showing categories of antiretroviral agents 
  There are five categories of the antiretroviral drugs shown in this table. 
 
Category 1 Category 11 Category 111 Category 1V Category V 
     
stavudine 
(dTT) 
 
 
zidovudine 
 
didanosine(ddl) 
 
 
zalcitabine(ddc) 
 
 
abacavir(abc) nevirapine 
(Nvp) 
favirenz 
indinavir 
(idv) 
nelfinavir(nfv 
 
 
 ritonavir 
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AZT(3TC) 
 
lamivudine 
 
 saquinavir 
softgel 
formulation) 
lopinavir/riton
avir 
combination 
___________________________________________________________________ 
 
 
 
 
2.2.2. Classes of antiretroviral agents used in public hospitals in South Africa 
Antiretrovirals are deferred until patients are prepared to commit themselves to long term 
treatment and to maintaining good adherence to the therapy. Table 2. below shows the 
classification of antiretrovirals used in South Africa. 
 
Table 2.  The classification of antiretrovirals used in public hospitals in South Africa 
and their specific  action 
  Classification of          Abbreviations      Enzyme inhibited          Specific action           
  antiretroviral agent  
___________________________________________________________________                                                          
  nucleoside reverse       NRTI‘S           reverse transcriptase        mimics the normal  
  transcriptase                                                                          building  blocks of 
   inhibitors                                                                                 HIV DNA.                                                                                                                                                
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  non –nucleoside         NNRTI‘S          reverse transcriptase         directly inhibits 
  transcriptase                                                                      reverse transcriptase  
  inhibitors                                                                                                                                                                      
                                                        
   protease inhibitors      PIs             protease                  inhibits late stages 
                                                                                          of HIV replication 
  _________________________________________________________________ 
                                                                                                                                                                                   
In July 2012 the WHO issued its first guidance to nations, considering providing ARVs 
(antiretrovirals) to HIV-negative, high risk people. WHO says its recommendations were 
based on human trials which showed that administering PrEP (pre-exposure prophylaxis) 
once daily to HIV-negative individuals who are at high risk of becoming infected is both safe 
and effective in helping prevent HIV infection. 
 
The first antiretroviral drug to be licensed, zidovudine, became available in 1987. Until 
December 1995, the antiretroviral drugs available and approved for clinical use in the United 
States consisted of only five individual drugs belonging to a single class of antiretroviral 
agents, nucleoside analogue reverse transcriptase inhibitors. Since then, numerous other 
antiretroviral drugs and classes of antiretroviral drugs have been introduced.  
 
There are currently more than 20 approved antiretroviral drugs in the US and Europe 
(including combined formulations) and many more in the expanded access 
programmes and trials. Most antiretroviral drugs have at least three names. 
Sometimes a drug is referred to by its research or chemical name, such as AZT. The 
second name is the generic name for all drugs with the same chemical structure; for 
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example AZT is also known as zidovudine. The third name is the brand name given 
by the pharmaceutical company; one of the brand names for zidovudine is Retrovir. 
Lastly, an abbreviation of the common name might sometimes also be used, such as 
ZDV, which is the fourth name given to zidovudine.  
 
Brand name of drugs and date of approved drugs by the US Food and Drug 
Administration (FDA) are classified as follows:  
Multi-class combinations: 
Combination               Brand name                       Date of FDA approval  
EFV + TDF + FTC                atripla                        12-Jul-06 
d4T + 3TC + NVP                 -                         tentative only*  
AZT + 3TC+ NVP                 -                         tentative only*  
    
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs):  
Abbreviation                  Generic name  
 
     Date of FDA approval  
3TC                 lamivudine  
 
               17-Nov-95  
ABC                 abacavir  
 
               17-Dec-98  
AZT or ZDV                 zidovudine 
 
               19-Mar-87  
d4T                 stavudine 
 
               24-Jun-94  
ddI                 didanosine 
 
               31-Oct-00  
FTC                 emtricitabine  
 
               02-Jul-03  
TDF                 tenofovir  
 
               26-Oct-01  
 
Combined NRTIs:  
Combination                  Brand name                 Date of FDA approval  
ABC + 3TC  
              epzicom (US)  
                       02-Aug-04  
              kivexa (Europe)  
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ABC + AZT + 3TC               trizivir                        14-Nov-00  
AZT + 3TC                combivir                         27-Sep-97  
TDF + FTC                truvada                         02-Aug-04  
d4T + 3TC  -                         Tentative only*  
 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):  
Abbreviation  Generic name                      Date of FDA approval  
DLV  delavirdine 
 
                             04-Apr-97  
EFV  efavirenz                               17-Sep-98  
 
ETR  etravirine 
 
                             18-Jan-08  
NVP  nevirapine  
 
                             21-Jun-96  
 
rilpivirine 
 
                             20-May-11  
 
Protease Inhibitors (PIs):  
Abbreviation                     Generic name                    
 
Date of FDA approval  
APV  amprenavir                           
 
                          15-Apr-99  
FOS-APV  fosamprenavir  
 
                          20-Oct-03  
 
ATV  atazanavir
8
 
  
                          20-Jun-03  
DRV  darunavir  
  
                          23-Jun-06  
IDV  indinavir  
  
                          13-Mar-96  
LPV/RTV  lopinavir+ritonavir  
 
                          15-Sep-00  
 
NFV  nelfinavir  
  
                          14-Mar-97  
RTV  ritonavir  
  
                          01-Mar-96  
SQV  saquinavir  
  
                          06-Dec-95  
 
Fusion or Entry Inhibitors:  
Abbreviation  Generic name                   Date of FDA approval  
T-20  enfuvirtide 
                            13-Mar-03  
 
MVC  maraviroc                                18-Sep-07  
 
Integrase Inhibitors:  
Abbreviation  Generic name      Date of FDA approval  
RAL  raltegravir                             12-Oct-07  
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The  South Afica Department of Health has endorsed the replacement of d4T with TDF for 
first-line regimens (South Afican DOH 2012). Table 3 presents the antiretroviral drugs 
currently avalable in South Africa. 
 
Table 3. Antiretroviral agents currently available in South Africa 
 
______________________________________________________ 
GENERIC NAME              TRADE NAME                   CLASS OF DRUG 
____________________________________________________________ 
zidovudine (AZT)   retrovir *   NRTI 
didanosine (ddI)   videx *   NRTI 
zalcitabine (ddC)   hivid       NRTI 
lamivudine (3TC)   3TC *    NRTI 
stavudine (d4T)   zerit *    NRTI 
abacavir    ziagen *               NRTI 
nevirapine    viramune *                   NNRTI 
efavirenz    stocrin    NNRTI 
nelfinavir    vira-cept *   PI 
indinavir    crixivan    PI 
ritonavir    norvir *                        PI 
saquinavir(hard gel 
formulation) 
invi-rase  PI 
saquinavir (soft gel 
formulation) 
forto-vase         PI 
amprenavir Preclir *      PI 
lopinavir/ritonavir Kaletra            PI 
 
* Available in paediatric formulations 
 
_______________________________________________________ 
  
 
 
2.2.3. South African HIV Clinicians Guidelines  for Antiretrovirals 
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 The primary goals of antiretroviral therapy are: 
 maximal and durable suppression of viral load; 
 restoration and/or preservation of immunological function; 
 improvement of quality of life and; 
 reduction of HIV related morbidity and mortality. 
In accordance with WHO and UNAIDS recommendations, the guidelines for the 
treatment of HIV endorse the use of NRTIs and NNRTIs as first-line therapy. 
For initiation of HAART therapy 2 NRTIs and an NNRTI (one drug from Category 1, 
one from Category 11, and one from Category 1V) is prescribed. If the viral load is 
<55 000 a third NRTI (Category 111) may be considered as part of a triple NRTI 
regimen.  
 
 
 
 
 
 
 
 
 
 
 
  Below are indications for starting antiretrovirals in South Africa (Table 4). 
     Source:(South Africa Clinicians Society Clinical Guideline). 
 
48 
 
      Table 4.  Indications for starting antiretrovirals in South Africa 
    Symptomatic patient                                          Treatment 
     ______________________________________________________ 
    Presence of HIV related symptoms,                   Treatment recommended 
    current or previous HIV associated                          
    disease* 
    Primary infection**                                               Treatment recommended 
 
     Asymptomatic patient with                                Treatment 
     CD4
+ 
count<200                                            Treatment recommended 
     CD4+ count 200 -350                                        Monitor CD4+ count  
                                                                         Commence treatment if 
                                                                         the  CD4 annual decline is in 
                                                                         excess of the expected 20-80 
                                                                          cells/year or if the  CD4  
                                                                          count approaches 200. 
                                                                               
     CD4+  count >350                                              Defer treatment 
  _____________________________________________________________________ 
 
   
      
                                                                                                                                                                                                                              
   2.2.4. Recommendations for changes in treatment pattern 
    In 2009 the  South Africa National Aids Council (SANAC) Treatment Technical Task Team 
(TTT) finalized recommendations for changes to the national standard treatment guidelines for 
adult,  paediatric management and treatment, as well as the changes in the prevention of mother 
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to child transmission (PMTCT)  of HIV guidelines. At the same time, the Department of Health 
convened a working group on costing the antiretroviral treatment (ART) programme, consisting 
of the Department of Health, the US Government, the Clinton Foundation Health Access 
Initiative, and the Boston University/Health Economics and Epidemiology Research Office. 
These two initiatives laid the groundwork for the announcement by the South African 
President, Mr Zuma on World AIDS Day (1 December 2009), for changes in the national 
HAART programme. Subsequently, additional changes were made to the treatment guidelines 
to be in line with these new Presidential mandates, which are effective as of the new 
government financial year, 1 April 2010.   Due to the high cost associated with ART, and the 
high burden of people in need of ART in South Africa, eligibility criteria have been adapted 
only for priority groups. These are:  
HIV-infected pregnant women; 
 HIV-infected infants; 
 people with both TB and HIV infection; and 
 people with multi-drug resistant (MDR) or extensively drug resistant (XDR) TB. 
 The other major change to the treatment guidelines is the decentralisation of HIV care and 
treatment to a primary health care (PHC) level, as contained in the 2007-2011 National 
Strategic Plan (NSP).  
2.2.5. Eligibility to Start ART  
The followings are the eligibility criteria for starting ART. 
 CD4 count <200cells/mm3 irrespective of clinical stage ;   
 CD4 count <350cells/mm3 in patients with TB/HIV co-infection, 
  or pregnant women ;  
 WHO stage 4 disease, irrespective of CD4 count ;   
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 MDR/XDR TB, irrespective of CD4 count.  
In addition, certain patients are fast-tracked to be initiated on ART, which means they should 
be started within two weeks of receiving their CD4 result, and choosing to start lifelong 
ART:  
 pregnant women;  
 patients with a CD4 level below 100;  
 any patient with WHO Stage 4 disease; 
 any patient with MDR or XDR TB;  
 any patient that tests HIV positive, but do not yet meet eligibility criteria, should be 
enrolled in a wellness programme, with repeat CD4 tests every 6 months. 
To assist with this, the Department of Health is introducing a national standard pre-ART 
register to allow for follow-up. If the TB screening rules out active TB, HIV-infected patients 
should be started on pimary prophylaxis against tuberculosis. 
 
2.2.6. National regimens for adults and adolescents 
National regimens for adults and adolescents are prescribed using first and second line 
drugs. 
2.2.6.1. First Line 
All new patients, including pregnant women: tenofovir + lamivudine/emtracitibine + 
efavirenz/nevirapine.  
Currently on a stavudine-based regimen, with no side-effects: stavudine + 
lamivudine + efavirenz.  
Patients with renal problems (for which tenofovir is contraindicated): zidovudine + 
lamivudine + efavirenz/nevirapine.  
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2.2.6.2. Second Line  
Failing on a stavudine or zidovudine-based first line regimen: tenofovir + 
lamivudine/emtricitabine + lopinavir/ritonavir. Failing on a tenofovir-based first line 
regimen: zidovudine + lamivudine + lopinavir/ritonavir.  
 
2.2.7. Clinical and Laboratory Monitoring  
There have been only minor changes to the guidelines in terms of monitoring tests, 
with the major change being the reduction in the periodicity of some tests (e.g. CD4 
and Viral Load only done at month 6, month 12, and then every 12 months only), and 
the addition of creatinine clearance to identify any toxicity to tenofovir.  
 
2.2.8. Children and HAART 
For children, eligibility criteria to start HAART are:  
 All children under 1 year of age, irrespective of CD4 level;  
 Children between 1 and 5 years with clinical stage 3 or 4, or a CD4 percentage of 25 or 
below, or with an absolute CD4 count under 750 cells/mm
3
;  
 Children over 5 years  and up to 15 years  with clinical stage 3 or 4, or CD4 350 cells/mm3 
and below.  
 
The first line regimens for children are:  
 Infants and children under 3: abacavir + lamivudine + lopinavir/ritonavir;  
 Children 3 years  and older: abacavir + lamivudine + efavirenz.  
If a child is currently on a stavudine-based regimen, and is not experiencing any side 
effects, the regimen should be maintained. Substitutions are only made once lipodystrophy is 
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suspected. 
 
2.3. The Vasculature 
The blood vessels are the part of the circulatory system that transports blood 
throughout the body. There are three major types of blood vessels: the arteries, which 
carry blood away from the heart; the capillaries, which enable the actual exchange of 
water and chemicals between the blood and the tissues; and the veins, which carry 
blood from the capillaries back toward the heart. The arteries and veins both have 
three layers, but the middle layer is thicker in the arteries than it is in the veins. 
 
 
 
 
 
Figure 6. is a cross section of a blood vessel showing the different layers. 
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Figure 6. A section of a blood vessel. 
Source:http://www.courseweb.uoottawa.ca/medicine. 
 
2.3.1. Arteries 
Arteries carry blood away from the heart. They are classified into three types according to 
their sizes: large or elastic arteries; medium (or muscular or distributive) arteries; and small 
arteries or arterioles, which are less than 0.5 mm in diameter. These types are all continuous 
with one another. A characteristic feature of arteries, regardless of size, is a well-defined 
lumen, rounded or oval, maintained by the muscularity of the vessel wall.  
 
 
Figure 7. shows the wall of a large  artery at 400x magnification. The blue arrow  indicates 
the tunica intima.  The black bracket represents the tunica media and the green bracket is the 
tunica adventitia.  
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Figure 7. A large artery. Source:(http://www.courseweb.uoottawa.ca/medicine. 
 
The aorta and its branches (brachiocephalic, subclavian, pulmonary, beginning of common 
carotid and iliac) are distinguished by their great elasticity. This helps them smoothen out the 
large fluctuations in blood pressure created by the heartbeat. During systole, their elastic 
laminae are stretched and reduce blood pressure. During diastole, the elastic rebound helps 
maintain arterial pressure. 
 
2.3.1.1. Tunica intima  
Large arteries often have  large subendothelial layers, which grow with age or disease 
conditions (arteriosclerosis). Both connective tissue and smooth muscle are present in the 
intima. The border of the intima is delineated by the internal elastic membrane. The internal 
elastic membrane may not be conspicuous because of the abundance of elastic material in the 
tunica media. 
2.3.1.2.Tunica media 
This is the thickest of the three layers. The smooth muscle cells are arranged in a spiral 
around the long axis of the vessel. They secrete elastin in the form of sheets, or lamellae, 
which are fenestrated to facilitate diffusion. The number of lamellae increase with age (few at 
birth, 40-70 in adult) and with hypertension. These lamellae, and the large sizes of the media, 
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are the most striking histological features of elastic arteries. In addition to elastin, the smooth 
muscle cells of the media secrete reticular and fine collagen fibres and proteoglycans.  
 
2.3.1.3.Tunica adventitia 
This is a relatively thin connective tissue layer. Fibroblasts are the predominant cell type, and 
many macrophages are also present. Collagen fibres predominate and elastic fibres (not 
lamellae) are also present. The collagen in the adventitia prevents elastic arteries from 
stretching beyond their physiological limits during systole. Blood vessels supplying the 
adventitia and outer media are  present and are called vasa vasorum ("vessels of the vessels"). 
The inner part of the media is supplied from the lumen via pinocytic transport.  
 
2.3.1.4. Medium arteries 
The majority of named arteries are medium (muscular or distributive) arteries (Figure 8). 
There is no sharp dividing line between elastic (large) and muscular (medium) arteries; 
Medium arteries have less elastic tissue than large arteries, the predominant constituent of the 
tunica media is smooth muscle.  
 
 Figure 8. Muscular or medium artery. 
Source:http://www.courseweb.uoottawa.ca/medicine. 
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2.3.1.4.1. Tunica intima of medium arteries 
The tunica intima is thinner in medium arteries than in large arteries, there are fewer smooth 
muscle cells and less elastic tissues. The outermost part of the intima is defined by a very 
prominent internal elastic membrane (not obscured by elastic lamellae as in large arteries). 
The basement membrane of the endothelium may rest directly on the internal elastic 
membrane, or be separated by a subendothelial layer. The tunica intima increases in thickness 
with age, and may also become expanded by lipid deposits.  
 
2.3.1.4.2.Tunica media  
Smooth muscle cells predominate in the tunica media, and little elastic material is present. As 
in large arteries, no fibroblasts are present. Elastic fibres (few), collagen, and ground 
substance are produced by the smooth muscle cells. These are arranged in a spiral fashion and 
their contraction help maintain blood pressure. In tissue preparation, the internal elastic 
membrane of the intima appears wavy due to the contraction of the smooth muscle of the 
media.  
 
2.3.1.4.3. Tunica adventitia  
The main constituent of the adventitia is collagen fibres, secreted by fibroblasts. Elastic fibres 
are also present, a concentration of such fibres at the inner boundary of the adventitia is 
called the external elastic membrane. The external elastic membrane is not as prominent as 
the internal, and as arteries get smaller it disappears much earlier. The tunica adventitia is 
relatively larger than in elastic arteries, it can be up to the same size as the media. Adipose 
cells may be present. 
 
2.3.1.5. Small arteries 
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The general features of small arteries are very similar to that of muscular arteries (figure 9). 
The media is still muscular and has up to 8-10 layers of smooth muscle cells. This number is 
reduced as the arteries get smaller, the smallest arterioles have 1-2 layers of smooth muscle 
cells. The adventitia becomes thinner and the external elastic membrane disappears. The 
intima becomes smaller and the internal elastic membrane also eventually disappears. 
However, it persists much longer than the external, and it is not uncommon to see very small 
arteries which still have an internal elastic membrane. Small arteries also maintain their 
shape, and tend to be round or oval.  
 
 
Figure 9. A small artery or arteriole.  
Source: (http://www.courseweb.uoottawa.ca/medicine). 
 
2.3.2.  Veins 
Veins are the vessels that return blood to the heart. Like arteries, they are classified as large, 
medium and small, and the sizes blend into one another with no sharp demarcations. 
Although the same layers (intima, media and adventitia) are present, they are often not as 
well defined as in arteries. A big difference between arteries and veins is the thickness of 
their walls and the relative amount of muscle tissue (media). In comparably sized vessels, 
arteries have thicker walls and a much larger media. In veins, the adventitia is larger than the 
media. Because of these features, veins do not retain their shape. They often appear floppy in 
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sections, and the lumen may not be patent. Veins are frequently of an irregular shape. Veins 
also have less elastic tissue than do arteries. Even in larger veins, the internal elastic 
membrane may be poorly developed or absent. Valves, which function to prevent the 
backflow of blood especially in the lower part of the body, are also seen quite frequently in 
veins. Veins often travel in close proximity to their arterial counterparts, which is convenient 
for histological comparison. The endothelium appears to have been stripped away as no 
endothelial cell nuclei are identifiable. Bundles of smooth muscle sit in the wavy collagen 
fibres of the adventitia. Blood vessels (vasa vasorum) are also present. 
 
2.3.2.1. Medium veins 
The tunica consists of the endothelium and a thin subendothelial layer with smooth muscle 
cells among the connective tissue elements. A thin internal elastic membrane may or may not 
be present. The tunica media is much thinner relative to that of an artery, and consists mostly 
of circularly arranged smooth muscle but also contains collagen fibres. The tunicas intima 
and media therefore tend to be less distinct from one another than is the case in arteries. The 
tunica adventitia is usually thicker than the media and is made up mostly of collagen fibres. It 
may contain longitudinally oriented smooth muscle bundles 
 
2.3.2.2. Small artery and vein 
The media of the small artery is much larger than that of the small veins. A few bulgy 
endothelial cells can be seen in the artery, but otherwise an intima is not distinguishable. 
Elastic tissue is also not identifiable. A few flattened endothelial cells appear to be present in 
the vein. The adventitia of the vessels blends in with the surrounding connective tissue.  
 
2.3.3. Capillaries 
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Capillaries are the smallest diameter vessels and the site of exchange of metabolites between 
blood and tissues. Capillaries are just wide enough to allow the passage of red blood cells, 
only one cell at a time. Capillaries consist of a single layer of endothelial cells and their 
basement membrane. The endothelial cells are joined together by tight junctions. At intervals, 
these tight junctions are interrupted, leaving small spaces allowing the passage of fluid 
between blood and extracellular fluid. These interruptions do not occur in the brain, and the 
lack thereof is responsible for the blood-brain barrier present in most of the brain. Endothelial 
cells also have pinocytotic vesicles which are involved in transporting macromolecules.  
 
2.3.4. The Endothelium 
The endothelium  as shown in Figure 10, lines the blood vessels throughout the body, from 
the larger arteries and veins down to the small capillaries that branch through organs. The 
endothelium is the thin layer of cells that lines the interior surface of blood vessels and 
lymphatic vessels, forming an interface between circulating blood and lymph in the lumen 
and the rest of the vessel wall. 
 
Figure 10. Cross section showing the endothelium of a blood vessel. 
Source:http://www.gettyimages.com/creative/endothelium. 
 
2.3.4.1. Structure of the Endothelium 
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Endothelial cells in direct contact with blood are called vascular endothelial cells whereas 
those in direct contact with lymph are known as lymphatic endothelial cells (figure 11). The 
cells are arranged, edge to edge, in a single layer. The wavy or denticulate edges of 
neighbouring cells fit into each other, being separated by a mere line of the intercellular 
substance which in this tissue has received the name of cement substance.  
The endothelium, the largest organ in the body, is strategically located between the wall of 
blood vessels and the blood stream. Endothelial cells possess thin membranous  bodies, 
except at the site of the nucleus. The intercellular substance is minimal in amount; clear and 
homogeneous in character.  The cells of endothelium vary somewhat in size and shape. They 
may be polygonal, rhomboid, or stellate in form, and during life are soft and extensible so 
that their sizes may be modified by stretching or tension in one or more directions. The cell-
bodies, or cytoplasm, are usually clear and apparently structureless or only slightly granular, 
but occasionally some of the cells are smaller and more granular than the majority. The 
endothelial cell layer represents a mechanical and biological barrier between the blood and 
blood and the vascular wall and is likely to serve as the ‗missing link‘ between any given risk 
factor and its detrimental vascular effects.  
 
The location of the endothelium as seen in the wall of a  blood vessel in Figure 11. It is such 
that it is often the first structure to be exposed to any changes in blood and is therefore the 
first to be able to respond to such changes.  
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 Figure  11.   The endothelium of a blood vessel. 
Source: http://www.gettyimages.com/creative/endothelium. 
 
 
 
2.3.4.2.  Some substances released from the endothelium 
Among the vasodilatory, vasoconstrictor and other substances, produced by the 
endothelium are nitric oxide (NO), prostacyclin, different endothelium-derived 
hyperpolarizing factors, and C-type natriuretic peptide (Table 4). The pioneering 
experiments of Furchgott and Zawadiski in (1980) first demonstrated an 
endothelium- derived relaxing factor that was subsequently shown to be nitric oxide 
(NO).  
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Table 5. Substances released by endothelium 
____________________________________________________________________ 
Substances                                     Examples 
 
___________________________________________________________ 
 
Vasodilators :                      Nitric oxide; bradykinin; prostacyclin; endothelium- 
derived hyperpolarizing factor; serotonin; 
histamine; substance P. 
Vasoconstrictors:                 Angiotensin II (AII); endothelin (ET-1); 
thromboxane A2; serotonin; arachidonic acid; 
prostaglandin H2; thrombin. 
Promoters:                            Platelet derived growth factor (PDGF); basic 
fibroblast growth factor (PGF); insulin-like growth 
factor – I (IGF-I); endothelin (ET1); Angiotensin. 
Inhibitors:                             Nitric oxide; prostacyclin; bradykinin; heparin 
sulfate; transforming growth factor I (TGFB). 
Adhesion molecules:            Endothelial leukocyte adhesion molecule; 
intercellular adhesion molecule (ICAM); vascular 
cell adhesion molecule (VCAM). 
Thrombolytic factors:   Tissue-type plasminogen activator; plasminogen 
activator inhibitor-1 (PAI-I); Thrombomodulin.             
___________________________________________________________ 
 
 
Source: http://geocities.com/agnihotrimed. and Chhobra, N., (2009) Internet Journal 
of Medical update vol 4. No1.  
                   
 
2.3.4.3. Functions of the endothelium 
The endothelium  performs multiple functions that are often modified by regional 
location. Endothelial cells which line the internal lumen of the vasculature are part of 
a complex system that regulates vasodilatation, vasoconstriction, and growth of 
vascular smooth muscle, inflammation and haemostasis. They also maintain proper 
blood supply to tissues and regulate inflammation (Zhang 2008).   
 
2.3.4.4. The endothelium and NO 
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 There is increased intercellular Ca
++
 in response to vasodilator agonists or shear stress which 
displaces the inhibitor caveolin from calmodulin (CaM), activating nitric oxide Synthase 
(eNOS). eNOS can be activated, upon stimulation of the endothelium by a variety of stimuli 
including shear stress, substance P and acetyl choline. The most critical of the substances 
released by the endothelium is nitric oxide (NO), which is produced by the conversion of the 
substrate L-arginine to L-citrulline by the enzyme, nitric oxide synthase (eNOS). This 
reaction requires a number of cofactors, including tetrahydrobiopterin (BH4) and 
nicotinamide adenine dinucleotide phosphate (NADPH) (Forstermann and Munzel 2006). NO 
thus formed diffuses into the underlying vascular smooth muscles to stimulate the activation 
of guanylate cyclase, which in turn converts guanosine triphosphate (GTP) to the smooth 
muscle relaxant compound cyclic guanosine monophosphate (c-GMP) in the vascular smooth 
muscle cells. The increase in c-GMP leads to activation of cyclic GMP- dependent protein 
kinase, which in turn leads to phosphorylation of potassium dependent channels with 
consecutive hyperpolarization and extrusion of calcium ions resulting in VSMC (vascular 
smooth muscle cell) relaxation.  
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Figure 12: Production of nitric oxide (NO) by eNOS from endothelial cells 
and its action on smooth vascular cell to produce relaxation. Source: 
Chhobra, N., (2009) Internet Journal of Medical update vol 4. No1.  
 
Nitric oxide not only produces vasodilatation, but it also participates in various processes that 
are beneficial to the vasculature such as reduction of vascular smooth muscle cell migration 
and growth, platelet aggregation and thrombosis, monocyte and macrophage adhesion and 
inflammation. In general the substances released by the endothelium have important 
autocrine as well as paracrine functions and help to maintain not only the normal health of 
vascular wall but also control the haemostatic functions and the haemodynamic balance of 
the entire body (Libby et al. 2002). 
 
Factors such as smoking, dyslipidemia, diabetes, aging and sedentary lifestyle have 
all been shown to reduce NO synthesis and therefore impair endothelial function. 
 
2.3.4.5. The endothelium,vasoconstrictors and other modulators  
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Vasoconstrictors include endothelin-1 (ET-1), angiotensin II (Ang II), thromboxane 
A2, and reactive oxygen species (ROS). Inflammatory modulators include NO, 
intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), 
E-selectin, and NF-κB. Modulation of haemostasis includes release of plasminogen 
activator, tissue factor inhibitor, von Willebrand factor, NO, prostacyclin, 
thromboxane A2, plasminogen-activator inhibitor-1, and fibrinogen.  
 
Endothelin-1 acts via 2 receptor subtypes, endothelin-A and endothelin-B (ET-A and 
ETB), which are expressed in varying quantities. Endogenous levels of ET-1 act via 
ET-A to induce coronary vasoconstriction but also serve to increase smooth muscle 
proliferation and induce cytokine production in vitro (Davignon & Ganz, 2004). 
Selective antagonism of ET-A receptors has been shown to improve endothelial 
function (Verhaar et al. 1998). The endothelium also contributes to mitogenesis, 
angiogenesis, vascular permeability, and fluid balance. Vasoactive mediators on the 
endothelium include bradykinin and thrombin.  
  
In addition to providing a balance between vasoconstriction, vasodilatation and pro-
coagulation, the endothelium is the source of growth factors and cytokines 
(Krishnaswamy et al. 2004). It is also involved in the remodeling of vascular 
structure and long term organ perfusion. 
 
 
2.3.4.6. Endothelial dysfunction 
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Endothelial dysfunction is broadly used to describe any defect in the endothelium. 
However it often refers to an impaired NO system either by reduced NO production 
or increased breakdown due to oxidative stress. 
 
Endothelial dysfunction is a systemic pathological state of the inner lining of the blood 
vessels. It can be broadly defined as an imbalance between vasodilating and vasoconstriction 
substances produced by (or acting on) the endothelium (Deanfield et al. 2007). What is 
generally referred to as endothelial dysfunction should be more appropriately considered as 
endothelial activation, which may eventually contribute to arterial disease when certain 
conditions are fulfilled. 
 
Endothelial activation represents a switch from a quiescent state to one that involves the host 
defence response (Deanfield et al. 2007). Endothelial dysfunction is now regarded as an early 
pivotal event in atherogenesis and has been shown to precede development of clinically 
detectable atherosclerotic plaques in the coronary arteries. It has also been considered an 
important event in the development of microvascular complications in diabetes. Endothelial 
dysfunction, aside from denoting impaired endothelium dependent vasodilatation, also 
comprises a specific state of ‗Endothelial activation‘ which is characterized by a pro-
inflammatory, proliferative and procoagulatory milieu that favours all stages of 
atherogenesis.  
 
 
2.3.4.7. Endothelial dysfunction and NO 
A key and quantifiable feature of endothelial dysfunction is the inability of arteries and 
arterioles to dilate fully in response to an appropriate stimulus that stimulates release of 
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vasodilators from the endothelium like NO. Endothelial dysfunction is commonly associated 
with decreased NO bioavailability which is due to impaired NO production by the 
endothelium and/or increased inactivation of NO by reactive oxygen species (Lopez et al. 
2005).This can be tested by direct administration of various vasoactive agents to segments of 
blood vessels.  It is thought that people with endothelial dysfunction have low NO 
bioavailability in their blood vessels. They also have a decreased capacity to dilate in 
response to certain stimuli compared to those with normal endothelial function (Deanfield et 
al. 2005). 
 
2.3.4.8. Endothelial dysfunction and artherosclerosis  
Endothelial dysfunction  is  a chronic inflammatory response in the walls of arteries, which 
cal also be caused largely by the accumulation of macrophage white blood cells and 
promoted by low-density lipoproteins. Endothelial dysfunction is thought to be a key event in 
the development of atherosclerosis and predates clinically obvious vascular pathology by 
many years (Mondy et al. 2008). Decreased NO and increased local mediators, increased 
adhesion molecules, cytokines and growth factors leads to vasoconstriction, plaque rupture 
and inflammation (Figure 13). 
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Figure 13. Role of endothelial dysfunction in the causation and progression of 
atherosclerosis.  
Source: http://geocities.com/agnihotrimed.  Chhobra, N., (2009) Internet Journal of Medical 
update vol 4. No1 
 
Given this relationship between endothelial dysfunction and atherosclerosis, it is likely that 
the status of endothelial function may reflect the propensity of an individual to develop 
atherosclerotic disease, and thus the presence of endothelial dysfunction may serve as a 
marker of an unfavorable cardiovascular prognosis (Kinlay & Ghanz, 1997). Although the 
association between cardiovascular risk factors and atherosclerotic disease is well 
documented, the mechanism by which these risk factors induce lesion formation leading to 
the events is not entirely defined (Kinlay & Ghanz, 1997).    
   
By reacting with NO, ROS may reduce vascular NO bioavailability and promote cell damage. 
Hence increased oxidative stress is considered a major mechanism involved in the 
pathogenesis of endothelial dysfunction and may serve as a common pathogenic mechanism 
of the effect of risk factors on the endothelium (Chhabra, 2009). 
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Risk to develop endothelial dysfunction increases with the number of risk factors present in 
an individual, but the potential to alter endothelial function may vary between risk factors 
(Chhabra 2009). Taken together, the status of endothelial function represent an integrated 
index of both the overall cardiovascular risk factor burden and the sum of all 
vasculoprotective factors in any given individual (Chhabra  2009). Given its pivotal role in 
the atherogenic process, endothelial dysfunction may be regarded as the ―ultimate risk of the 
risk factors‖ indicating the existence of a specific atherogenic vascular milieu which is 
associated with perfusion abnormalities and cardiovascular events (Bonneti et al 2003).  
 
Endothelial dysfunction is characterized by a reduced ability of vessels to vasodilate. 
Subsequently, there is an accumulation of platelets, fibrin and monocytes over the injured 
endothelium; these then release substances such as platelet derived growth factor (PDGF), 
and tissue growth factor B, (TGF-B) which stimulate smooth muscle proliferation and 
connective tissue production. Most cardiovascular risk factors activate molecular machinery 
in the endothelium that results in expression of chemokines, cytokines and adhesion 
molecules. These are designed to interact with leucocytes, platelets and target inflammation 
to specific tissues (Hanson 2006).  
HIV associated activated macrophages may predispose subjects to endothelial dysfunction 
and enhance atheroma formation. Consistent association between HIV infection and
 
elevated 
risk of atherosclerosis suggested a connection between
 
virus-induced changes in cholesterol 
metabolism and atherogenesis,
 
but the mechanisms of such connection have not been 
identified
 
(Bukrinsky et al 2006, Cui et al 2009). Both endothelial dysfunction and arterial 
stiffness are considered surrogate markers of cardiovascular disease and future risk. Several 
studies have assessed endothelial function in HIV infected patients with associated 
cardiovascular risk factors. Jose et al (2006) reported a link between endothelial function and 
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cardiovascular risk in HIV infected patients under treatment, when he compared these 
patients to treatment naïve and control patients.  
 
Atherosclerosis is a hardening of an artery specifically due to an atheromatous plaque.  
Atherosclerosis (also known as arteriosclerotic vascular disease or ASVD) is a condition in 
which an artery wall thickens as a result of the accumulation of fatty materials such as 
cholesterol. It is a syndrome affecting arterial blood vessels. Atherosclerosis is a chronic 
disease that remains asymptomatic for decades (Finn et al 2010). The progression of 
atherosclerosis is due to endothelial dysfuncyion and starts ealy in life (Okumura et al 2005) 
(Figure14). 
 
Atherosclerosis is a complex disease involving the arterial part of the vasculature. It is a 
fibroproliferative inflammatory process that proceeds through a series of pathological events 
involving the cardiovascular system, the inflammatory and immune systems, lipid and 
cholesterol handling mechanisms and blood clotting mechanisms. The disease is modulated 
by genetic and environmental factors with respect to the end point presentation of the 
atherosclerotic plaque.  
 
The term atherogenic is used for substances or processes that cause atherosclerosis. The 
following terms are similar, yet distinct, in both spelling and meaning, and can be easily 
confused: arteriosclerosis, arteriolosclerosis, and atherosclerosis.  Arteriosclerosis is a general 
term describing any hardening (and loss of elasticity) of medium or large arteries. 
Arteriolosclerosis is any hardening (and loss of elasticity) of arterioles.   
 
71 
 
Atherosclerosis develops from low-density lipoprotein molecules becoming oxidized (LdL-
ox) by free radicals, particularly reactive oxygen species (ROS).  When oxidized 
LDL comes in contact with an artery wall. 
 
 
 
Figure 14. Section through a blood vessel showing endothelial dysfunction leading to 
atherosclerosis. Source: The American Heritage @medical Dictionary Copyright @2010 by 
Houghton Mifflin Harcourt Publishing Company. 
 
The LDL molecule is globular shaped with a hollow core to carry cholesterol throughout the 
body. Once inside the vessel wall, LDL molecules become susceptible to oxidation by free 
radicals (Sparrow et al 1993), and become toxic to the cells. Oxidatively modified LDL 
induces the vascular wall cells to synthesize a chemoattractant cytokine, MCP-1 (Romano et 
al 2000, Munro et al. 1996). Cytokines (protein mediators of inflammation) such as IL-1 and 
TNF-α  induce or augment the expression of the adhesion molecules (VCAM-1 and ICAM-1) 
on the endothelial surface (Libby et al. 2002). VCAM-1 is an immunoglobulin-like adhesion 
72 
 
molecule expressed on activated endothelial cells (Osborn et al. 1989). It is  is expressed 
principally on endothelial cells, where it is cytokine-inducible and facilitates leukocyte 
adhesion. VCAM-1 up-regulation has been shown to be important in inflammatory diseases 
including atherosclerosis, where induction precedes leukocyte adhesion and transmigration 
across the vascular endothelium (Ley & Huo 2001).  VCAM-1 binds to α4β1 integrin, which 
is constitutively expressed on  T lymphocytes, monocytes, and eosinophils, the first step of 
invasion of the vessel wall by inflammatory cells. The expression of VCAM-1, ICAM-1, and 
E-selectin plays a role in the initiation of the inflammatory process. Monocytes are 
transformed to lipid-loaded foam cells.  (Libby 2002). 
 
LDL is formed in the early stages of atherosclerosis, while ox-LDL is formed in the later 
stages (Kuhn & Chan 1997). Although LDL binds to LDL receptor and ox-LDL binds to 
scavenger receptor, the vascular effects of minimally modified LDL and ox-LDL are similar. 
Both of these derivatives activate endothelial cells, smooth muscle cells and monocytes. They 
also facilitate vasoconstriction, thrombosis and platelet aggregation associated with the 
activation of intracellular protein kinases and transcription factors such as NFκB or activator 
protein-1. Ox-LDL also induces a vasoconstrictor state by reducing the formation of the 
endothelium-derived vasodilators NO and prostaglandin while enhancing the production of 
the vasoconstrictor endothelin-1 (ET-1).   
  
The damage caused by the oxidized LDL molecules triggers a cascade of immune responses 
which over time can produce an atheroma. A series of reactions occur to repair the damage to 
the artery wall caused by oxidized LDL.  Platelets also play an important role in the 
pathophysiology of atherosclerosis in that they induce the formation of monocyte 
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chemotactic protein 1 (MCP-1) and the expression of  Intercellular adhesion molecule 
(ICAM-1).  
 
Once resident in the intima, the monocytes differentiate into macrophages and cause the 
enhanced expression of scavenger receptors, which bind lipoproteins for endocytosis. In an 
effort to clear the lipids, these macrophages first attach the lipoproteins to the scavenger 
receptors, and they result in the formation of foam cells. The formation of foam cells is the 
hallmark of atherosclerotic lesions. Ox-LDL is chemotactic for monocytes and T-cells. Lack 
of the LDL receptors responsible for endocytosis is seen in patients with familial 
hypercholesterolemia, where they have an abundance of arterial lesions and multiple 
xanthomata containing foam cell-rich lesions. Macrophages engulfing the modified 
lipoproteins produce cytokines and growth factors, which in turn cause further recruitment of 
the macrophages and vascular smooth muscle cell to the site of the lesion. 
The atheromatous plaque is divided into three distinct components: 
 The atheroma which is the nodular accumulation of a soft, flaky, yellowish material at the 
center of large plaques, composed of macrophages nearest the lumen of the artery; 
 underlying areas of cholesterol crystals; 
 calcification at the outer base of older/more advanced lesions. 
The pathophysiology of atherosclerotic lesions is very complicated but generally, stable 
atherosclerotic plaques, which tend to be asymptomatic, are rich in extracellular matrix and 
smooth muscle cells, while unstable plaques are rich in macrophages and foam cells and the 
extracellular matrix separating the lesion from the arterial lumen (also known as the fibrous 
cap) is usually weak and prone to rupture. Ruptures of the fibrous cap expose thrombogenic 
material, such as collagen  to the circulation and eventually induce thrombus formation in the 
74 
 
lumen (Didangelos et al. 2009). Upon formation, intraluminal thrombi can occlude arteries 
outright (i.e. coronary occlusion), but more often they detach, move into the circulation and 
eventually occlude smaller downstream branches causing thromboembolism.  
 
These complications of advanced atherosclerosis are chronic, slowly progressive and 
cumulative. Most commonly, soft plaque suddenly ruptures, causing the formation of a 
thrombus that will rapidly slow or stop blood flow, leading to death of the tissues fed by the 
artery in approximately 5 minutes . One of the most common recognized scenarios is called 
coronary thrombosis of a coronary artery, causing myocardial infarction. The same process in 
an artery to the brain is commonly called stroke. Another common scenario in very advanced 
disease is claudication from insufficient blood supply to the legs, typically caused by a 
combination of both stenosis and aneurysmal segments narrowed with clots (Williams & 
Tabas 1995).  
 
Atherosclerosis affects the entire artery tree, but mostly larger, high-pressure vessels such as 
the coronary, renal, femoral, cerebral, and carotid arteries. These are termed "clinically silent" 
because the person having the infarction does not notice the problem and does not seek 
medical help, or when they do, physicians do not recognize what has happened. The main 
cause of atherosclerosis is yet unknown, but is hypothesized to fundamentally be initiated by 
inflammatory processes in the vessel wall in response to retained low-density lipoprotein 
(LDL) molecules (Williams & Tabas 1995).  
 
2.3.4.9. Endothelial markers and HIV 
HIV may influence endothelial function via activated monocytes and resultant cytokine 
secretion, and via a direct effect of the secreted HIV proteins tat and gp120. A simple 
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measure of the chronic inflammation in HIV-infected patients is the higher levels of high 
sensitivity C-reactive protein (CRP) found in HIV-infected patients compared to control 
subjects, indicating a higher risk for cardiovascular events (Hsue et al. 2004).  
 
Other inflammatory markers such as interleukins are said to be elevated in HIV infection. 
Endothelial markers are increased as well, including soluble vascular cell adhesion molecule 
(sVCAM-1), soluble intercellular adhesion molecule (sICAM-1), and von Willebrand factor 
(vWF) (Wolf et al. 2002). These markers indicate chronic endothelial activation and 
subsequent endothelial dysfunction, which may trigger inflammation and a hypercoagulable 
state. Endothelial activation also triggers platelet activation, which can upregulate adhesion 
molecules.  
 
 
 
2. 4. Lipids and lipoproteins 
A lipoprotein is a biochemical assembly that contains both proteins and lipids. 
Lipoproteins are small spherules that transport fats in the body and consist of protein, 
cholesterol, triglycerides, and phospholipids. The terms "good" and "bad" cholesterol refer to 
High Density Lipoproteins (HDL-C) and Low Density Lipoproteins (LDL-C), respectively. 
High levels of LDL are associated with coronary atherosclerosis, whereas high levels of HDL 
appear to protect against cardiovascular diseases.  
 
The lipoproteins are linked to cholesterol (Figure 15).  
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Figure 15. Cholesterol molecule. Source: USDA National Nutrient Database for Standard 
Reference, Release 18 (2005). 
 
The outer layer of a lipoprotein consists of a water-soluble (hydrophilic) layer of 
apolipoproteins, phospholipids and cholesterol. The center of a lipoprotein is 
composed of cholesteryl esters, triglycerides, fatty acids and fat-soluble vitamins 
(Figure 16). 
 
Figure 16.  The structure of a lipoprotein. Source: USDA National Nutrient Database for 
Standard Reference, Release 18 (2005). 
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The proteins serve to emulsify the lipid (otherwise called fat) molecules. Many enzymes, 
transporters, structural proteins, antigens, adhesins, and toxins are lipoproteins. Examples 
include the high-density (HDL) and low-density (LDL) lipoproteins, which enable fats to be 
carried in the blood stream. 
 
Listed from larger and less dense to smaller and denser. Lipoproteins are larger and less 
dense when the fat to protein ratio is increased. Lipoprotein particles range in size from 10 to 
1000 nanometers. The largest lipoproteins are about one tenth the size of a red blood cell. The 
density of lipoproteins increases in proportion to their ratio of proteins to lipids. In general, as 
the density of a lipoproteins increases, the size of the particles decreases. Lipoproteins are 
characterized by density ,class, diameter, concentration of proteins, cholesterol, 
phospholipids, triacylglycerol and choleterol esters (Table 6). They are classified on the basis 
of electrophoresis and ultracentrifugation. 
Table 6. Characteristics of diferent classes of lipoproteins. Source: Wilkipedia the free 
encyclopaedia 
__________________________________________________________________ 
 
Density (g/ml)      Class  Diameter     Protein    Cholesterol  Phospholipids   Triglycerol&                                                       
                                       (nm)         (%)          (%)            (%)        cholesterol 
          ester% 
>1.063-1.019 HDL     5-1            33          30     29                      4 
1.063                  LDL     18-28         25          50      21              8 
1.006-1.019 IDL     25-50         18           29     22             31 
0.95-1.006 VLDL   30-80         10           22     18             50 
<0.95       Chylomicrons   100-1000    <2          8       7             84 
_______________________________________________________________________________ 
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Chylomicrons carry triglycerides (fat) from the intestines to the liver, to skeletal muscle, and 
to adipose tissue. 
 Very-low-density lipoproteins (VLDL) carry (newly synthesised) triglycerides from the liver 
to adipose tissue. 
 Intermediate-density lipoproteins (IDL) are intermediate between VLDL and LDL. They are 
not usually detectable in the blood. 
 Low-density lipoproteins (LDL) carry cholesterol from the liver to cells of the body. LDLs 
are sometimes referred to as the "bad cholesterol" lipoprotein. 
 High-density lipoproteins (HDL) collect cholesterol from the body's tissues, and bring it back 
to the liver. HDLs are sometimes referred to as the "good cholesterol" lipoprotein. 
 
2.4.1. Metabolism of lipoproteins 
The handling of lipoproteins in the body is referred to as lipoprotein metabolism. It is divided 
into two pathways, exogenous and endogenous, depending in large part, on whether the 
lipoproteins in question are composed chiefly of dietary (exogenous) lipids or whether they 
originated in the liver (endogenous). 
2.4.1.1. Exogenous pathway 
Epithelial cells lining the small intestine readily absorb lipids from nutritive substances. 
These lipids, including triglycerides, phospholipids, and cholesterol, are assembled with 
apolipoprotein B-48 into chylomicrons. These nascent chylomicrons are secreted from the 
intestinal epithelial cells into the lymphatic circulation in a process that depends heavily on 
79 
 
apolipoprotein B-48. As they circulate through the lymphatic vessels, nascent chylomicrons 
bypass the liver circulation and are drained via the thoracic duct into the bloodstream. 
 
In the bloodstream, HDL particles donate apolipoprotein C-II and apolipoprotein E to the 
nascent chylomicron; the chylomicron is now considered mature.  Apolipoprotein C-II, 
mature chylomicrons activate lipoprotein lipase (LPL), an enzyme on endothelial cells lining 
the blood vessels. LPL catalyzes the hydrolysis of triacylglycerol (i.e., glycerol covalently 
joined to three fatty acids) that ultimately releases glycerol and fatty acids from the 
chylomicrons. Glycerol and fatty acids can then be absorbed in peripheral tissues, especially 
adipose and muscle, for energy and storage. The hydrolyzed chylomicrons are now 
considered chylomicron remnants. The chylomicron remnants continue circulating until they 
interact via apolipoprotein E with chylomicron remnant receptors, found chiefly in the liver. 
This interaction causes the endocytosis of the chylomicron remnants, which are subsequently 
hydrolyzed within lysosomes. Lysosomal hydrolysis releases glycerol and fatty acids into the 
cell, which can be used for energy or stored for later use. 
 
2.4.1.2. Endogenous pathway 
The liver is another important source of lipoproteins, principally VLDL. Triacylglycerol and 
cholesterol are assembled with apolipoprotein B-100 to form VLDL particles. Nascent VLDL 
particles are released into the bloodstream via a process that depends upon apolipoprotein B-
100. As in chylomicron metabolism, the apolipoprotein C-II and apolipoprotein E of VLDL 
particles are acquired from HDL particles. Once loaded with apolipoprotein C-II and E, the 
nascent VLDL particle is considered mature. Again like chylomicrons, VLDL particles 
circulate and encounter LPL expressed on endothelial cells. Apolipoprotein C-II activates 
LPL, causing hydrolysis of the VLDL particle and the release of glycerol and fatty acids. 
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These products can be absorbed from the blood by peripheral tissues, principally adipose and 
muscle. The hydrolyzed VLDL particles are now called VLDL remnants or intermediate-
density lipoproteins (IDLs). VLDL remnants can circulate and, via an interaction between 
apolipoprotein E and the remnant receptor, be absorbed by the liver, or they can be further 
hydrolyzed by hepatic lipase. Hydrolysis of VLDL by hepatic lipase releases glycerol and 
fatty acids, leaving behind IDL remnants, called low-density lipoproteins (LDL), which 
contain a relatively high cholesterol content. LDL circulates in the blood and is absorbed by 
the liver and peripheral cells. Binding of LDL to its target tissue occurs through an interaction 
between the LDL receptor and apolipoprotein B-100 or E on the LDL particle. Absorption 
occurs through endocytosis, and the internalized LDL particles are hydrolyzed within 
lysosomes, releasing lipids, chiefly cholesterol (Kumar 2011). 
 
2.4.2. Lipoproteins and atherosclerosis 
Epidemiological studies have shown a positive relationship between total cholesterol 
concentrations and mortality from coronary heart disease (CHD). Total cholesterol does not 
accurately predict the risk of CHD in many patients, however, because it is the sum of all 
cholesterol carried not only by atherogenic lipoproteins (eg, very-low-density lipoprotein 
(VLDL), low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL) but also by 
antiatherogenic lipoproteins (ie, high-density lipoprotein (HDL).  
 
The decision to treat is based on LDL-cholesterol values. Yet, treatment decisions may also 
need to take into account LDL heterogeneity, which has been recognized for many years. 
Small, dense LDL particles are more atherogenic than large, buoyant LDL particles, and 
oxidation of LDL also increases its atherogenicity. In addition, LDL belongs to the group of 
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lipoproteins that contain apolipoprotein (apo) B-100. Some of the particles in this highly 
heterogeneous group contain other apolipoproteins, such as apo C-II, apo C-III, and apo E. 
 
Some particles are larger and rich in triglycerides (large VLDL), whereas others are smaller 
and rich in cholesteryl esters (small VLDL, IDL). It is now known that remnant lipoproteins 
containing apo C-III are highly atherogenic, as is lipoprotein(a) [Lp(a)] another member of 
the apo B-100 group. The small, dense LDL phenotype rarely occurs as an isolated disorder. 
It is most frequently accompanied by hypertriglyceridemia, reduced HDL-cholesterol levels, 
abdominal obesity, and insulin resistance (all of which are components of the metabolic 
syndrome) and by a series of other metabolic alterations predictive of an impaired endothelial 
function and increased susceptibility to thrombosis.  
 
Results from the Québec Cardiovascular Study have indicated that persons displaying 
elevated plasma concentrations of insulin and apo B together with small, dense LDL particles 
showed a remarkable increase in CHD risk (Lamarche et al 1999). 
 
2.4.3. Oxidized LDL and atherosclerosis 
It has been suggested for 20 years that oxidative stress, and particularly LDL oxidation, could 
induce atherosclerosis (Toshima et al 2000),  and that markers of LDL oxidation in plasma 
(circulating oxidized LDL, autoantibodies against oxidized LDL) could be used to assess the 
development of atherosclerosis in patients. Circulating oxidized LDL is additive to the global 
risk score based on age, sex, total and HDL cholesterol, diabetes mellitus, hypertension, and 
smoking as  useful markers for identifying persons at risk for CAD. 
Circulating oxidized LDL was associated with both subclinical atherosclerosis (clinically 
silent ultrasound-assessed atherosclerotic changes in the carotid and femoral arteries) and 
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inflammatory variables (C-reactive protein and the inflammatory cytokines interleukin-6 and 
tumor necrosis factor-α (Sherer et al 2001). Autoantibodies against oxidized LDL have been 
reported to be associated with atherosclerosis. However, the data are not consistent: some 
studies have reported a positive relationship between autoantibodies against oxidized LDL 
and CHD (Erkkila et al.  2000), whereas another did not (Leinonen et al 1998). There is a 
strong cross-reactivity between autoantibodies against oxidized LDL and anticardiolipin 
antibodies, which have been positively associated with CHD.  Many studies have found 
elevated LDL-cholesterol levels are associated with a high risk of CHD, and LDL cholesterol 
continues to be the primary target of therapy for the prevention of CHD (Grundy et al. 2004). 
 
Triglyceride-rich lipoproteins comprise a great variety of nascent and metabolically modified 
lipoprotein particles differing in size, density, lipid and apolipoprotein composition. Studies 
have shown an inverse relationship between the size of lipoproteins and their ability to cross 
the endothelial barrier to enter the arterial intima. Chylomicrons and large VLDLs are 
probably not capable of entering the arterial wall. On the other hand, small VLDLs can enter 
the arterial intima. Therefore, certain triglyceride-rich lipoproteins are atherogenic, whereas 
others are not. A large body of evidence suggests that small VLDLs and IDLs are 
independently associated with atherosclerosis. A study (Sniderman 2001) in 174 patients with 
type 2 diabetes mellitus who were not receiving lipid-lowering therapy concluded that the 
severity of CHD (as examined by angiography) was related to the number of circulating 
fasting triglyceride-rich lipoprotein particles. This relationship was stronger in women than in 
men and was independent of HDL and LDL. 
 
Remnant-like particles (RLPs) can be isolated from the plasma or serum by an antibody-
based assay. In the Framingham Offspring Study (Carmena et al 2004)  mean RLP 
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cholesterol and RLP triglycerides were highly significantly (P<0.0001) increased in diabetic 
women and significantly (P<0.001) increased in diabetic men compared with respective 
controls. Apo C-III in VLDL is associated with denser, smaller VLDL subclasses and is 
believed to be particularly atherogenic. Remnants associated with apo C-III are more related 
to the development of atherosclerosis than are triglycerides. Fasting remnant lipoproteins 
could predict future clinical coronary events independently of other risk factors. The 
concentration of apo C-III in VLDL and IDL particles has been significantly correlated with 
development of coronary stenosis.  
 
 
 
2.4.4. HIV and dyslipaedimia 
It has been demonstrated that patients on highly active antiretroviral therapy are at increased 
risk for developing metabolic abnormalities that include elevated levels of serum 
triglycerides and low-density lipoprotein cholesterol and reduced levels of high-density 
lipoprotein cholesterol (Ridler et al. 2003). This dyslipidemia is similar to that seen in the 
metabolic syndrome, raising the concern that highly active antiretroviral therapy also 
potentially increases the risk for cardiovascular complications. The natural history of HIV 
infection changed abruptly in the developing world in 1995, subsequent to the introduction of 
highly active antiretroviral therapy (HAART), resulting in markedly lower mortality rates. 
However, treatment-associated toxicities were soon recognized, including a constellation of 
metabolic and body composition alterations, often referred to as HIV-associated 
lipodystrophy. Their development initially was ascribed solely to protease inhibitor (PI) 
therapy but later found to also be related to certain nucleoside reverse transcriptase inhibitors 
(NRTIs). The similarities of HIV-associated lipodystrophy to the metabolic syndrome 
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suggested that cardiovascular (CV) risk may also be elevated, a concern that has been 
corroborated in several, but not all analyses.  
 
An association between dyslipidemia and myocardial infarction (MI) has long been 
recognized, as has the great overlap in serum cholesterol concentrations seen between those 
who do and do not develop symptomatic CVD. The latter observation implies the presence of 
other risk factors. Two general patterns of dyslipidemia are related to CVD. The first is an 
increase in the concentration of low-density lipoprotein cholesterol (LDL-C), usually with a 
genetic predisposition. A different defect leads to elevated serum triglyceride and low high-
density lipoprotein cholesterol (HDL-C) concentrations and often is seen in obese patients 
with other components of the metabolic syndrome such as central obesity, diabetes mellitus, 
and hypertension (Kotler 2008). Some authors have considered untreated HIV infection to be 
an example of the type of inflammation that might promote atherosclerosis (Kotler 2008). 
 
2.4.5. Atherosclerosis  
Atherosclerosis, which is the buildup of fat and cholesterol-laden plaque in the walls of the 
arteries, can result from lipid disorders (Ginsberg 1997). When the coronary arteries are 
affected by arteriosclerosis, the person can develop angina, heart attack, congestive heart 
failure, or abnormal cardiac rhythms. When the arteries of the brain are affected by 
arteriosclerosis, the person can develop transient ischemic attack, or stroke.  
 
Hardening of the arteries is a progressive condition that may begin in childhood. Fatty streaks 
can develop in the aorta shortly after birth. In those people with familial history of high 
cholesterol, the condition may worsen rapidly in the early 20s and progressively become 
more severe in the 40s and 50s.  
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The body's immune system responds to the damage to the artery wall caused by oxidized 
LDL by sending specialized white blood cells (macrophages and T-lymphocytes) to absorb 
the oxidized-LDL forming specialized foam cells. Unfortunately, these white blood cells are 
not able to process the oxidized-LDL, and ultimately grow, then rupture, depositing a greater 
amount of oxidized cholesterol into the artery wall. This triggers more white blood cells, 
continuing the cycle (Ross et al, 1999). Eventually, the artery becomes inflamed. The 
cholesterol plaque causes the muscle cells to enlarge and form a hard cover over the affected 
area. This hard cover is what causes a narrowing of the artery as in Figure 16. The plaque 
reduces the blood flow and increases blood pressure. This eventually leads to atherosclerosis.   
 
Atherosclerosis is a complex disease involving the arterial part of the vasculature. The 
disease is modulated by genetic and environmental factors with respect to the end point 
presentation of the atherosclerotic plaque (Figure 16). 
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Figure 16. Formation of plaques in the blood vessel. Source: The American Heritage 
@medical Dictionary Copyright @2010. 
 
 
 
The main cause of atherosclerosis is yet unknown, but is hypothesized to fundamentally be 
initiated by inflammatory processes in the vessel wall in response to retained low-density 
lipoprotein (LDL) molecules. 
 
The development of atherosclerosis probably begins by damage in the endothelium. This 
damage causes cholesterol and fat to penetrate into the vessel walls and deposit there. This 
also induces cells to proliferate. Later, calcium salts are also deposited (Holt 2010). 
 
Factors that may cause endothelial damage and thus atherosclerosis are: 
 high content of cholesterol in the blood ; 
 high content of blood fat and especially saturated fat;  
 Inflammation in the blood vessels. A sign of such inflammation is the presence of C-reactive 
protein;  
 high amount of oxidizing agents in the blood ; 
 high blood pressure ; 
 high content of low density lipoprotein (LDL) in the blood serum, and low content of high 
density lipoprotein (HDL) in the blood;  
 diabetes ; 
 advancing age;  
 smoking;  
 men have a somewhat higher chance of getting this condition than women;  
 high content of the amino acid homocystein in the blood serum. (Holt, 2010). 
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Atherosclerosis can affect any artery in the body, including arteries in the heart, brain, arms, 
legs, pelvis, and kidneys. As a result, different diseases may develop based on which arteries 
are affected. 
 
2.4.5.1. Atherosclerosis and inflammation 
Inflammation appears to be an important pathogenic event in the progression of 
atherosclerosis and in the rupture of the plaque's fibrous cap, which is usually the key event 
leading to acute ischemic accidents. Infection-induced chronic inflammation may thus 
contribute to the increased incidence of cardiovascular events in HIV-infected individuals. 
 
Endothelial cells have been shown to express interleukin-1 (IL-1), IL-5, IL-6, IL-8, IL-11, IL-
15, several colony-stimulating factors (CSF), granulocyte-CSF (G-CSF), macrophage CSF 
(M-CSF) and granulocyte-macrophage CSF (GM-CSF), and the chemokines which are 
monocyte chemotactic protein-1 (MCP-1), RANTES, and growth-related oncogene protein-
alpha (GRO-alpha ), IL-1 and tumor necrosis factor-alpha (TNF-alpha).  Endothelial cells can 
be induced  to express several of these cytokines as well as adhesion molecules. Induction of 
these cytokines in endothelial cells has been demonstrated by such diverse processes as 
hypoxia and bacterial infection. 
 
Recent studies have demonstrated that adhesive interactions between endothelial cells and 
recruited inflammatory cells can also signal the secretion of inflammatory cytokines. This 
cross-talk between inflammatory cells and the endothelium may be critical to the 
development of chronic inflammatory states (Krishnaswamy et al 2004). 
 
2.4.5.2. Antiretroviral therapy and atherosclerosis 
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The role of antiretroviral therapy and HIV infection itself in the development of 
atherosclerosis is not well known, however it is known that they induce changes in lipid 
profile and insulin resistance.  
 
HIV infection may lead to changes in the vascular endothelium by depressed immunity, 
sustained inflammation, and viral replication. At the present we do not know if HIV infection 
itself is an independent risk factor for the onset and progression of atherosclerosis. Some 
studies have shown an increased arterial stiffness in HIV infected patients who were not 
receiving ARV therapy (Charakida et al 2009 a). 
 
2.4.5.3. Arterial stiffness and pulse wave velocity 
Arterial stiffening occurs mainly because of structural alterations in connective tissue 
proteins in the intima media, endothelial and smooth muscle cells. This alterations  may 
influence the visco- elastic properties of the arterial wall thereby affecting the arterial 
stiffness (Malik et al. 2008). The arterial pressure waveform is a composite of the forward 
pressure wave created by ventricular contraction and a reflected wave. Waves are reflected 
from the periphery, mainly at branch points or sites of impedance mismatch. In elastic 
vessels, because PWV is low, reflected wave tends to arrive back at the aortic root during 
diastole.  
 
In the human body, wave reflections originate in various locations, including peripheral 
bifurcations of conducting arteries (Taylor 1964) and smaller muscular arteries. The 
geometry, number of arterioles, and the architecture of the microvascular network play an 
important role in wave reflection. With increased arterial stiffness, as observed, for example, 
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in older subjects or hypertensive patients, the reflected wave travels more rapidly along the 
arterial tree.   
 
Both small and large arteries contribute to early reflected waves because of pulse pressure 
amplification between central and peripheral arteries. 
 
The arterial tree does not have separate conduit and cushioning functions: both functions are 
features of the aorta and its major branches, which are distensible tubes. In addition, there is a 
progressive loss of the cushioning function, from the ascending aorta (the most elastic artery) 
to the more muscular and less elastic peripheral arteries, and an increasingly predominant 
conduit function of large arteries from the heart to the periphery. The respective amounts of 
cushioning and conduit functions in adjacent arterial segments determine this heterogeneity 
(Boutouyrie et al 1994).   Peripheral arteries are stiffer than central arteries in healthy 
subjects, and this phenomenon leads to an increase in the amplitude of the pressure wave in 
the vessels, from the heart to the periphery, known as pressure amplification. In addition, the 
stiffness of medium-sized peripheral arteries is modulated by the vasomotor tone, either 
depending on the endothelial function or the sympathetic nervous system (Boutouyrie et al 
1994) or the renin–angiotensin system (Giannattasio al 1995). When modeling the arterial 
tree, O‘Rourke et al (1982, 1986) have also suggested that because the tube‘s end has a high 
level of resistance, waves are reflected and retrograde waves are generated. This would 
account for the secondary fluctuations of the pressure waveform in diastole and differences in 
the amplitude of the pressure wave between central and peripheral arteries. This fits well with 
pathophysiological observations.  
 
2.4.5.3.1. Arterial stiffness and augmentation index 
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Carotid pressure waveform is recorded by applanation tonometry. The arterial waveform has 
two components; the forward moving wave when the left ventricle contracts and the reflected 
wave returning from the periphery. When the reflected wave arrives back at the central 
arteries earlier this leads to an augmentation of central aortic pressure. The arrival time and 
degree of augmentation  depends on the stiffness of the arteries. This can be quantified 
through the augmentation pressure which is the difference between the forward and reflected 
systolic pulse wave peaks. When expressed as a percentage of the pulse pressure it is called 
augmentation index (Figure 18). 
 
The augmentation index has been also identified as an independent risk marker of the severity 
of premature coronary artery disease and as a predictor of cardiovascular disease among 
healthy individuals (Weber et al 2004). The height of the late systolic peak (P1) above the 
inflection (P2) defines the augmentation pressure, and the ratio of augmentation pressure to 
pulse pressure (PP) defines the AIx (75) (in percent) (Figure 18). Apart from a high PWV, 
also changes in reflection sites can influence the AIx (75). In clinical investigation, not only 
diastolic blood pressure (dbp) and height, which are related to reflection sites, but also age 
and aortic PWV, are the main determinants of the augmentation index. In the case of stiff 
arteries, PWV rises, and the reflected wave arrives back at the central arteries earlier, adding 
to the forward wave and augmenting the systolic pressure. This phenomenon can be 
quantified through the augmentation index AIx (75) which is the augmentation index at a 
normal heart rate of 75 beats per minute for standardization, (Figure 18). 
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Figure 18. Carotid pressure waveform recorded by applanation tonometry. Source: 
O'Rourke MF, Pauca A, Kon N, et al. 1999. Am J Hypertens. 1999;12.  
 
 
2.4.5.3.2. Arterial stiffness and the endothelium derived factors. 
Endothelium derived factors including nitric oxide affect several biological processes in the 
arterial wall which includes smooth muscle reactivity. They may have both short and long 
term effects on the degree of arterial stiffness (Wilkinson et al 2004). An association between 
regional endothelial function and arterial stiffness in different vascular beds has been 
demonstrated using invasive methods in experimental animals as well as in human volunteers 
(Wilkinson et al 2002). 
 
 
2.4.5.3.3. Measurement of arterial stiffness 
In recent years, great emphasis has been placed on the role of arterial stiffness in the 
development of cardiovascular (CV) diseases. Indeed, the assessment of arterial stiffness is 
increasingly used in the clinical assessment of patients. Several papers have previously 
addressed the methodological issues concerning the various indices of arterial stiffness 
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currently available, and their clinical applications, (Laurent et al 2003). Clinicians and 
researchers still report difficulties in selecting the most appropriate methodology for their 
specific use. The measurement of aortic stiffness, which integrates the alterations of the 
arterial wall, may also reflect parallel lesions present at the site of cerebral vasculature. 
 
The measurement of PWV is generally accepted as the most simple, non-invasive, robust, and 
reproducible method to determine arterial stiffness. Carotid-femoral PWV is a direct 
measurement, and it corresponds to the widely accepted propagative model of the arterial 
system. PWV is usually measured using the foot-to-foot velocity method from various 
waveforms. These are usually obtained, transcutaneously at the right common carotid artery 
and the right femoral artery (i.e. ‗carotid-femoral‘ PWV), and the time delay (Dt or transit 
time) measured between the feet of the two waveforms. Carotid-femoral PWV has been used 
in the epidemiological studies demonstrating the predictive value of aortic stiffness for CV 
events. PWV is measured in various segments of the arterial circulation. When two pressure 
waves are recorded at two different sites of the vascular tree such as the carotid and femoral 
arteries, it is possible due to the propagation of the waves, to measure the time delay (t) and 
the distance (D) between these two waves. 
  
Arterial PWV can be determined by the foot –to foot flow wave velocity method. (Avolio et 
al 1983). The foot of the flow wave will be identified between the two recording sites as the 
beginning of the sharp systolic up-stroke. The time delay is measured between the feet of the 
flow waves recorded at these different points and designated as pulse transmit time.  
 
Carotid-femoral PWV is considered as the ‗gold-standard‘ measurement of arterial stiffness. 
The higher the arterial stiffness, the higher the speed of travel of forward and retrograde 
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waves. Local arterial stiffness can be measured directly, and noninvasively, at various sites 
along the arterial tree. A major advantage of the regional and local evaluations of arterial 
stiffness is that they are based on direct measurements of parameters strongly linked to wall 
stiffness.  
 
The aorta is a major vessel of interest when determining regional arterial stiffness for at least 
two reasons: the thoracic and abdominal aorta makes the largest contribution to the arterial 
buffering function. During each heart beat a pulse wave travels from the heart down the 
arterial wall in advance of blood flow (Lakatta 1999). The more rigid the wall of the artery, 
the faster the wave moves. When the wave hits the major branching points, such as the renal 
and femoral arteries, these waves are reflected back so that they reverse direction and travel 
back to their point of origin. Normally the reflected waves get back to the starting point after 
the aortic valve is closed. This amplifies diastolic pressure and facilitates blood flow to the 
coronary arteries. However the increased wave velocity of the initial wave and the subsequent 
reflected wave that occurs with age means the wave can get back to the point of origin before 
the aortic valve closes which increases systolic rather than diastolic pressure. Increased wave 
velocity also decreases the contribution of the reflected wave to the filling of the coronary 
arteries. These changes can have significant clinical implications in terms of coronary artery 
blood flow and can contribute to an increase in systolic blood pressure, pulse pressure and 
thus aortic stiffness. 
 
Pulse wave velocity is a well-accepted index of arterial stiffness. In humans, pulse wave 
velocity is usually in the range 500-2,000 cm/sec. Pulse wave velocity (PWV) is related to 
Young's modulus (E), by the Moens Kortewig equation. PWV= square root of E.h/2r.P where 
h is arterial wall thickness, r is internal radius, and p is density of blood. Another commonly 
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used measure of arterial stiffness is the aortic characteristic impedance (Zc), which can be 
determined from pressure and flow waves recorded simultaneously in the ascending aorta 
(O‘Rourke et al 1983). When expressed in terms of linear flow velocity (dyne-sec-cm"3, not 
volume flow) this is numerically very similar to pulse wave velocity according to the 
Waterhammer formula Zc=PWV x blood density (Fitchett et al. 1988). 
 
Carotid-femoral PWV is a direct measurement, and it corresponds to the widely accepted 
propagative model of the arterial system. It is measured along the aortic and aorto-iliac 
pathway, it is the most clinically relevant, since the aorta and its first branches are what the 
left ventricle (LV) ‗sees‘ and are thus responsible for most of the pathophysiological effects 
of arterial stiffness (Pannier 2005). 
 
2.4.5.3.4. Terminology and Physical Principles 
Young's modulus, pulse wave velocity, and characteristic impedance all increase with rise in 
stiffness and decrease with its fall (Fitchet et al. 1988). A higher value denotes a stiffer artery. 
The media of an artery is responsible for its physical properties. This is regarded as a "two 
phase "structure with tension at low distending pressure borne by the elastin fibers and at 
high pressure predominantly by less extensible collagen fibers (Roach et al. 1957).  
 
A number of alternative non invasive approaches have been developed to study vascular 
biology. These rely on the ability of the β2 agonist salbutamol to reduce arterial stiffness in a 
nitric oxide dependent manner without significant reduction in blood pressure when given by 
inhaler at standard clinical doses (Hayward 2002). 
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Celermajer et al (1994) reported a non invasive ultrasound based test to assess conduit artery 
vascular function in the systemic circulation. In this method, brachial artery diameter was 
measured before and after an increase in shear stress that is induced by reactive hyperemia 
(FMD). Using a sphygmanometer, the cuff placed on the forearm distal to the brachial artery 
is inflated to 200mmHg and subsequently released four to five minutes late. FMD (Flow 
mediated dilation) occurs predominantly as a result of local endothelial release of NO.  
 
There are modern software development of this method. There are practical challenges that 
need to be overcome such as environmental, and physiological like exercise, eating and 
caffeine ingestion. Variations in temperature have to be overcome and some of these 
equipments are expensive (Corretti et al. 2002). 
 
2.4.5.4. HIV, arterial stiffness and increased cardiovascular morbidity  
In the last two decades the introduction of efficient antiviral therapy transformed HIV 
infection into a chronic disease but, at the same time, a positive correlation between this 
therapy and an increased cardiovascular risk was also reported. Patients with HIV infection 
have the same classical cardiovascular risk factors as the general population  in addition to 
HIV infection itself (Papita et al. 2011). Malik et al (2008) demonstrated that impaired 
vascular reactivity and arterial stiffening are manifestations of vascular dysfunction in the 
presence of cardiovascular risk factors. There might be other factors causing arterial 
stiffening leading to atherosclerosis especially in HIV patients. Schillaci et al (2005) in their 
study showed that aortic stiffness is increased in HIV-positive individuals receiving 
antiretroviral therapy including a protease inhibitor. The study also showed that pulse wave 
velocity increased with longer exposure to protease inhibitors. They also hypothesized that 
atherosclrosis is a side effect of antiretroviral treatment including a protease inhibitor.  
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Aortic and large artery stiffening which are hallmarks of vascular aging, are predictive of 
cardiovascular events, particularly in subjects with hypertension and components of the 
metabolic syndrome (Cecelja et al. 2010). One hypothesis is that stiffening is a consequence 
of the combined insult of risk factors on the vascular wall (Cecelja et al. 2010). However, 
some  cross-sectional studies show little association of arterial stiffness with conventional 
risk factors other than blood pressure. An elevation in mean arterial pressure stretches the 
arterial wall, leading to a functional increase in stiffness. Stiffening associated with a chronic 
elevation of blood pressure (ie, hypertension) may be because of distention of the arterial 
wall but could also be explained by structural changes of the arterial wall. The effect of 
increased stiffening is to increase pulse pressure and systolic blood pressure. An increased 
arterial stiffness can increase the risk of stroke through several mechanisms, including an 
increase in central PP, influencing arterial remodeling both at the site of the extracranial and 
intracranial arteries. Increased arterial stiffness can also increase  carotid wall thickness and 
the development of stenosis and plaques, the likelihood of plaque rupture, and the prevalence 
and severity of cerebral white matter lesions (Van der Heijden et al. 2002). 
 
The assessment of arterial stiffness is increasingly used in the clinical assessment of patients. 
The amplification of pulse pressure between central and peripheral arteries has made it 
inaccurate to use brachial pulse pressure as a surrogate for aortic or carotid pulse pressure, 
particularly in young subjects. In younger subjects, the central arteries are usually more 
elastic than peripheral arteries. However, this gradient can be reversed with ageing or  
hypertension. The stiffness of the common carotid artery is six-fold higher in a 70-year-old 
normotensive subject than at the age of 20 (Laurent et al 2006).  In elderly patients with 
hypertension or diabetes, the carotid artery may become stiffer than either the common 
femoral or radial arteries, which stiffen little with age or hypertension.  
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The aorta is strong and elastic; it expands to contain the blood ejected during systole. It then 
contracts and pushes the blood forward, helping to maintain an even flow throughout the 
cardiac cycle. As the aorta gets stiffer and less elastic and distensible, it can't expand as well 
during systole so it can't hold as much blood in reserve so its contribution to forward flow is 
diminished. This contributes to the widening pulse pressure that is often seen in older adults. 
A widened pulse pressure is increasingly viewed as an important cardiovascular risk factor.  
 
2.5. Cytokines 
Cytokines are a category of signaling molecules that are used extensively in cellular    
communication. Cytokines can be classified as proteins, peptides, or glycoproteins; the term 
"cytokine" encompasses a large and diverse family of regulators produced throughout the 
body by cells of diverse embryological origin. The term "cytokine" has been used to refer to 
the immunomodulating agents, such as interleukins and interferons.  They are proteins 
produced by the white blood cells that act as chemical messengers between cells. They are 
also produced by many different cells of the immune system which act upon other cells.  
 
They attach to receptors on the outside of cells causing the target cell to produce a certain 
reaction, depending on the cell and the cytokine. Often the target cell produces other 
cytokines in response to the initial cytokine. This complicated relationship is called the 
cytokine network, and it is one of the most important ways that the immune system  
communicates and orchestrates appropriate responses to various challenges, including 
viruses, bacteria, fungi and even tumours. 
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Most cytokines are produced by T-lymphocyte cells and to a lesser degree by monocytes and 
macrophages (Babakhanian 1995). Cytokines have been classed as lymphokines, interleukins, 
and chemokines, based on their presumed function, cell of secretion, or target of action. The 
term chemokine refers to a specific class of cytokines that mediates chemoattraction 
(chemotaxis) between cells.  
 
Biochemists disagree as to which molecules should be termed cytokines and which 
hormones. Classic protein hormones circulate in nanomolar (10
-9
) concentrations that usually 
vary by less than one order of magnitude. In contrast, some cytokines (such as IL-6) circulate 
in picomolar (10
-12
) concentrations that can increase up to 1,000-fold during trauma or 
infection. The widespread distribution of cellular sources for cytokines may be a feature that 
differentiates them from hormones. Virtually all nucleated cells, but especially 
endo/epithelial cells and resident macrophages (many near the interface with the external 
environment) are potent producers of IL-1, IL-6, and TNFα (Dowlati et al. 2010, Tien at al. 
2006). In contrast, classic hormones, such as insulin, are secreted from discrete glands (e.g., 
the pancreas). As of 2008, the current terminology refers to cytokines as immunomodulating 
agents. However, more research is needed in this area of defining cytokines and hormones. 
 
Cytokines can stimulate or inhibit the growth and activity of various immune cells in 
response to the particular type of disease present. They are major determinants of the make-
up of the cellular infiltrate, the state of cellular activation, and the systemic responses to 
inflammation. Most cytokines are multifunctional. They are involved in extensive networks 
that involve synergistic as well as antagonistic interactions and exhibit both negative and 
positive regulatory effects on various target cells. 
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2.5.1.Cytokines and HIV  
There is growing evidence that initial HIV infection disrupts the normal balance of cytokines 
by causing the levels of certain cytokines to rise. As the disease progresses to AIDS, the 
production of these cytokines declines whilst the production of another group of cytokines 
increases. Some scientists think that this change from one group of cytokines to the other 
group directly causes many of the symptoms associated with AIDS including wasting, 
lymphomas, neurological damage and dementia (Babakhanian 1995). Cytokine imbalances 
may also help HIV to target CD4 cells and the lymph nodes, leading to the progressive 
immunosuppression and the opportunistic infections that follow (Babakhanian 1995). 
 
This theory - that the shift in cytokine balances causes the progression from HIV infection to 
AIDS - is called the Th-1/Th-2 theory. Th-1 refers to the group of cytokines that seem to be 
produced by T-lymphocyte or T helper cells  in response to the initial HIV infection. This 
group of cytokines includes gamma interferon and interleukins 2 and 12 (IL-2 and IL-12). 
During the asymptomatic period of  HIV infection, the levels of these cytokines remain high. 
This may itself help to suppress levels of Th-2 cytokines; for example gamma interferon 
appears to inhibit the production of Th-2 cytokines. For those people in whom HIV 
progresses to AIDS, a shift begins to occur during this asymptomatic period. Levels of the 
Th-1 cytokines start to fall and levels of the Th-2 cytokines - interleukins 4, 5, 6 and 10 (IL-4, 
IL-5, IL-6 and IL-10) and Tumour Necrosis Factor (TNF) alpha - start to rise. Precisely why 
this shift occurs is not known. But one thing that seems to contribute to and amplify this shift 
is the way that high levels of one cytokine can affect the production of others. For example, 
high levels of IL-4 (a Th-2 cytokine) can stimulate production of more Th-2 cytokines 
(including IL-4 itself) creating a continuous loop, or vicious circle (Babakhanian 1995). Th-1 
cytokines are associated with a cellular immune response in which immune cells such as CD8 
100 
 
cells are used to fight infections. Th-2 cytokines are associated with a humoral immune 
response, which relies more on the use of antibodies (Janeway et al. 2001). 
 
2.5.2. Interleukin -6 
The term interleukin was initially used by researchers for those cytokines whose presumed 
targets are principally leukocytes. It is now used largely for designation of newer cytokine 
molecules discovered every day and bears little relation to their presumed function. The vast 
majority of these are produced by T-helper cells.  IL-6 is a protein that in humans is encoded 
by the IL-6 gene. It acts as both a pro-inflammatory and anti-inflammatory cytokine. It is 
secreted by T cells and macrophages to stimulate immune response, e.g. during infection and 
after trauma, especially burns or other tissue damage leading to inflammation.  
 
2.5.2.1. The structure of Interleukin -6  
The structure is composed of a four helix bundle linked by loops and an additional mini-
helix. 157 of 185 residues are well defined in the final structure, with 18 N-terminal and 8 A–
B loop amino acids displaying no interpretable electron density (Figure 19).  
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Figure 19.  Structure of IL6.  Source: A crystal structure of interleukin 6: implications for a 
novel mode of receptor dimerization and signaling (Somers at al 1997 EMBO J. v16 pp.989-
997, 1997). 
 
IL-6 is one of the most important mediators of fever and of the acute phase response. It is 
capable of crossing the blood brain barrier and initiating synthesis of prostaglandin E2 in the 
hypothalamus, thereby changing the body's temperature setpoint. In muscle and fatty tissue, 
IL-6 stimulates energy mobilization which leads to increased body temperature. IL-6 can be 
secreted by macrophages in response to specific microbial molecules, referred to as pathogen 
associated molecular patterns (PAMPs). IL-6 is responsible for the production of neutrophils 
in the bone marrow. It supports the growth of B cells and is antagonistic to regulatory T cells. 
Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-
inflammatory cytokine. IL-6's role as an anti-inflammatory cytokine is mediated through its 
inhibitory effects on TNF-alpha and IL-1, and activation of IL-10 (Janeway et al. 2001). 
Interleukin 6 is both an anti-inflammatory and a pro-inflammatory cytokine and it is 
produced in response to infection and tissue injury. IL-6 exerts its effects on multiple cell 
types and can act systemically.  
 
IL-6 stimulates liver secretion of acute phase proteins. IL-6 stimulates B-lymphocytes to 
produce antibodies. IL-6 in concert with IL-1 causes T-cell activation. IL-6 is released in 
response to IL-1 and TNF-b. The IL-6 receptor is found on many cell surfaces, including 
resting normal T-cells, activated normal B-cells, myeloid cell lines, hepatoma cell lines, 
myeloma cell lines, and on Epstein-Barr virus (EBV) modified B-cells, in which it promotes 
proliferation. (Hirano et al. 1988, Tosato & Pike, 1989). IL-6 can lead to the transcription of a 
wide variety of proteins through all three major signal transduction pathways; Protein kinase 
C, cAMP/protein kinase A, and the calcium release pathway (Nakajima et al. 1989). IL-6 has 
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many molecular forms and each molecule has a different function when secreted by different 
cells in distinct situations activated through diverse stimuli (Lee et al. 1989). 
 
2.5.2.2.    IL-6 and acute phase reaction 
Il-6 stimulates the acute-phase reaction, which enhances the innate immune system and 
protects against tissue damage (Abbas et al. 1997). It results in the release of certain proteins, 
called acute-phase proteins into the blood plasma by liver cells and the decrease in rate of 
synthesis of other proteins. Acute phase proteins mimic antibodies but have a very broad 
specificity. The acute phase proteins have been defined as a set of plasma proteins with 
concentrations that increase (positive acute phase proteins) or decrease (negative acute phase 
proteins) by at least 25% in inflammatory disorders. These inflammation associated cytokines 
include IL-6, IL-1β, tumour necrosis factor-α, interferon-γ, transforming growth factor-β and, 
possibly, IL-8. They are produced by a variety of cell types, but the most important sources 
are macrophages and monocytes at inflammatory sites. Acute phase changes reflect the 
presence and intensity of inflammation, and they have long been used as a clinical guide to 
diagnosis and management. 
 
Overall, in a normal host, one function of inducible IL-6 during acute responses is to suppress 
the level of proinflammatory cytokines without compromising the level of anti-inflammatory 
cytokines. In addition, IL-6 stimulates the production of IL-1 receptor antagonist, which is an 
anti-inflammatory mediator. IL-6 therefore can have a protective effect. IL-6 increases the 
synthesis of the two major acute-phase proteins, C-reactive protein (Crp), which increases the 
rate of phagocytosis of bacteria, and serum amyloid A (SAA) by regulating changes in the 
gene transcription rate of these proteins. In the same way it also increases the synthesis of 
fibrinogen, an important clotting agent. Albumin and transferrin levels are decreased in the 
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presence of IL-6 (Abbas et al. 1997, Kushner et al. 1993). The acute phase local reaction 
leads to a systemic reaction which includes: fever, increased erythrocyte sedimentation rate, 
increased secretion of glucocorticoids, and the activation of the complement and clotting 
cascades (Castell et al. 1990). 
 
2.5.2.3.    IL-6 and cellular immune response  
In chronic diseases, typically exemplified by immune stressors such as chronic intracellular 
infections and tumours, IL-6 not only serves as an inducer of acute phase reactions but also is 
an important player in eliciting cellular immune responses to affected cells and mucosal 
humoral responses directed against reinfection. The main switch from acute to chronic 
inflammation is the recruitment of monocytes to the area of inflammation. IL-6 is important 
to the transition between acute and chronic inflammation.  Interleukin-6 is especially 
important in the early stages of T-cell differentiation. In this phase, it reinforces the effect of 
IL-2 and promotes the differentiation of CD4 cells into T-helper 2 cells. (Janeway et al. 
2001). It controls the growth and proliferation of early progenitor cells in the thymus and 
bone marrow and is later important in both T-cell and Natural Killer (NK) cell activation 
(Lee et al. 1989). Interleukin-6 is very important in the stimulation of differentiation and 
proliferation of B-cells. The knockout of IL-6 has severe effects on the immune system, 
including a major decrease in the acute phase immune reaction and in the production of IgA 
antibodies (Janeway et al. 2001). An uncontrolled or defective production of this protein most 
often leads to disease and is involved in the pathogenesis of many diseases and autoimmune 
disorders (Tovey et al. 1989). 
 
In chronic inflammation, IL-6 has a detrimental role that favours mononuclear cell 
accumulation at the site of injury, through continuous MCP-1 secretion, angioproliferation 
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and anti-apoptotic functions on T cells . This may increase serum levels of IL-6 and provide 
the basis for the amplification step of chronic inflammatory proliferation. Levels of 
circulating IL-6 may be elevated in several inflammatory diseases.  
 
2.5.3. Tumor necrosis factor (TNF) 
Cachexin or cachectin formerly known as tumor necrosis factor-alpha or (TNFα) is a 
cytokine involved in systemic inflammation and is a member of a group of cytokines that 
stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although 
it can be produced by other cell types as well. TNFα stimulates the production of free 
radicals. Moreover, enhanced levels of free radicals are likely to increase TNFα in various 
cells.  TNFα is expressed on all somatic cells, particularly on the cell membrane where it 
becomes hydrolyzed to its soluble form. TNFα is considered as one of the most highly 
studied pro-inflammatory cytokines because it plays a critical role in the origin and 
progression of diseases such as HIV-1 (Bahia & Silakari 2010). The primary role of TNFα is 
in the regulation of immune cells. TNFα, being an endogenous pyrogen, is able to induce 
fever, to induce apoptotic cell death, to induce sepsis (through IL-1 & IL-6 production), to 
induce cachexia, induce inflammation, and to inhibit tumorigenesis and viral replication. 
 
2.5.3.1. Structure of TNFα or cachectin 
TNFα exists as a trimer (Beutler & Cerami 1988). It is  one of the products of activated 
macrophages/monocytes, fibroblasts, mast cells, and some T and natural killer (NK) cells 
(figure 20). TNFα is primarily produced as a 212-amino acid-long type II transmembrane 
protein arranged in stable homotrimers.  
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Figure 20.  The structure of TNFα. Source: Oxford Journals Life Sciences & Medicine 
2010 Transmembrane TNFα: structure, function and interaction with anti-TNF agents.  
Rheumatology. (499) 1215-1228. 
  
 
2.5.3.2. Synthesis of TNFα.  
 
TNFα was thought to be produced primarily by macrophages, but it is produced also 
by a broad variety of cell types including lymphoid cells, mast cells, endothelial cells, 
cardiac myocytes, adipose tissue, fibroblasts, and neuronal tissue. Large amounts of 
TNFα are released in response to lipopolysaccharide, other bacterial products, and 
Interleukin-1 (IL-1). In the skin, mast cells appear to be the predominant source of 
pre-formed TNFα, which can be released upon inflammatory stimulus.  
2.5.3.3. Functions of TNFα 
It has a number of actions on various organ systems, generally together with IL-1 
and Interleukin-6 (IL-6). 
 
On the hypothalamus it has the following functions: 
 stimulation of the hypothalamic-pituitary-adrenal axis by stimulating the release of 
corticotrophin releasing hormone (CRH); 
 suppressing appetite; 
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On the liver: 
 it stimulates the acute phase response, leading to an increase in C-reactive protein and a 
number of other mediators; 
 it also induces insulin resistance by promoting serine-phosphorylation of insulin receptor 
substrate-1 (IRS-1), which impairs insulin signaling; 
 it is a potent chemoattractant for neutrophils, and promotes the expression of adhesion 
molecules on endothelial cells, helping neutrophils migrate; 
 on macrophages: stimulates phagocytosis, and production of IL-1 oxidants and the 
inflammatory lipid prostaglandin E2;  
 on other tissues TNFα is related to  increase in insulin resistance. 
A local increase in concentration of TNFα will cause the cardinal signs of inflammation to 
occur: heat, swelling, redness, pain and loss of function.  High concentrations of TNFα 
induce shock-like symptoms but the prolonged exposure to low concentrations of TNFα can 
result in cachexia, a wasting syndrome. This can be found, for example, in cancer patients 
(Locksley et al. 2001).  
 
2.5.3.4.  TNFα, inflammation, atherosclerosis and HIV 
TNFα promotes inflammatory response, which, in turn, causes many of the clinical 
problems associated with autoimmune disorders such as rheumatoid arthritis, 
ankylosing spondylitis, inflammatory bowel disease, psoriasis, and refractory asthma. 
These disorders are sometimes treated by using a TNFα inhibitor. Beneficial 
functions of TNFα include its role in the immune response to bacterial, and certain 
fungal, viral, and parasitic infections as well as its role in the necrosis of specific 
tumors.  TNFα is an acute phase protein which initiates a cascade of cytokines and 
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increases vascular permeability, thereby recruiting macrophage and neutrophils to a 
site of infection.  TNFα secreted by the macrophage causes blood clotting which 
serves to contain the infection. 
 
High levels of TNFα correlate with increased risk of mortality (Rink & Kirchner 
1996).  Exogenous and endogenous factors from bacteria, viruses, and parasites 
stimulate production of TNFα and other cytokines. TNFα exhibits chronic effects as 
well as resulting in acute pathologies. 
 
TNFα influences many aspects of atherogenesis, including increasing permeability of 
endothelial cells, promoting monocyte adhesion, inducing macrophage differentiation, and 
promoting foam cell formation. In vivo, TNFα induces arteriosclerosis-like lesions in 
coronary arteries (Fukumoto 1997). TNFα also regulates bone turnover, inhibiting 
osteoblastic function and stimulating bone resorption.  
 
HIV infected monocytes have been shown to exhibit increased adherence to endothelial cells 
and to transverse the endothelial barrier. TNFα has also been show to be one of the cytokines 
produced by monocytes in response to stimulation by HIV (Kauschic et al. 2010). According 
to Kauschic et al (2010) exposure to HIV can directly disrupt cellular barriers whose function 
is to keep out pathogens. The process discovered accidentally depends on a still-mysterious 
interaction between an HIV surface protein and mucosal epithelial cells. The interaction 
causes the cells to release a signaling molecule that damages their tight junctions with each 
other, allowing HIV and other pathogens to slip though. Kauschic and his colleagues in their 
experiment also found out that epithelial cells exposed to HIV increased production of 
signaling molecules, including TNFα, which is known to disrupt the barrier. Although TNFα 
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might be expected to be a protective component of an antiviral immune response, several 
lines of evidence suggest that TNFα and other  virally-induced cytokines actually may 
contribute to the pathogenesis of HIV infection (Alfano & Poli 2005).  Based on the 
activation of HIV replication in response to TNFα, HIV appears to have evolved to take 
advantage of host cytokine activation pathways.  
 
Antibodies to TNFα are present in the serum of normal individuals as well as in certain 
autoimmune disorders, and may modulate disease progression in the setting of HIV infection. 
Persistent exposure to HIV and HIV-infected cells may eventually skew the immune system 
toward producing higher-than-normal levels of chemical signals (cytokines) that foster 
inflammation of many organs and tissues. Some researchers worry that chronic inflammation 
associated with HIV may increase the risk for or accelerate the development of complications 
in HIV-positive people that are traditionally seen in older (HIV-negative) people, including 
cardiovascular disease, thinning bones, dysfunctional kidneys and diabetes. TNFα is a highly 
pleiotropic cytokine and plays an important role in regulating HIV-1 replication. It may 
compromise the integrity of the blood-brain-barrier and, thus, may contribute to the 
neurotoxicity of HIV-1-infection, (Miller & Krangel 1992). 
 
2.6. Adhesion molecules 
All adhesion molecules are integral membrane proteins that have cytoplasmic, 
transmembrane and extracellular domains. The cytoplasmic tail often interacts with 
cytoskeletal proteins which serve as the actual anchor within the cell. The extracellular 
domains of adhesion molecules extend from the cell and bind to other cells or matrix by 
binding to other adhesion molecules of the same type (homophilic binding), binding to other 
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adhesion molecules of a different type (heterophilic binding) or binding to an intermediary 
'linker' which itself binds to other adhesion molecules (Figure 21).  
 
 
 
Figure 21. Binding of  adhesion molecules. Source lib.bioinfo.pl/courses/view/232. 
 
Dozens of different adhesion molecules have been identified, but, at least so far, 
they fall into four major families:  
 cadherins cause adhesion via homophilic binding to other cadherins depending on the 
extracellular calcium, (i.e. removal of extracellular calcium disrupts binding). Among other 
things, cadherins is critical in embryology and acts by segregating embryonic cells into 
tissues. Cadherins anchor cells through cytoplasmic actin and intermediate filaments in 
desmosomes and adherens junctions;  
 
 immunoglobulin-like adhesion molecules include a large group of molecules that are 
generated from a smaller number of genes by alternative RNA splicing. The best-studied 
members of this group are the neural cell adhesion molecules (N-CAMs) which are expressed 
predominantly in nervous tissue and the intercellular cell adhesion molecules (ICAMs); 
 
 Integrins are a diverse and large group of heterodimeric glycoproteins. The two subunits, 
designated as alpha and beta, both participate in binding. Integrins participate in cell-cell 
adhesion and are of great importance in binding and interactions of cells with components of 
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the extracellular matrix such as fibronectin. Importantly, integrins facilitate "communication" 
between the cytoskeleton and extracellular matrix, allow each to influence the orientation and 
structure of the other. A feature of integrins is that some exist in "active" and "inactive" 
states. For example, a group of integrins responsible for binding of white blood cells to 
endothelium are normally inactive, allowing the blood cells to circulate freely, but become 
activated in response to inflammatory mediators, resulting in the white cells being "pulled" 
from blood into inflammed tissues. It follows that deficits in expression of certain integrins 
can result in diseases characterized by abnormal inflammatory responses; 
 
 Selectins are expressed primarily on leukocytes and endothelial cells and, like integrins, are 
important in many host defense mechanisms involving those cells. In contrast to other cell 
adhesion molecules, selectins bind to carbohydrate ligands on cells and the resulting binding 
forces are relatively weak. For example, selectin-mediated interactions between leukocytes 
and endothelial cells promotes rolling of the leukocytes along the endothelium and integrin-
binding allows the leukocytes to be stopped in place.  
 
 
2.6.1. E-Selectin  
E-selectin (Endothelial Leukocyte Adhesion Molecule-1, (ELAM-1) belongs to the selectin 
family of adhesion molecules (Lasky et al. 1991). E-selectin mediates the initial interactions 
of leukocytes and platelets with endothelial cells. Selectins provide the first, loose contacts of 
polymorphonuclear cells with the endothelium in areas of inflammation. E-selectin is 
expressed on cytokine-activated endothelial cells, and promotes the adhesion of leukocytes to 
the endothelium. E-selectin, also known as CD62 antigen-like family member E (CD62E), 
endothelial-leukocyte adhesion molecule 1 (ELAM-1), or leukocyte-endothelial cell adhesion 
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molecule 2 (LECAM2), is a cell adhesion molecule expressed only on endothelial cells 
activated by cytokines.  
 
Like other selectins, it plays an important part in inflammation. In humans, E-selectin is 
encoded by the SELE gene ( Morrol et al. 2001). E-selectin is not stored in the cell and has to 
be transcribed, translated, and transported to the cell surface. The production of E-selectin is 
stimulated by the expression of P-selectin which is stimulated by tumor necrosis factor α 
(TNFα), and it can also be stimulated by interleukin-1 (IL-1) and lipopolysaccharide (LPS). It 
takes about two hours, after cytokine recognition for E-selectin to be expressed on the 
endothelial cell's surface, with maximal expression of E-selectin occurring around 6-12 hours 
after cytokine recognition by the cell. E-selectin production levels-out 24 hours after the 
cytokine signal, and continues to be expressed for three days.  
 
During inflammation, E-selectin plays an important part in recruiting leukocytes to the site of 
injury. The local release of cytokines IL-1 and TNFα by damaged cells induces the over-
expression of E-selectin on endothelial cells of nearby blood vessels. Leukocytes in the blood 
expressing the correct ligand will bind with low affinity to E-selectin, also under the shear 
stress of blood flow, causing the leukocytes to "roll" along the internal surface of the blood 
vessel as temporary interactions are made and broken. As the inflammatory response 
progresses, chemokines released by injured tissue enter the blood vessels and activate the 
rolling leukocytes, which are now able to tightly bind to the endothelial surface and begin 
making their way into the tissue (Morrol et al. 2001).   .  
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CHAPTER 3. 
METHODS 
3.1.Study design  
The design of the study was a descriptive and analytical cross sectional study. The study was 
from October 2008 to December 2012. 
 
3.2. Study population: 
The proposed study was carried out amongst diagnosed HIV participants referred to the 
Infectious Disease Clinic, Stamford Terrace Clinic, Gateway clinic and Ngagalizwe clinic in 
Mthatha. The HIV seronegative participants were people with minor complaints from 
Stamford terrace clinic in Mthatha, Gateway clinic and Walter Sisulu University in Mthatha 
(Figure 22). They were all of African descent. 
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Figure 22. The Map of the Eastern Cape showing Mthatha. 
Mthatha is a town in the old Transkei with a relatively poor community. The population of 
Mthatha and its environs is about 500,000. The few well to do go to the private clinics, while 
majority of the people go to these Government clinics in which the study took place. Most of 
them were unemployed eating mostly carbohyrate food once a day. 
  
A convenient sampling method was used. 
Out of the 169 participants, 63 were HIV negative, 52 were HIV positive not on treatment 
and 54 were HIV positive on treatment. Of the 169, there were 62 males and 107 females.  
There were 88 participants below the age of 35, and 81 above the age of 35 years.  
 
The first group of participants were people who are HIV negative.  
 
The second  group  are people who are HIV positive and  antiretroviral naïve. 
 
The third group of participants are those who are HIV positive and on treatment.  
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3.3.  Calculation of Sample size 
There was insufficient information from literature for the sample size(Ni) calculation. 
The dichotomous outcome with up to a frequency (p) of 0.05 (5%), is usually one of the best 
ways to increase power.The general formula for p (expected proportion), the desired total  
(W) of the confidence level and the confidence interval  of (1-α), was as follows: 
Zα= the standard normal deviate for a two sided α, where (1- α) is the confidence level of 
95%. 
Since α=0.05, Zα=1.95; 
Then the total number of participants was  Ni=4x(Zα)2x P(1-P)/W2;  
   
=4(1.96)
2 
x0.50 x0.50/(0.15)
2
; 
 =3.84/0.0225; 
=171 participants required for evaluation. 
 
3.4. Participant selection 
300 participants were recruited because of envisaged drop out rate, with 169 completing the 
study. There was a high drop out rate of 41% because many of the participants who were 
willing to take part in the study did not have a steady source of income. Death, drug side 
effects, change of address and phone numbers, lack of compliance and drop out of patients 
from the study reduced the number of patients from 300 to 169.  
 
3.4.1. Inclusion criteria for HIV positive participants 
The following participants were included: 
 those on antiretroviral therapy for at least 6 months; 
 newly diagnosed HIV positive patients not on antiretroviral therapy; 
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 documentation of HIV 1 infection by any licensed ELISA test kit and confirmed by a second 
method; 
 able to provide informed consent. 
 
3.4.2. Exclusion criteria for HIV positive participants 
The following criteria  served to exclude certain individuals: 
 participants who had high blood pressure, diabetes mellitus or jaundice before starting 
treatment; 
 use of slidenafil (Viagra) within 12 hours of the vascular (Sphygmocor) studies; 
 recent life threatening opportunistic infections; 
 history of liver disease; 
 inability to provide informed consent; 
 pregnant women; 
 breastfeeding women; 
 HIV positive participants not on first line antiretroviral; 
 those on ARV for less than 6 months and have detectable RNA copies of the virus; 
 those who were not willing to fast overnight. 
 
3.5. Consent from the participants 
Informed consent was obtained from the participants after due explanation of the procedures 
to them. They were informed that they may refuse to participate or withdraw from the study 
at any time without fear of victimization. Those who agreed to be tested for their HIV status 
were counseled and post counseled. Participants were informed of the purpose of the research 
as well as of any other implications of the research. Participants were assured of total 
confidentiality and there will be no information that identified them in any manner. The 
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information will only be utilized for the purposes as stipulated and all possible steps will be 
taken to ensure that the information remained confidential. They were informed in the local 
language making sure they understood. After these they signed the consent form. They were 
referred to the necessary specialist clinic if they wanted to. 
 
3.6.  Ethical approval 
Ethical approval was obtained from the Ethics Committee, Faculty of Health Sciences, 
Walter Sisulu University for ethical and bio-safety clearance. Ethical clearance certificate 
number 0043/009. 
 
3.7.  Administration of questionnaires and follow up 
Translated questionnaires were administered to the participants by someone who spoke fluent 
Xhosa. The administrator of the questionnaire was trained by me. After administration of the 
questionnaire, those participants selected were informed and given appointments. First visit 
involved taking their baseline blood profile and their anthropometric measurements. The 
second appointment  required them to fast. They fasted overnight from 8pm to 8 am before 
their blood samples were taken for assays and their vasular function was evaluated. For all 
these appointments they were contacted on phone and given incentives for transport. 
 
3.8. Anthropometric measurements 
Height was measured using the Harpenden stadiometer (Holtain Ltd, Crymych, Dyfed, 
United Kingdom). Participants were bare- footed with heels together, arms to the side, legs 
together, legs straight, shoulders relaxed. Head was positioned in the Frankfort horizontal 
plane. The heels, buttocks, scapulae and back of the head were placed against the vertical 
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board of the stadiometer. The measurement was to the nearest 0.1 cm. the eye leveling with 
the headboard to avoid errors. Averages of two readings were taken. 
 
For weight measurement the participant stood in the middle of the scale without touching 
anything. They had minimal clothing. The weight was read to the nearest 100gm (0.1kg) and 
recorded immediately. The average of the weights measured was taken. Body Mass Index 
(BMI) was calculated using the following formula. Weight (in Kilograms) divided by height 
(in meters) squared=wt (kg)/(ht (m)². 
 
Waist circumference was measured in cm at a level midway between the lower rib margin 
and iliac crest with the tape all around the body in horizontal position in cm.  
Hip circumference was measured as the maximal circumference over the buttocks in cm.  
 
Blood pressure was measured using the Omron sphygmomanometer (Omron, Guangdong, 
China). Three blood pressure measurements were taken 5 minutes apart and the average of 
these readings was used in the analysis. The first appearance of sound (phase 1) is used to 
define systolic blood pressure (Sbp). One intern whom I supervised took all the 
anthroprometric measurements . 
 
 
3.9. Blood Sample collection 
20 ml of blood was collected after fasting overnight and divided into aliquots into plain tubes 
centrifuged at 3000rpm for five seconds and stored at -80
0
C until when needed for the 
estimation of serum HDL-C, TC, and Triglycerides. C-Reactive protein was assayed in the 
NHLS laboratory using the Hitachi/Cobas C system. 
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Elisa was used for determining the levels of the following, TNFα, IL-6 and E-selectin in 
serum. 5 ml of blood was collected in EDTA bottles and sent to the National Health 
Laboratory Service (NHLS) for the determination of HIV antibodies. Full blood count, 
including monocytes and platelets were also analyzed in the NHLS laboratory using the 
Coulter counter (Model Sysmex XT 2000 i). 
 
3.9.1. Centrifugation protocol 
Blood was spun at a speed of 3000 rpm in a cold centrifuge for 5 minutes to obtain serum 
samples. 
 
 
 
 
3.10. Total cholesterol analysis 
3.10.1. Principles 
Cholesterol esters are cleaved by the action of cholesterol esterase to yield free cholesterol 
and fatty acids. Cholesterol oxidase catalyzes the oxidation of cholesterol to cholest-4-en-3-
one and hydrogen peroxide. In the presence of peroxidase, the hydrogen peroxide formed 
affects the oxidative coupling of phenol and 4-aminophenzone to form a red quinone-imine 
dye. The colour intensity of the dye formed is directly proportional to the cholesterol 
concentrations. It is determined by measuring the increase in absorbance. 
 
3.10.2.  Quantitative Colorimetric determination of Total cholesterol  
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The determination of total cholesterol was by the CHOP-PAP method (Enzymatic 
colorimetric Determination of serum cholesterol). Reference number CHOL-MC-0530 N.S 
BIOTEC combined with the method of Trinder (1969).  It is as follows: 
 
                                            Cholesterol esterase 
Cholesterol esters + H2O ----------------------------- cholesterol + RCOOH                             
                                           Cholesterol oxidase 
Cholesterol +O2              ----------------------------  4 Cholestenone + H2O2 
                                                                           Peroxidase                               
2H202  + 4-aminophenazone + phenol----------   4-(p-benzoquinone-monoiminophenazone+ 
4H2O. 
 
3.10.3. Procedure 
The tubes for reagent solution, standard and serum were labeled in duplicate. The wavelength 
of the spectrophotometer was set at 500nm. 20µl of sample was pipetted into sample tubes.  2 
ml of reagent solution was pipetted into reagent blank (RB) and sample tubes. The contents in 
the tubes were mixed and incubated for 10 minutes at 20-25
0
C. The absorbance was read 
against RB within I hour = A sample. The concentrations of cholesterol in the sample was 
calculated as follows; 14.9mmol/l xA sample. 
 
3.10.4.  Measurement  and test priciple of Triglycerides by Enzymatic colometric 
method 
To quantitate the amount of triglycerides in a serum sample the following method was used. 
(Peridochrom Triglycerides GPO-PAP method) by (Medichem) Clinical Chemistry Reagents. 
A modification of Trinders method (1969). 
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Triglycerides are hydrolyzed to glycerol followed by oxidation to dihydroxyacetone 
phosphate and hydrogen peroxide. The hydrogen peroxide produced reacts with 4-
aminophenazone and 4-chlorophenol under the catalytic action of peroxidase to form a red 
substance. The colour intensity of the red substance formed is directly proportional to the 
triglyceride concentrations and measured photometrically. 
 
 
 
The reaction  takes place according to the following equations: 
                                    Lipase 
Triglycerides + 3H20 --------------.> glycerol + 3 RCOOH 
                                     GK 
Glycerol  +  ATP     -------------  glycerol-3-phosphate  +  ADP                                   
                                                      Mg++ 
Glycerol -3 –phosphate + O2 __GPO______>dihydroxyacetone phosphate +H2O2 
                                                          
                                                                Peroxidase 
H2O2     + 4 aminophenazone + 4-chlorophenol-  4 – (p-benzoquinone- monoimino)  
phenazone+ 2H2O2   + HCL. 
 
3.10.5. Procedure for the measurement of triglyceride level  
The stored serum was thawed. The tubes for reagent solution, standard and serum samples 
were labeled in duplicate. The wavelength of the spectrophotometer was set at 546nm. 20 µl 
of standard solution was pipetted into tube 1 and 20μl of serum into the remaining labeled 
tubes. 2 ml of reagent solution was pipetted into each of the labeled tubes including the 
standard solution. The content in each tube was mixed and incubated for 10 minutes at 20-
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25
0
C. The absorbance of serum sample (Asample) and Standard (Astandard) was read against 
reagent solution within 60 minutes. 
The concentrations of triglycerides was calculated as follows:  (mmol/l)                                    
                                         = 2.29 x (A sample) 
                                                                             ____________ 
                                                                            ( A standard) 
Where (A sample) is absorbance of the serum sample and (A standard) is the absorbance of the 
standard from the colorimetic reading where 2.29 is a constant. 
3.10.6. Measurement and Test Principle  of HDL cholesterol by CHOD-PAP method (cat 
No.  543004, Boehringer Mannheim; Mannheim, Germany). 
 
On adding phosphotungstic acid and magnesium ions to the serum samples, chylomicrons, 
VLDL, and LDL are precipitated. HDL is then left in the supernatant after centrifugation. 
The HDL cholesterol is then determined enzymatically. 
 
 
3.10.7. Procedure for HDL-C 
The tubes for reagent solution, standard and serum samples were labeled in duplicate. The 
wavelength of the spectrophotometer was set at 500nm. 200μl of serum sample and 500µl of 
precipitant were pipetted into labelled centrifuge tubes except for tube 1 which  contained 
200μl standard and 500µl precipitant. The contents of the tubes were mixed and allowed to 
stand for 10 minutes at room temperature.  The contents were centrifuged for 10 minutes at 
4000rpm. After centrifugation, the clear supernatant was separated within 2 hours. 100µl 
distilled water was pipetted into reagent blank (RB) and 100µl supernatant into each of the 
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sample tubes. The content in the tubes were mixed and incubated for 10 minutes at 20-25
0
C. 
The absorbance of sample (A sample) at 500nm against RB was measured within I hour.  
The value of HDL cholesterol was calculated using the formula: 5.67xA sample. 
 
3.10.8. Determination of LDL cholesterol (Optimized colorimetric assay method) 
 LDL was calculated from the values of Total cholesterol, Triglycerides and HDL cholesterol 
for each sample. This was according to Friedewalds formula (1972). 
 LDL cholesterol in mmol/l = total cholesterol—triglycerides - HDL cholesterol/5.  
 
3.11.1. Cytokines 
3.11.1.1. Interleukin- 6  
IL-6 is a multi functional cytokine. The method for the assay is The RayBio ® Human IL-6 
using the Elisa technique (Cat #ELH-IL6-001). 
3.11.1.2. Test principles  
ELISA (Enzyme linked Immunosorbent Assay) which is an in vitro enzyme –linked 
immunosorbent assay for the quantitative measurement of human IL-6 in serum was utilized. 
This assay employs an antibody for human IL-6 coated on a 96 –well plate. Standards and 
samples were pipetted into the wells. IL-6 present on a sample is bound to the wells by the 
immobilized antibody. A tetramethyl-benzidine (TMB) substrate solution is added to the 
wells and a color develops  in proportion to the amount of IL-6 bound after washing the 
wells. 
 
3.11.1.3. Procedure 
The levels of  Il-6 were measured in sera derived from 169 participants using a quantitative 
ELISA. 
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3.11.1.4. Reagents 
The following reagents were used: 
 IL-6 Microplate (Item A): 96 wells (12 strips x 8 wells) coated with anti-human IL-6; 
 wash buffer concentrate (20x) item B: 25ml of 20x concentrated solution; 
 standards (Item C) : 2 vials, recombinant human IL-6; 
 assay diluent A (Item D): 30 ml, 0.09% sodium azide as preservative. 
 
3.11.1.5. Reagents for standard/Sample(serum/plasma) diluent 
Reagents for standard diluent used were as follows: 
 detection Antibody IL-6 :2 vials of biotinylated anti-human IL-6;  
 HRP-Streptavidin concentrate : 8µl 30000x concentrated HRP- conjugated streptavidin; 
 TMB One–Step Substrate Reagent:12ml of 3,3‘,5,5‘ tetramethyl-benzidine(TMB) in buffered 
solution; 
 Stop Solution: 8ml of 2M sulphuric acid. 
 
3.11.1.6. Reagent preparation 
All reagents and samples were brought to room temperature. The vials containing  the 
standards were spun and 400µl assay diluent A was added into the item C standard vial to 
prepare a 50 ng/ml standard solution. The powder was dissolved by gently mixing it. 20µl of 
IL6 standard from the vial of Item C was added into a tube with 980µl Assay Diluent A  to 
prepare a 1000 pg/ml stock standard solution. 400µl of assay diluent A was pipetted into each 
tube. The stock standard solution was used to produce a dilution series. Each tube was mixed 
thoroughly before the next transfer. The tubes were  gently vortexed and mixed. Assay 
Diluent A served as the zero standard.  
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3.11.1.7. Assay procedure: 
All the standards and samples were ran in duplicates. 100µl of each standard and sample 
were added into appropriate wells. They were covered and incubated for 2.5 hours at room 
temperature after gentle shaking. The solution was discarded and washed four times. It was 
washed by filling each well with wash buffer (300µl) using a multi-channel pipette. There 
was complete removal of liquid at each step. After the last wash, remaining wash buffer was 
removed by aspirating or decanting. The plate was inverted and blotted against clean paper 
towels. 100µl of 1x prepared biotinylated antibody was added to each well. These were 
incubated for an hour at room temperature after gentle shaking. The solution was discarded 
and washed again for four times. 
 
100µl of prepared Streptavidin solution was added to each well and incubated for 45 minutes 
at room temperature after gentle shaking. Solution was discarded and again washed four 
times. 100µl of TMB substrate reagent was added to each well and incubated for 30 minutes 
at room temperature in the dark with gentle shaking. 50µl of stop solution was added to each 
well and read at 450nm immediately. 
 
 
3.11.1.8. Calculation of results 
The mean absorbance for each set of duplicate standards, controls and samples were 
calculated and the average zero standard opical density was substracted. The standard curve 
was plotted on log-log graph paper with standard concentration on the x-axis and absorbance 
on the y- axis. 
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3.11.2. Measurement of TNFα (Tumour Necrosis Factor) using ANOGEN (Canada)  
method from Catalogue number EL10019. 
3.11.2.1. Principle of the assay 
According to the testing system, the provided standard was diluted (2-fold) with the 
appropriate Calibrator Diluent and assayed at the same time as the samples. A standard curve 
of Optical Density (O.D) versus TNF-α concentration (pg/ml) was produced. The 
concentration of TNF-α in the samples was determined by comparing the O.D. of the samples 
to the standard curve. Human TNFα Elisa Kit was used for the determination of human tumor 
necrosis factor alpha concentrations in the serum samples (Catalogue no EL 10019). Elisa 
technique applied is called a quantitative sandwich immunoassay. 
 
The microtiter plate provided in the kit was pre-coated with a monoclonal antibody specific 
to TNF-α. The plate had 96 wells. Reagents provided included the following; 
 7 ml of biotin conjugate; 
 12 ml of avidin conjugate (avidin conjugated to horseradish peroxidase); 
 2 vials of TNFα standard ; 
 22ml of calibrator diluent 1, ; 
 60 ml Wash buffer( 29 fold concentrated solution of buffered surfactant); 
 11 ml Substrate A (Buffered solution with H2O2);  
 11 ml substrate B (Buffered solution with TMB),  
 14 ml Stop solution.   
 
3.11.2.2. Preparation of reagents 
To prepare the reagents all the kit reagents were allowed to reach room temperature (20-
25
0
C). Wash buffer was reconstituted by adding 1 volume of wash buffer to 19 volumes of 
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distilled water. Substrate A and substrate B were mixed in equal volumes 15 minutes before 
use (Since there are 96 wells with 12 strips, 7 ml of substrate A was mixed with 7 ml of 
substrate B).  
 
TNFα standard was reconstituted with 4.0 ml of calibrator diluent 1 which produced a stock 
solution of 1000 pg/ml. This stock solution was used to produce a serial 2-fold dilution series 
within the range of 15.625 to 1000pg/ml. 0.5ml of the calibrator dluent was added to each test 
tube. The contents of each test tubes were mixed thoroughly. The undiluted TNFα stock 
solution served as the high standard (1000pg/ml) and the calibrator diluent serving as the zero 
standard (0pg/ml). The tubes then ranged from 1000 to 500, 250, 125, 62.50, 31.25 to 
15.625pg/ml. 50 µl of Biotin Conjugate was added to the antibody precoated microtiter plate. 
100µl of standard or sample was added to the appropriate wells. It was mixed well. The plate 
was covered and incubated for 1 hour at room temperature. The microtiter plate was washed 
five times. After the final wash the plate was inverted and blot dried by hitting the plate onto 
adsorbent paper until no moisture appeared. 100 µl of Avidin conjugate was added to each 
well. Avidin was added in order to quantify the amount of TNF-α   present in the sample. 
(Avidin is a tetramer containing four identical subunits in which each has a high affinity-
binding site for biotin.) The plate was covered and incubated for 1 hour at room temperature.  
 
Washing was repeated. 100µl substrate solution was added into each well. The plate was 
again covered and incubated for 20-30 minutes at room temperature. 100µl stop solution was 
added to each well and mixed. The enzyme-substrate reaction was terminated by the addition 
of the stop solution which contained a sulphuric acid solution. The colour change was 
measured spectrophotometrically at a wavelength of 450 nm. The standard curve was used to 
determine the amount of TNFα in an unknown sample. The standard curve was generated by 
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plotting the average O.D.(450nm) obtained for each of the standard concentrations on the 
vertical axis(Y) versus the corresponding TNFα concentration (pg/ml) on the horizontal 
axis(X) axis. 
 
3.11.3. E-Selectin with test principle 
 Method used for the determination of the level of E Selectin in the samples is Elisa. (Cat 
/ELA-E Selectin-od by RayBiotech.Inc). 
 
Anti-E-selectin monoclonal antibody is adsorbed onto microwells. The pair of monoclonal 
antibodies used in this ELISA detects the soluble form of E Selectin present in the serum. 
Soluble E-selectin present in a sample or standard  binds to antibodies adsorbed to the 
microwells. A second, HRP-conjugated monoclonal anti-E-selectin antibody is added and 
binds to E-selectin captured by the first antibody. Unbound enzyme-conjugated anti-E-
selectin is removed with washing and HRP substrate solution is added to the wells. An 
amount of colored product is formed, proportional to the amount of soluble E-selectin present 
in the sample. The reaction is terminated by addition of acid.  Absorbance is measured at 450 
nm. A standard curve is prepared from six E-selectin standard dilutions and the E-selectin 
sample concentration is determined. 
 
3.11.3.1. The components of the Kit  
One aluminum pouch with a Microwell Plate coated with Monoclonal Antibody (murine) to 
human E-Selectin:  
 1 vial (150 μL) HRP-Conjugated Anti-E-Selectin Monoclonal (murine) Antibody; 
 2 vials (100 ng/mL each, reconstituted) soluble E-selectin standard, lyophilized; 
 1 vial control (high), lyophilized; 
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 1 vial control (low), lyophilized; 
 1 bottle (50 mL) wash buffer concentrate 20X (PBS with 1% Tween 20); 
 1 vial (5 mL) assay buffer concentrate 20X (PBS with 1% Tween 20 and 
10% BSA); 
 1 bottle (12 mL) sample diluent (buffered protein matrix); 
 1 vial (15 mL) substrate Solution; 
 1 vial (15 mL) stop solution (1M phosphoric Acid); 
 1 microwell strip holder; 
 2 adhesive plate covers. 
Stored serum samples in cryo tubes were  thawed. Prior to this all reagents except for HRP-
Conjugate was prepared in advance before starting the test procedure. 
 
3.11.3.1.1. Preparation of Assay Buffer 
Just prior to use a 1:1000 dilution of assay buffer solution was prepared in a clean plastic 
tube. Contents of assay buffer concentrate (%ml) was added to 95 ml of deionized water and 
mixed gently. It was stored in the fridge. 
 
3.11.3.1.2. Preparation of reagents 
In the preparation of E-selectin standard, distilled water was added to the vial labelled E-
selectin standard. The vial was mixed. 20 minutes was allowed for the standard to 
reconstitute. 
 
3.11.3.1.3. Preparation of controls 
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The positive controls were reconstituted by adding 200µl of distilled water. It was mixed 
gently to ensure complete and homogenous solubilisation. The controls were treated like a 
sample in the assay. Phosphoric acid was supplied as a stop solution. 
 
 
3.11.3.1.4. Preparation of the wash buffer 
All the 50 ml of the wash buffer was poured into a clean 1000ml graduated cylinder. The 
final volume was brought to 1000 ml with deionized water. It was mixed gently to avoid 
foaming. The pH of the final solution was 7.4. The final solution was transferred to a clean 
wash bottle and stored between 2
0
C and 20
0
C. 
 
3.11.3.2.  Procedure 
All reagents were thoroughly mixed before use, to avoid foaming. Each sample, standard, 
blank and optional controls were assayed in duplicate. Microwell strips coated with 
monoclonal antibody to human E-selectin were removed from their aluminium pouches 
immediately prior to use. The microwell strips were loaded into the 96 microwell strip holder 
making sure that the first microwell strip is in row 1. 
 
The microwell strips were washed twice with approximately 300µL wash buffer per well 
with thorough aspiration of microwell contents between washes. After the last wash the wells 
were emptied and microwell strips were tapped on a paper towel to remove excess wash 
buffer. 100µl of sample diluent was added in duplicate to all standard wells. Standard 
dilutions were prepared by pipetting 100µl of soluble E-selectin standard in duplicate , into 
wells A1 and A2. 100µl was transferred  to well B1 and B2 respectively. The contents were 
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mixed by repeated aspiration and ejection and 100µl was transferred to well C1 and C2 
respectively. 
 
 
The procedure was repeated to create two rows of E-selectin standard solutions ranging from 
50 to 0.8ng/ml. 100µl of the contents from the last microwells (G1 and G2) used was 
discarded. 100µl of sample diluent was added to all blank wells. 80µl of sample diluent was 
added to all sample wells. 20µl of each sample was added in duplicate to the designated wells 
and mixed. 50µl of diluted (1:100) HRP conjugate was added to each well including blank 
wells. The plate was covered with a plate cover and incubated at room temperature (18
0
 to 
25
0
C) for 2 hours. The plate cover was removed and the wells emptied. The microwell strips 
was washed 3 times.  
 
100 μL of mixed TMB Substrate Solution  was pipetted into all wells including the blank 
wells. The microwell strips  was incubated at room temperature (18° to 25°C) for about 10 
minutes,  on a rotator set at 100 rpm. Direct exposure to intense light was avoided. The 
enzyme reaction  was stopped  quickly by pipetting 100 μL of Stop Solution into each well, 
including the blank wells. Results were read immediately. The absorbance of each microwell 
was read on a spectrophotometer using 450 nm as the primary wavelength. The absorbance of 
both the samples and the E-selectin standards was determined. 
 
3.11.3.3. Calculation of Results 
The average absorbance values for each set of duplicate standards and samples were 
calculated. A standard curve was created by plotting the mean absorbance for each standard 
concentration on the ordinate against the soluble E-selectin concentration on the abscissa. A 
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best fit curve through the points of the graph was drawn.The concentration of circulating E-
selectin for each sample was then determined from the graph. 
 
3.12. Measurement of Pulse wave analysis and pulse wave velocity using the  The 
Sphygmocor(Atcor Medical, Australia) 
3.12.1.   Principles 
The SphygmoCor is one of the recently-developed
 
computerized, portable and simple-to-use 
devices used to assess
 
pulse waveforms. The probe incorporates a high-fidelity
 
strain-gauge 
transducer at the tip, which has a small pressure-sensitive
 
ceramic sensor area with a 
frequency response of >2 kHz that
 
is coplanar with a longer area (7 mm diameter) of flat 
surface
 
in contact with the skin overlying the arterial pulse (Millar
 
Instruments). The probe's 
technology is based on the principle
 
of applanation tonometry, as used in ocular tonometry 
for the
 
assessment of intraocular pressure. The SphygmoCor provides a continuous calibrated 
blood pressure waveform at the ascending aorta, using a recording of the radial artery blood 
pressure waveform (figure 23).  
 
 
 
 
 
 
 
3.12.1.1. The Sphygmocor 
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Figure 23. The Sphygmocor. source: http;//www.atcormedical.com. 
 
The Sphygmocor Vx system performs analysis to provide a quantitave aortic cardiovascular 
data such as: 
 systolic pressure; 
 diastolic pressure 
 augmentation pressure;  
 ejection duration and  
 subendocardial viability index.  
 
3.12.2.1 PWA (Pulse wave analysis)  
This is a reproducible non invasive method for assessing central blood pressure and 
augmentation index (AIx(75)). Augmentation pressure (AP) is defined as the 
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difference between the second and the first systolic peak. Augmentation index 
(AIx(75)) is expressed as a percentage of the pulse pressure. The pulse pressure is 
the difference between the systolic and diastolic pressure. Augmentation index is a 
measure of the contribution that wave reflection makes to the arterial pressure 
waveform. The amplitude and timing of the reflected wave ultimately depends on 
the stiffness of the small preresistance and large arteries and thus AIx provides a 
measure of systemic arterial stiffness (Wilkinson et al 1998). 
 
Carotid pressure waveform is recorded by applanation tonometry. The height of the late 
systolic peak (P1) above the inflection (P2) defines the augmentation pressure, and the ratio 
of augmentation pressure to PP defines the AIx (75) (in percent) (Figure 24). 
 
Figure 24.  The Carotid pressure waveform. Source: O‘ Rouke& Yahima 1984. Wave 
reflection and the arterial pulse. Arch. Intern. Med.  
 
Figure 25. and Figure 26. showing the investigator measuring the pulse wave velocity of 
a participant 
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Figure 25. Atonometer applied  to the carotid artery for the measurement of PWV. 
 
 
 
 
 
 
Figure 26. Waveforms as seen on the screen. 
 
3.12.2.2. Pulse wave analysis measurement 
The SphygmoCor system (Pulse wave velocity system PWV, SphygmoCor Vx version 7.01 
software Atcor Medical, Sydney, Australia) was used for pulse wave analysis; The 
participants having fasted, abstained from caffeine, smoking and using viagra for at least 
three days. The procedure took place in a quiet room and participants were not allowed to 
talk. The participant‘s personal details such as the name, date of birth and gender were 
entered into the patient screen. The height, weight and blood pressure of the participants were 
measured and also entered into the corresponding Sphygmocor software fields. The 
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participants sat comfortably beside a table with their arm on the table and their palm facing 
upward in a quiet room.  
 
The location of the strongest pulse was felt on top of the skin and the tonometer placed 
directly on that location. Peripheral pressure waveforms were recorded from the right radial 
artery using applanation tonometry. After 30 sequential waveforms had been acquired, a 
validated generalized transfer function was used to generate the corresponding central aortic 
pressure waveform, from which the augmentation index was obtained (AIx(75)). This was 
calculated as the ratio between augmentation pressure and pulse pressure. 
 
Because AIx is influenced by heart rate, an index normalized for heart rate of 75 bpm 
AIx(75) was applied. Larger values of AIx(75) indicate increased wave reflection from the 
periphery or early return of the reflected wave as a result of increased  pulse wave velocity 
due to increased arterial stiffness. Only high-quality recordings, defined as an in-device 
quality index 80% (derived from an algorithm including average pulse, height, pulse height 
variation, diastolic variation, and the maximum rate of rise of the peripheral waveform and 
acceptable curves on visual inspection) were included in the analysis. 
 
3.12.2.3. Measurement of Pulse wave velocity 
Three main arterial sites can be evaluated, mainly the aortic trunk (carotid-femoral) (Figure 
27) and the upper (carotid-brachial) and lower (femoral-dorsalis pedis) limbs.  
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Figure 27.  Measurement of carotid-femoral PWV with the foot to foot 
method. Source: O‟ Rouke & Yahima 1984. Wave reflection and the arterial pulse. 
Arch Intern. Med. 
 
To perform a Sphygmocor control measurement of the pulse wave velocity, the participant 
was told to abstain from alcohol at least 12 hours prior to the measurement and abstain from 
tobacco and caffeine 4 hours prior to the measurement. Participants had their blood pressure 
taken 5 minutes before the measurements. The participants laid on their supine position with 
the limbs cleaned with an alcohol swab. Electrodes were placed on the participant‘s wrists 
and on the left leg. For carotid artery measurements the participant laid on a bed with his or 
her head tilted slightly to the back and to one side (either left or right) in the absence of a 
pillow (Figure 25 and 26). The position of the strongest pulse was felt using the index finger 
and the tonometer placed directly on top of the skin at the base of neck. Femoral artery 
measurements involves the participant lying supine and the femoral pulse felt by pressing 
directly backward at a point that is midway between the anterior superior iliac spine and the 
front of the pubic bone, with the thigh slightly flexed at the hip joint, moved away from the 
midline of the body and rotated away from the body. The probe was held on the skin over the 
maximal arterial pulsation by hand and pressed down on the artery against the underlying 
bone. Arterial PWV was determined by the foot-to-foot flow wave velocity method. The foot 
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of the flow wave was identified between the two recording sites as the beginning of the sharp 
systolic up-stroke. The time delay was measured between the feet of the flow waves recorded 
at these different points and designated as pulse transmit time (All these were displayed on 
the machine). 
 
The distance traveled by the pulse wave was measured over the surface of the body with a 
tape measure. ECG gating permitted the time lapse between pulse waves at the carotid and 
femoral sites to be calculated from sequential rather than simultaneous measurements. PWV 
was calculated as the distance: transit time ratio and is expressed as meters per second. (This 
was also recorded automatically on the sphygmocor machine). 
3.13. DATA ANALYSIS 
Data was analyzed using the statistical program SPSS version 19. All quantitative 
variables in the text are expressed as means +_ SD. Univariate and multivariate 
(logistic regression model) analyses was used to analyze the data. (P values <0.05 
will be significant for statistical differences). 
Data was tested for normal distribution. Statistically, ANOVA was used for variables with 
normal distribution and Non parametric tests were used for variables with skewed 
distribution. Post Hoc test (tukey and LSD) were administered to establish which of the 3 
groups is the cause of the significance difference observed within and between the 3 groups. 
Kruskal-Wallis Non parametric test was used for variables with skewed distribution to 
establish significant difference. Data were expressed as means and standard deviations. 
Results were expressed as mean ± SD or as proportion (%) for the different parameters. 
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CHAPTER  4. 
4.1. RESULTS 
A total of 169 participants  completed the study  
4.1.1.  The three groups of participants: 
Among 169 participants 63 were HIV negative, 52 were HIV positive not on treatment and 
54 were HIV positive on treatment (Figure 28). 
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Figure 28. Proportion of participants in each group. 
Group 1 HIV Negative, Group 2 HIV posititve not on treatment, Group3 HIV positive on 
treatment.  
 
4.1.2. Age 
The mean ages were significantly different (P<0.001) across the study groups ( Figure 29). 
For HIV negative participants the mean age is 30.34±10.65 years, HIV positive participants 
not on treatment it is 36.25±10.79 years and for HIV positive on treatment it is 40.21±9.56 
years. 
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Figure 29. The mean ages of the different groups. 
 
 
 
 
The mean values of all anthropometric parameters were similar (P>0.05) across the HIV 
status groups (Table 7). The highest mean age was  in HIV positive participants on treatment. 
Post hoc the age group was most significant between the HIV negative and HIV positive on 
Treatment (p<0.001). 
 
Table 7. Comparisons of mean levels of age and anthropometric variables according to 
HIV status groups 
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variables                      HIV -ve     HIV +ve not   HIV+ve on P-value 
     on treatment   treatment ANOVA 
                                 n=63       n=54   n=52 
Age in years           30.34±10.646
            
36.25±  10.785   40.21± 9.554       <0.000* 
Weight(Kgm)          71.35± 15.45    71.31±  19.64   68.50±13.72   0.583 
Height(cm)          164.77± 8.40          162.87±
 
 7.61   162.72±8.03         0.322 
WC (cm)          85.43± 15.32          85.84±
 
 21.41   90.39±10.58   0.209       
HC (cm)               105.44±14.02          102.12±13.94   103.69±10.30   0.439 
BMI (Kgm/m
2
)  33.10± 38.57  26.38± 5.80            25.78± 4.79     0.170 
WHR (%)                0.83±0.09             0.80±0.19              0.88±0.21            0.130 
_______________________________________________________________________ 
 WC  Waist circumference.  
 HC   hip circumference. 
 WHR  Waist to hip ratio 
 BMI Body Mass Index 
 
 
4.1.3. Participant gender distribution within the three groups 
In total there were 169 participants with 63 males and 106 females, there were 35 (57%) male 
participants who were HIV negative, 15 (23%) HIV positive not on treatment, and 13 (20%) 
HIV positive on treatment. 27 (25,5%) HIV female participants who were HIV negative  37, 
(34.9%) were positive but not on treatment, 42 (39.6%) were positive and on treatment 
(Figure 30). 
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Figure 30. The HIV status and the gender.  
 
One can see that females were more in all the three groups especially with the HIV positive 
participants. This is because most of the willing participants who are HIV positive 
participants were females and our public health hospitals were mostly patronized by females. 
 
4.1.4. Haemodynamic profile across the study groups 
The aortic and brachial blood pressures are as below Table 8. The mean heart rate in the 
group of participants not on treatment was significantly higher in the three groups (p=0.017) . 
Post hoc this was more significant between the HIV treatment naïve groups and the HIV 
negative groups (p= 0.034). However the levels of other variables did not vary (P>0.05) 
across the study group. 
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Table 8. Chararacteristics of both the brachial and  aortic blood pressure in all the 3 
groups of participants 
 
variables               HIV -ve n=63 HIV +ve            HIV+ve on P-value 
 not on treatment
 ANOVA 
 treatment n=52 
 n=54 
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Spa(mm/Hg)         110.60±14.90      115.41± 14.72    111.63± 18.06    0.257         
Dpa(mm/Hg)         80.21± 9.88         83.75±  9.90    84.80±  12.62    0.053     
MP(mm/Hg)         92.76± 15.34       98.22±  11.25     97.33±  12.62    0.063        
Ppa(mm/Hg)         30.39± 8.79       31.69±  10.06     28.09±  10.49    0.162       
Sbp(mm/Hg)        121.25±14.52       123.40± 21.99    126.44± 17.83    0.312       
dbp(mm/Hg)         79.72± 9.57       82.88± 12.05      84.63± 11.60    0.059         
Pbp(mm/Hg)         75.43± 11.88       77.29± 18.27      79.33± 18.69    0.458       
HR(b/ min )          67.58± 9.50        73.31± 11.54    72.83±  14.40      0.017* 
____________________________________________________________________ 
 
Spa       Systolic centra(aortic) blood pressure 
Dpa       Diastolic central(aortic blood pressure 
MP        This is MAP or mean arterial pressure 
Ppa       Aortic(central) pulse pressure 
Sbp       Systolic brachial pressure 
Dbp       Diastolic blood pressure 
Pbp       Bracial pulse pressure 
HR        Heart Rate 
 
 
 
 
 
 
4.1.5. Lipid profile by study groups  
Lipid profile by study groups is shown in (Table 9). Both the  means of High Density 
Lipoprotein cholesterol (HDL-C) and Total Choleterol (TC) levels in the HIV participants on 
treatment were significantly higher than the two other groups (p=002 and p=0.005) 
repectively. However, the values of triglycerides did not vary (p>0.05) across the study 
group. Post hoc there was a marked significance between the levels of HDL-C in those who 
are treatment naïve and those on treament (p<0.05). Post hoc the cholesterol levels in 
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participants who are treatment naïve differed significantly from those who are on treatment 
(P=0.06). 
 
Table 9. The lipid profile of  the 3 groups of participants 
Variables HIV -ve  HIV +ve             HIV+ve    P-value 
  n=63  not on                 on  ANOVA 
  treatment           treatment 
   n=54                n=52 
HDL-C(mmol/l)    1.39± 0.42      1.14± .34          1.56±.74         0.002 
TC (mmol/l)            4.23± 1.09      3.64± 1.14        4.38± .96           0.005 
TG (mmol/)              0.97± 0.40     1.06± 0.46        1.19±.51         0.092 
LDL-C (mmol/l)          2.40± 1.16     2.50± 2.76        2.34± .90           0.919 
___________________________________________________________________ 
TC Total cholesterol, TG Tryglyceride 
HDL-C High density lipoprotein chlesterol 
TG  Triglyceridess 
LDL-C Low density lipoprotein chholeterol 
 
4.1.6. Values of cytokine levels across study groups  
The cytokine levels exhibited variability across the study groups (Table 10). The participants 
who were HIV negative had the lowest figure of IL-6, E-Selectin and C-reactive protein 
(Crp) but these were not significant in these study groups. IL-6 and TNFα showed a marked 
increase in participants who are HAART naïve compared to the other two groups whilst Crp 
was higher in the HIV positive participants on treatment. However, the levels of IL-6 and Crp 
were similar (P> 0.05) between the study groups. 
 
Table. 10. Cytokine levels in the three groups of participants 
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variables HIV -ve  HIV +ve not       HIV+ve on      P-value 
 n=63 on treatment      treatment       ANOVA 
 n=54                 n=52 
Tnf-α (pg/ml)      106.61± 10.0      161.30±16.73 81.30±10.09     0.468 
IL-6(pg/ml)         1.59±2.33   6.70± 18.57 1.90±1.61     0.122 
Crp(mg/ml)         3.79±5.48   4.84±6.43         13.14± 3.64     0.122 
E-Selectin( ng/ml)  66.73±31.21   76.81± 33.93      70.74± 35.12    0.498 
___________________________________________________________________ 
 
Tnfα   Tumour Necrosis factor alpha 
IL-6    Interleukin 6 
Crp     C reactive protein 
 
 
 
4.1.7.  The value of CD4
 
count across study group 
The CD4 count and white blood results exhibited variabiliy as shown below (Table 11). The 
CD4 counts of the participants who are HIV negative is the highest followed by those 
participants who are on treatment (p<0.001). The neutrophil count of participants who are on 
treatment is also the highest( p=0.034). The lymphocyte counts of the HIV positive 
participants in both groups are lower than the HIV negative participants (p=0.013) (Table 
11). However, the values of platelets and monocytes were not significantly different (p>0.05) 
across the groups. 
 
Table 11. CD4 count and blood count results in the three groups of participants 
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Variables           HIV -ve             HIV +ve not            HIV+ve on                 P-value  
                                                on treatment          treatment                 ANOVA                                                                               
                        n=63                  n=54                   n=52 
CD4(cells/cm
3
)    946.12±298.09    434.26±307.27  457.85± 255.60       <0.001* 
Platelets(gm/L)   280.07± 59.74     280.88± 91.73  275.12± 63.25       0.925 
Neutrophills(%)   47.26±9.85     48.74±12.83  53.83±8.25                0.034*          
Monocytes(%)    7.99± 2.29     8.84± 2.33  7.96± 2.22                0.157           
Lymphocytes(%) 41.23± 8.98   38.26±12.81  38.70±10.54              0.013*    
___________________________________________________________________________ 
 
 
 
The PWV and other cardiac functions as shown exhibited marked  significant differences 
across the study group (Table 12). The ED% was lowest n the HIV negative participants and 
highest in those that are not on treatment. The AIx(75) is  lowest in the HIV negative 
participants and highest in those that are on treatment. The SEVR% is highest in the HIV 
negative participants and lowest in HAART naïve participants. The PWV is highest in HIV 
participants who are HAART naïve but lowest in HIV negative participants.  Post hoc there 
was stastical difference in the levels of AIx(75) between HIV negatives and HIV positive 
participants on treatment (p= 0.025) whilst there was a significant differece in the values of 
SEVR in HIV positive on treatment and HIV negative participants (p= 0.06). PWV was 
stastically significant between treatment naïve participants and HIV negatives (p=0.033). 
 
Table 12. PWV and other cardiac functions  in the three groups of participants 
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variables                 HIV -ve n=63 HIV +ve           HIV+ve on          P-value 
 not on             treatment            ANOVA 
 treatment         n=52 
 n=54 
ED(%)                     33.71±3.80        36.31± 3.56    36.15± 4.431  0.001* 
AIx(75)           15.56±13.20      19.92± 12.20    21.87± 12.26  0.024* 
SEVR(%)           176.16±29.55      155.04± 24.55    159.80±28.559  0.000* 
PWV(m/s)           6.38   ±1.67       7.21±  2.17     6.84±1.17          0.037* 
_______________________________________________________________________ 
ED     Ejection duration 
AIx(75) Augmentation index at a heart rate of 75 beats per minute 
SEVR  Subendocardial viability ratio 
PWV   Pulse Wave velocity 
 
4.1.8. Pulse wave velocity (PWV)  
The box plot (figure 31) below demonstrated that the mean of the Pulse Wave Velocity of 
those participants who are HIV negative is 6.38 , those participants who are d HIV positive 
and not on treatment have a mean value of 7.21 and those on treatment have a mean value of 
6.84. This is significant (P<0.05). The high pulse wave velocity of the antiretroviral naïve 
group is clearly shown in this box plot. Post hoc the PWV of the HIV negatives was 
significantly different from that of the treatment naïve HiV participants (p=0.033). 
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Figure 31. PWV of the three  study groups using a box plot. 
4.1.9. The augmentation index in the three groups of participants 
The ratio of augmentation and central pulse pressure (difference between central systolic and 
diastolic pressure) varied significantly (p<0.05) across the groups (Figure 32). The 
augmentation index which is also a measure of arterial stiffness is greatest in the HIV 
positive partcipants on antiretrovirals. Post hoc this is significant between those on treatment 
and and HiV negatives (p=0.025). 
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Figure 32. Augmentation index in the three groups of participants. 
 
 
 
 
4.1.10.  Waist circumference 
Figure 33. shows the variations of waist circumference by the study groups.The highest level 
of waist circumference was in positive participants on HAART but this was not significant 
(P>0.05). 
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Figure 33. The waist circumferences in the three groups of participants. 
 
 
 
 
 
 
 
4.1.11. Waist to hip ratio  
Waist to hip ratio is highest in the group on treatment (figure 34). The highest, intermediate 
and lowest levels of the waist to hip ratio were in HIV positives on HAART; negatives; and 
in positives not on HAART (p<0.05) respectively.The values are not significant (p>0.05). 
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Figure 34. The waist to hip ratio in the three groups of participants. 
 
 
 
 
 
4.1.12.  Systolic brachial blood pressure (Sbp) 
The HIV positive participants on treatment had the highest brachial systolic blood pressure 
(Figure 35). The levels of systolic brachial blood pressure across the study groups were not 
statistically significant (p>0.05). 
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Figure 35. The  systolic  brachial blood pressure in the three groups. 
 
 
 
 
 
 
 
4.1.13. Systolic aortic (central) blood pressure 
This is the blood pressure measured at the level of the aorta when the heart is contracting 
(Figure 36).The highest level of systolic aortic pressure was amongst the Haart naïve HIV 
positive participants, compared to the levels in those who are on HAART and those who are 
HIV negative. The values are not stastically significant (p>0.05). 
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Figure 36.  The  systolic aortic blood pressure in the three groups.   
 
 
 
 
 
 
4.1.14 Diastolic brachial blood pressure 
The participants on treatment had the highest diastolic brachial blood pressure (figure 
37).There was no statistical difference (p>0.05) in comparing the values between the study 
groups. 
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Figure 37. The  diastolic brachial blood pressure in the three groups.  
  
 
 
 
 
 
4.1.15. Diastolic aortic (central) blood pressure  
The  diastolic aortic blood pressure was highest in participants who are HIV positive but 
slightly higher in those who  are on treatment (Figure 38). The difference was not statistically 
significant (p>0.05) across the study groups. 
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Figure. 38. The  diastolic aortic blood pressure of the three groups of participants. 
 
 
 
 
 
4.1.16. Pulse pressure (brachial) 
The brachial pulse pressure was highest in the group on antiretroviral therapy (Figure 39). 
The difference was statistically not significant (P>0.05) across the study groups. 
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Figure 39. The brachial pulse pressure in the three groups of participants. 
 
 
 
 
 
 
4.1.17. Pulse Pressure (aortic) 
The aortic (central) pulse pressure is highest in the group of antiretroviral naïve HIV positive 
participants (Figure 40). Their values were not significant (p>0.05) across the study groups. 
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Figure 40. Box plot of aortic (central)  pulse pressure in the participants. 
 
 
 
 
4.1.18. Mean arterial pressure (MAP or MP) 
MAP is highest in the antiretroviral naïve group (figure 41). The difference was not 
statistically significant (p>0.05) in all the study groups. 
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 Figure 41. The mean arterial pressure of the three group of participants.  
 
 
 
 
 
 
 
 
4.1.19. Heart rate  
Figure 42. presents a significant and unequal variation of heart rate across the study groups. 
Post hoc there is a significant difference between participants on treatment and HIV negatives 
(p=0.034). 
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Figure 42.  Graph of the heart rates in the three groups of participants.   
 
 
 
 
 
 
 
 
4.1.20. Ejection duration index (ED %) 
The mean values of ED% varied significantly (p<0.05) across the study groups. Post hoc, 
there is significant difference between Negatives and treatment naïve participants (p<0.002) 
and between Negatives and those on treatment (p<0.003), (figure 43). 
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Figure. 43. Ejection duration in the three groups of participants. 
 
 
  
 
 
4.1.21. Subendocardial viability ratio 
The antiretoviral naïve group of HIV positive participants has the lowest values for SEVR%, 
whilst the HIV negative participants has the highest level (figure 44). These values varies 
significantly (p<0.05) across the study groups. Post hoc there is significant difference 
between HIV positive participant on treatment and HIV negatives.(p=0.033). 
 
162 
 
 
                 Figure 44.  SEVR% in the three study groups. 
 
 
 
 
4.1.22.  E- Selectin  
Levels in the three groups of participants are shown (Figure 45). E selectin level is highest in 
the antiretroviral naïve group of HIV positive participants. However, the differences are not 
statistically significant (p>0.05) across the study groups. 
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Figure. 45. The E-selectin levels in the three groups of participants.  
 
 
 
 
 
 
4.1.23. IL-6  
IL-6 levels in the three groups of participants (Figure 46). IL- 6 level is highest in the 
antiretroviral naïve group. However, the difference across the study groups was not 
significant (p>0.05).  
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Figure. 46. IL-6 levels in the three groups of participants. 
 
 
 
 
 
 
4.1.24. TNFα 
TNFα levels in the three gropus of participants (Figure 47). The TNFα level in the HAART 
naïve group is highest, whereas the difference was not statistically significant (p>0.05) across 
the three groups. 
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Figure 47. TNFα in the three groups of participants.  
 
 
 
 
 
 
4.1.25. Cholesterol 
Box plot below depicting the cholesterol levels of the the three groups of participants (Figure 
48). The level of cholesterol is highest in HIV positive participants on treatment. Post hoc 
there is a statistical differece between Negatives and participants on treatment (p=0.036), and 
between participants who are on treatment and those who are treatment naïve (p=0.006). 
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Figure 48. Cholesterol levels in the three groups. 
 
 
 
 
4.1.26. Triglycerides 
Triglyceride levels in the three groups of participants (Figure 49). The highest level was in 
HIV positive participants on HAART but the diffrence is not significant (p>0.05).  
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Figure 49. Levels of triglycerides in the three groups of participants. 
 
 
 
 
 
4.1.27. HDL-C level  
The box plot compares the levels of HDL-C  in the three groups of paticipants (figure 50). 
Post hoc there is a stastistical difference between those paricipants who are on treatment and 
those who are not on treatment (p=0.001). 
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Figure 50. HDL-C levels in the three groups of participants. 
 
 
 
 
 
4.1.28. LDL-C   
The levels of LDL-C is similar (p>0.05) in the three groups of participants as shown by the 
box plot (Figure 51).  
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                     Figure 51. LDL-C levels of the three group of participants. 
              
 
 
 
 
 
4.1.29. Monocytes 
 There is no stastistical difference in the level of monocytes in the three groups of participants 
(p>0.05), with the  antiretroviral naïve group having the highest monocyte level (Figure 52).  
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Figure 52. Monocyte count levels in the three groups of participants. 
 
 
 
 
4.1.30.  Neutrophils 
The values of the neutrophils  are compared using a box plot (Figure 53). The netrophil levels 
of HIV positive participants on treatment are the highest and there is a statistically difference 
(p<0.05) across the study groups. Post hoc there is a sifnificant difference between the 
Negatives and HIV positive on treatment (p=030). 
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Figure 53. Levels of the Neutrophil count in the three groups of participants. 
 
 
 
4.1.31. Platelets 
The levels  of platelets, was similar (p>0.05) across the study groups as shown in figure 54. 
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Figure 54. The platelet count in the three groups of participants. 
 
 
 
 
 
 
4.1.32.  Lymphocytes  
Comparing the lymphocyte levels across the three groups of participant,  their values varied 
significantly (p<0.05) with the lowest level in positives on HAART (figure 55). Post hoc 
significant difference is observed between the negatives and participants who are on 
treatment (p=0.010). 
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Figure 55. Lymphocyte counts in the three groups of participants. 
  
  
 
 
4.1.33. C-reactive protein (Crp)  
The box plot graph was used to demonstrate the lack of significant diffrence (p>0.05) for the 
values of Crp across the study groups (figure 56). 
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Figure 56. Crp values in the three groups of participants. 
 
4.2. Influence of advanced age in all anthropometric parameters  
4.2.1. Anthropometric parameters  
 High values of waist and waist to hip ratio were significantly associated with advanced age 
(p<0.05) whereas values for weight and height  were similar between older and younger 
participants ( p>0.05) (Table 13). 
 
Table 13. The means of the age and anthropometric measurements of participants aged 
below 35 years and above 
variables Age more        Age less                 P-value 
 than 35        than 35                  ANOVA 
                        years         years 
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Age (years)                45.47±  8.55         27.71± 4.38             0.000* 
smoke cigarettes(n)       1.87±  0.34                 6.88 ±13.85     0.334 
weight(Kgm)               72.25± 18.47             62.90± 8.00            0.217 
height(cm)                164.26± 8.14             185.95± 7.98     0.313 
WC(cm)                92.68± 15.87             82.95± 14.39         0.000* 
WHR(%)                0.88 ±0.07                 0.81± 0.14            0.001* 
_____________________________________________________________________ 
WC waist circumference 
WHR waist to hip ratio 
 
4.2.2. Haemodynamic parameters according to age groups 
The comparisons of the mean values of haemodynamic data. The comparisons of the mean 
values of haemodynamic data according to age groups are presented for all participants  in 
Table 14. The levels of brachial pulse pressure and HR are similar (p>0.05) between 
participants with age>35 years and those with age <35 years while the values of 
Sbp,Dbp,Spa,Dpa,MP,and Ppa are significant (p<0.005) in participants with advanced age 
than those from participants aged less than 35 years. 
 
 
 
Table 14. The means of the aortic and brachial blood pressure  of participants aged 
below 35 years and above. 
Variables              Age more                 Age less                 P-value 
                           than 35                   than 35                  ANOVA 
                   years                     years 
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Sbp(mmHg)         127.78±20.10          120.30±15.13  0.007* 
Dbp(mmHg)          84.82±
 
10.58          80.31± 10.97           0.012* 
Pbp(mmHg)          78.54±19.74          76.36±12.88           0.403 
Spa (mmHg)          116.37±18.74        109.35±12.36           0.003* 
Dpa(mmHg)          84.55±11.21          81.58±9.94           0.050* 
MP(mmHg)          99.04± 12.42          93.68
 
±13.43           0.006* 
Ppa(mmHg)          32.77± 12.00          27.77±6.95           0.001* 
HR(beats/secs)      71.08± 13.96         70.91±10.56           0.934 
_____________________________________________________________________ 
Sbp     bracial systolic blood pressure 
Dbp    brachial diastolic blood pressure 
Pbp     brachial pulse pressure 
Spa     Aortic (central) blood pressure 
Dpa     Aortic (central) diastolic bloood pressure 
  
MP Mean aortic (central) blood pressire 
Ppa Aortic (central) blood pressure 
HR heart rate 
 
4.2.3. Cytokines 
There was not a significant association (p>0.05) between the levels of TNFα ,IL-6, E-Selectin 
and aging (Table 15) 
 
Table 15. The means of some cytokine levels  of participants aged below 35 years and 
above 35 years. 
variables Age more      Age less   P-value 
                      than 35 years          than 35 years   ANOVA 
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Tnfα(pg/mL)              87.25 ±16.48     171.64± 184.69          0.185 
IL-6(pg/mL)              2.58± 2.46              3.22± 12.31  0.755 
E-Selectin(ng/mL)       77.88 ±36.75          65.37± 29.51             0.091 
_____________________________________________________________________ 
Tnfa Tumour necrosis alpha 
IL-6  Interleulin 6 
 
4.2.4. Immmunity and haematological data 
Table 16. summarizes the mean values of CD4 count, platelets, neutrophils, monocytes and 
lymphocytes according to age groups. The influence of advanced age is neutral and  
indifferent (p>0.05) with monocytes and with CD4 (p>0.05). Platelets, neutrophils and 
lymphocytes has significant value (p<0.05) between the two groups of participants. The 
values of CD4 count and lymphocytes are lower in participants with advance age compared 
to participants who are less than 35 years, whereas the levels of platelets and neutrophils of 
participants aged more than 35 years are higher than those aged less than 35 years. The levels 
of monocytes in the two groups are almost the same. 
 
Table 16. The means of CD4 and blood counts  of participants aged below 35 years and 
above 35 years. 
variables                  Age more  Age less P-value 
                             than 35 years  than 35 years ANOVA 
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CD4(cells/cm
3
)         505.54±358.29  743.82±362.80        0.059 
Platelets(gm/L) 290.10±86.32  269.34± 53.86        0.018* 
Neutrophils(%) 52.65±10.39           47.11±10.59                 0.018* 
Monocytes(%) 8.32 ±2.53           8.26±2.17                 0.793 
Lymphocytes(%)  35.81± 10.58          40.74± 10.10               0.016* 
_____________________________________________________________________ 
 
4.2.5. Cardiac functions using the Sphygmocor 
The AIx(75) and PWV in  participants older than 35 years are higher (p<0.05) than those 
aged  less than 35 years, whereas the levels of ED% and SEVR% were similar (p>0.05) 
between both examined participants according to age groups(Table 17). 
 
 
 
 
 
 
 
Table 17. The means of PWV and some cardiac functions using some spygmocor 
variables  in  participants aged below 35 years and above 35 years. 
Variables            Age more Age less P-value 
                        than 35                      than 35 ANOVA 
                years                           years 
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ED (%)       35.30± 3.99          35.30±4.21                       0.888 
Alx (75)     24.52± 11.06          14.34 ±12.22               0.000* 
SEVR (%)    162.71± 26.72             165.7±30.95                       0.420 
PWV(m/s)             7.46± 2.15                6.2±1.02                         0.000* 
____________________________________________________________________ 
ED(%)        Ejection duration index 
AIx(75)       Augmentation index at a heart rate of 75 beats per minute 
SEVR(%)    Subendocardial viability ratio 
PWV(m/s)    Pulse Wave Velocity in metres per second 
 
4.3. Influence of gender 
4.3.1. Anthropometric data 
There was no significant (p>0.05) influence of gender on the variations of age, weight, waist,  
BMI and WHR, while females were shorter (p<0.05) and heavier (p<0.05) by BMI levels 
than males (Table 18). 
 
 
 
Table 18. The means of age and anthropometric characteristics in the male and female 
groups of participants  
Variables  Males                      Females P-value 
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Age (years)      35.53± 12.08         35.02± 10.49              0.773 
weight  (kgm)     69.73± 12.83        70.855±17.81              0.671 
height(cm)      170.00±7.501        159.75±5.64              0.000* 
WC(cm)      84.24± 11.95        88.96± 17.66              0.071 
HC (cm)      97.64± 10.42       107.17±12.78              0.000* 
BMI (kgm/m
2
)    24.11± 4.07             30.18± 24.96              0.069 
WHR(%)            0.87± 0.07                0.84± 0.13                0.320 
_____________________________________________________________ 
 
WC    waist circumference 
HC     hip circumference 
WHR   waist to hip ratio 
BMI    body mass index 
 
4.3.2. Haemodynamic data in males and females 
The mean values of Sbp,Dbp,Spa,Dpa,HP,Ppa,and HR did not vary(p>0.05) between males 
and females (Table 19). 
 
 
 
 
 
Table 19. The means of the aortic and brachial blood pressure measurements in both 
male and females participants  
Variable  Males          Females  P-value 
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Sbp(mmHg)        126.22±18.34     121.96± 17.58               0.151 
Dbp(mmHg)        81.42± 10.64      82.78± 11.39               0.459 
Pbp(mmHg)        74.91± 16.79      78.60± 15.72               0.177 
Spa (mmHg)       112.89± 14.94      111.99± 16.48               0.725 
Dpa(mmHg)        82.81±  10.86      82.79±  10.65               0.990 
MP(mmHg)       96.58±  11.77      95.50±  14.28               0.613 
Ppa(mmHg)       30.08±  8.84      29.85±  10.35               0.883 
HR(b/secs)       69.53±  11.80      71.88 ± 12.13               0.223 
___________________________________________________________ 
Sbp     bracial systolic blood pressure 
Dbp    brachial diastolic blood pressure 
Pbp     brachial pulse pressure 
Spa     Aortic (central) blood pressure 
Dpa     Aortic (central) diastolic bloood pressure  
MP      Mean aortic (central) blood pressire 
Ppa     Aortic (central) blood pressure 
HR      heart rate 
 
4.3.2. Lipid profile in males and females 
Table 20 presents no significant variations (p>0.05) in LDL-C and total cholesterol but 
significant (p<0.05) variations of HDL-C and triglycerides between males and females. 
Females had lower levels of HDL-C and triglycerides than males. 
Table 20. The means of the lipid profiles between male and female groups  in  the 
participants 
Variable                   Male                  Female                 P-value 
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LDL-C   (mmol/l)   2.58± 2.57          2.32± 1.02       0.441 
HDL-C   (mmol/l)   1.49± 0.77          1.27± 0.32       0.027* 
TG       (mmolo/l)   1.17± 0.48          0.99± .43       0.026* 
TC        (mmol/l)      4.20± 1.02           4.02±1.15        0.372 
______________________________________________________________ 
TG  Triglycerides.  
TC  Total cholesterol 
LDL-C  Low density lipoprotein cholesterol 
HDL-C High density lipoprotein cholesterol  
 
4.3.3. Cytokine values in males and females 
There were no significant difference (p>0.05) in the levels of TNFα, IL-6, E-selectin and Crp 
in both males and females (Table 21). 
 
 
 
 
 
 
Table 21. The means of some cytokine levels between male and female participants. 
Variables Males Females P-value 
Tnfα (pg/mL)         82.95± 16.50           131.17± 130.83        0.487 
IL-6(pg/mL)         4.18± 14.56           2.07± 2.06                 0.332 
E-Selectin(ng/mL)   77.26± 33.77   65.74± 31.58        0.098 
Crp (mg/L)          4.58± 6.44            8.91± 7.45                 0.301 
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_____________________________________________________________ 
Tnfa     Tumour necrosis factor alpha 
IL-6      Interleukin 6 
E-Selectin 
Crp       C-reactive protein 
4.3.4. Immunity and haematological data in males and females 
In Table 22, there were no significant differences (P>0.05) in the values of CD4 count, 
platelets, lymphoctes and neutrophils in both males and females while monocytes were lower 
significantly (P<0.001) in females than males. 
 
 
 
 
 
 
Table 22.  The means of the CD4 count and blood counts between male and female 
participants 
Variables                    Male                        Female            P-value 
CD4count(cells/mm
3
)   680.13±391.20      621.22±369.41    0.398 
Platelets x10
9
(gm/L)    283.42± 77.48      283.05±66.79    0.441 
Lymphocytes (%)        36.89± 11.42      39.94 ±9.78    0.120 
Neutrophils (%)          49.12± 10.16      48.12±9.60         0.962 
184 
 
Monocytes (%)            9.17± 2.43            7.60 ±1.97        <0.000* 
______________________________________________________________ 
 
4.3.5. Cardiac  functions in males and females 
Compared with males, females had similar levels of PWV (P>0.05), higher levels of ED% 
and AIx(75), (P<0.05), but lower values for SEVR% (Table 23). 
 
 
 
 
 
 
 
 
 
Table 23.  The means of PWV and some sphygmocor variables between male and 
female participants 
Variables                Males                  Females             P-value 
 
ED (%)            33.73± 4.16          36.15± 3.81      < 0.000* 
AIx (75)           14.64± 11.78 21.15 ±12.81       0.001* 
SEVR (%)           177.10±31.02 157.52±25.47     <0.000* 
PWV(m/sec)             6.99± 1.64          6.65± 1.77         0.220 
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____________________________________________________________________ 
 
ED(%)       Ejection duration index 
AIx (75)     Augmentation index at a heart rate of 75 beats per minute 
SEVR         Subendocardial viability ratio 
PWV         Pulse wave velocity in metres per second 
 
4.4. Bivariate (Univariate) analysis 
4.4.1. Simple correlations between age, anthropometric measurements and PWV 
Table 24, shows correlations between ages, anthropometric parameters, number of cigaretes 
smoked per day and PWV in each study group. In HIV –negatives, there is a significant 
(P<0.05) positive correlation between age, number of cigarettes, weight, waist circumference 
and PWV, but a (P>0.05) negative correlation between height and PWV. In HIV positive not 
on HAART there is a significant (P<0.05) positive correlation between weight, waist and 
PWV. With positives on HAART there is a significant positive correlation between age WHR 
and PWV and anegative correlation with height. On the other hand the other variables in each 
group were not significantly correlated with PWV (P>0.05). 
 
Table 24. Simple linear regression analysis of PWV with biometry by the study groups     
variables HIV-ve         HIV+ve not on HIV+ on treatment 
             treatment 
 
 r
    
p-value   r
    
p-value        r
           
P-value 
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Age(years)         0.606  <0.000*     0.269      0.057   0.641    <0.000 
HC(cm)         0.086     0.512        0.012      0.389         -0.033     0.816 
BMI(Kgm/m
2
)        0.164     0.202        0.195      0.229          0.069     0.629 
weight(kgm)         0.123      0.003*      0.439      0.004         0.096      0.495     
WHR(%)         0.479   0.585        0.211      0.345         0.319      0.037*   
Cigarettes(smk/day) 0.071   0.015*      0.094      0.439         0.024      0.866    
height(cm)          -0.012      0.928        0.046     0.770         -0.399     0.003   
waist(cm)   0.252     0.050*     0.406      0.008          0.185     0.185  
 
BMI     Body mass Index 
HC      Hip circumference 
WHR   Waist to Hip ratio 
              
 
 
 
 
4.4.2. Haemodynamic correlates of PWV by the study groups 
The haemodynamic parameters were differently correlated with PWV across the study groups 
(Table 25). In HIV negatives and except for HR (P>0.05) there is a significant (P<0.05) 
correlation between Ppa, MP,Spa, Dbp,and PWV. In HIV positive participants not on 
HAART and HIV positive participants on HAART Ppa, MP and Spa are significantly and 
positively correlated with PWV, respectively. In both HIV positive groups, HR and Dbp are 
not significantly (P>0.05) correlated with PWV. 
 
Table 25.   Correlations between haemodynamic data and PWV 
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variables HIV-ve          HIV+ve not on        HIV+ on treatment 
             treatment 
 
 r
 
P-value     r
            
P-value           r
                
P-value 
HR(b/min)            0.075      0.561       0.212     0.173           0.057         0.693 
Ppa (mmHg          0.472    <0.000      0.338      0.012            0.338         0.012 
MP(mmHg)           0.446    <0.000      0.515     <0.000          0.400         0.003 
Spa (mmhg)         0.635    <0.000      0.369       0.012           0.369         0.006 
Dbp(mmHg)         0.436    <0.000      0.114       0.423           0.114         0.413 
 
_________________________________________________________________________ 
Dbp    brachial diastolic blood pressure 
Spa     Aortic (central) blood pressure 
MP      Mean aortic (central) blood pressire 
Ppa     Aortic (central) blood pressure 
HR      heart rate 
4.4.3. Lipid correlates of PWV 
Only total cholesterol in HIV negatives and triglycerides in HIV positives not on HAART are 
significantly and positively correlated with PWV (P<0.05), whereas the other lipid 
parameters are not significantly (P>0.05) correlated with PWV in each study group (Table 
26). 
 
Table 26. Correlation between lipid profile and PWV 
 
Variables HIV-ve             HIV+ve not on HIV+ on treatment 
             treatment 
 
  r
       
P-value     r
        
P-value      r
 
        P-value 
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TC (mmol/L)       0.148      0.339        0.004   0.999           0.370      0.019* 
TG (mmol/L)       0.233      0.119        0.028   0.861           0.490      0.002* 
HDL-C (mol/L)    0-.106     0.501       -0.124   0.143            0.239     0.143 
LDL-C(mmol/L)   0.136       0.384       0.006   0.971            0.229      0.166  
________________________________________________________________________           
TC   total cholesterol 
TG   triglycerides 
HDL-C High density Lipoprotein cholesterol 
LDL-C  Low density Lipoprtein cholestrol 
 
 
 
 
4.4.4.Correlation between CD4 count, haematologic data and PWV 
Only platelets in HIV positive participants not on HAART and neutrophils in HIV positives 
on HAART are significantly and positively correlated with PWV (P<0.05), while monocytes 
and CD4 count in HIV positives on HAART are significantly but negatively correlated with 
PWV (P<0.05). Both CD4 count and haematologic data are not significantly correlated 
(P.0.05) with PWV in HIV negatives (Table 27). 
 
Table 27.Correlation between  haematologic data and PWV                           
variables HIV-ve             HIV+ve not on HIV+ on treatment 
             treatment 
 
  r
       
p-value      r
        
p-value         r
 
          p-value 
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Platelet(gm/L)         0.148        0.339          0.370   0.019*     .013       0.940 
Lymphocyte(%)      -0.145       0.299          -0.235   0.237          -0.232     0.155 
Monocyte(%)          -0.091       0.591         -0.054   0.745          -0.320     0.047* 
Neutrophil(%)         0.186        0.182          0.212   0.228           0.341     0.034*      
CD4 (cell/mm
3
)       -0.159        0.271          0.149   0.423          -0.446     0.009* 
_________________________________________________________________________ 
 
 
 
 
 
 
4.4.5. Inflammatory markers as correlates of PWV 
All inflammatory markers in HIV negatives and HIV positives on HAART are not significantly 
correlated with PWV, TNFα and CRP in HAART naive HIV positives are also not significantly 
correlated with PWV, While IL-6 and E-selectin in HAART naïve HIV positive participants  are 
significantly and positively correlated with PWV(P<0.05) (Table 28). 
 
Table 28.  Correlation between cytokines and PWV   
variable HIV-ve       HIV+ve not on         HIV+ on treatment 
        treatment 
   r
 
P-value         r
        
P-value         r
 
        P-value 
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Tnfα(pg/mL)          -         -            -0.235      0.654           -0.235    0.654 
IL-6(pg/mL)        0.282  0.179        0.889      0.031           0.083     0.712 
E-Selectin(ng/ml) 0.260   0.110       0.843      0.029           0.296     0.142 
Crp(mg/mL)      0.136   0.391      - 0.153      0.360           0.601     0.095 
_______________________________________________________________________ 
Tnfa    Tumour necrosis alpha 
IL-6    Interleukin 6 
Crp    C reactive protein 
 
 
 
 
 
4.4.6. Correlation between indices of cardiac function and PWV 
Aix(75), ED%,and SEVR% in HIV positives not on HAART and HIV positives on HAART are not 
significant in relation to PWV (P>0.05) and same applies to ED% and SEVR% which are not 
significantly related to PWV (P>0.05). Only AIx(75) is significantly and positively related to PWV 
(P>0.05) (Table 29). 
 
Table 29. Correlation between Aix(75), ED%,SEVR%,and PWV 
variables HIV-ve          HIV+ve not on HIV+ on treatment 
             treatment 
 
 r
    
P-value   r
     
P-value   r
 
          P-value 
Alx(75)             0.850      0.004          0.027    0.027            0.109        0.451 
ED(%)              0.015      0.906         -0.151    0.275           -0.151       0.275          
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SERVR%          -0.043      0.742         -0.031    0.825           -0.205       0.150 
_________________________________________________________________ 
 
AIx(75)      Augmentation index at a heart rate of 75 beats per minute 
ED(%)       Ejection duration index 
SEVR         Subendocardial viability ratio 
 
 
 
 
 
 
4.5. Multivariate analysis 
Different independent determinants of the variations (total R
2
 and adjusted R
2
) of PWV and 
AIx(75) as the dependent variables using multiple linear regression models. 
 
4.5.1. Most important determinants of PWV 
4.5.5.1. HIV negatives  
Table 30 identifies Spa, age and triglycerides as the only independent and significant 
determinants of PWV among HIV negatives. 
 
Table 30. Independent determinants of PWV in HIV negative participants 
Variables Beta P-value 
192 
 
Spa 0.509 ‹0.0001 
Age 0.386 ‹0.0001 
Triglycerides       0.196        0.027 
 
R
2
 =56.9% (adjusted R
2
=54.7%). Model adjusted for gender, anthropometric parameters, 
HDL-C, TC, LDL-C, haematologic data, haemodynamic data, cytokines, smoking, alcohol. 
The positive equations or regression plots of these explanatory variables are plotted in 
Figures 57-59. 
 
Figure 57.  Partial Regression plot for PWV as the dependent variable and triglycerides 
as the independent variable among HIV negative participants. 
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Figure 58.  Partial Regression plot for PWV as the dependent variable and age as the 
independent variable among HIV negative participants. 
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Figure 59.   Partial Regression plot for PWV as the dependent variable and Spa as the 
independent variable among HIV negative participants..    
 
 
 
 
 
 
 
 
4.5.1.2. HIV positive participants not on HAART 
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Only MP and waist circumference are identified as the most important and significant 
independent determinants of PWV in HIV positive participants not on treatment (Table 31) 
 
Table 31. Independent determinants of PWV in HIV positive participants not on 
HAART 
 
Variables Beta P-value 
MP 0.443 ‹0.001 
Waist circumference 0.272   0.031 
 
R
2
 =33.4% (adjusted R
2
 =30.6%). Model adjusted for gender, weight, height, hip 
circumference, waist to hip ratio, Lipid profiles, haematological data, cytokines adhesion 
molecules, smoking, alcohol, other haemodynamic parameters and CD4 count. 
 
 
 
 
 
 
 
 
The positive associations of both partial regression plots are shown in Figures 60 and 61. 
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Figure 60. Partial Regression plot for PWV as the dependent variable and MP as the 
independent variable among HIV positives not on HAART. 
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Figure 61.  Partial Regression plot for PWV as the dependent variable and waist 
circumference as the independent variable in HIV positives not on HAART. 
 
 
 
 
 
 
 
4.5.1.3. HIV positive participants on HAART 
Age, MP, HDL-C, and triglycerides were identified as the significant independent 
determinants of the variations of PWV in HIV positive participants on HAART (Table 32). 
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Table 32. independent determinants of PWV in HIV positives on HAART 
Variables Beta  P-value 
Age 0.506 ‹0.0001 
MP          0.294       0.003 
HDL-C          0.272               0.006 
Triglycerides         0.212               0.043 
 
R
2
 =57 % (adjusted R
2
 =53.5%). Model adjusted for gender, anthropometric data, smoking, 
alcohol, cytokines, adhesion molecules, total cholesterol, LDL-C, haematological data, CD4 
count, and other haemodynamic parameters. 
 
 
 
 
 
 
 
The positive association between identified explanatory and PWV in HIV positives  on 
treatment are highlighted in Figures 62-65. 
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Figure 62. Partial Regression plot for PWV as the dependent variable and age as the 
independent variable in HIV positives on HAART. 
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Figure 63.  Partial Regression plot for PWV as the dependent variable and MP as the 
independent variable in HIV positives on HAART. 
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Figure 64. Partial Regression plot for PWV as the dependent variable and triglyceride 
as the independent variable in HIV positives on HAART. 
  
 
 
 
 
 
 
 
4.5.2. Significant determinants of AIx(75)  
4.5.2.1. HIV negatives 
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 In HIV negatives the multiple linear regression model, identified age (positive correlation), 
height (negative correlation), CD4 (positive correlation) and MP (positive correlation) as the 
independent and significant determinants of AIx (75) among HIV negatives (Table 33). 
Table 33. Independent determinants of AIx(75) in HIV negatives 
Variables Beta P-value 
Age 0.506 ‹0.0001 
MP          0.294       0.003 
HDL-C          0.272    0.006 
Triglycerides         0.212    0.043 
 
R
2
 =46.3% (adjusted R
2
 =42.5%). Model adjusted for gender, smoking alcohol, weight, waist 
circumference, hip circumference, waist to hip ratio, lipid profiles, cytokines, adhesion 
molecules, haematological data, and other haemodynamic parameters. 
 
Figure 66-69 demonstrate the partial regression plot or equations between identified 
independent variables and the dependent variable PWV among HIV negatives. 
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Figure 65. Partial Regression plot for AIx(75) as the dependent variable and age as the 
independent variable in HIV negative participants. 
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Figure 66. Partial Regression plot for AIx(75) as the dependent variable and MP as the 
independent variable in HIV negative participants. 
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Figure 67. . Partial Regression plot for AIx(75) as the dependent variable and MP as the 
independent variable in HIV negative participants. 
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Figure 68. Partial Regression plot for AIx(75) as the dependent variable and Height as 
the independent variable in HIV negative participants. 
 
   
 
 
 
 
 
 
4.5.2.2. HIV positive participants not on HAART 
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Table 34 shows that Spa and Age are independently and significantly associated with the 
variations of AIx(75) among HIV positives not on HAART. On the other hand height is 
negatively and significantly associated with AIx(75) amongst HIV positives not on HAART. 
 
Table 34. Independent  determinants of AIx(75) in HIV positive participants not on 
HAART 
Variables                                   Beta                               P-value 
Spa                                          0.264                              0.031 
Height                                     -0.505                            <0.001 
Age                                         0.421                             <0.001 
 
R
2
 =43.1% (adjusted R
2
 =39.4%) Model adjusted for gender, smoking, alcohol intake, 
cytokines, weight, waist circumference, hip circumference, waist to hip ratio, cytokines, CD4, 
haematological data, lipid profiles, and other haemodynamic parameters. 
 
 
 
 
 
 
Figures 69-71 highlight Age, Spa and Height correlations with PWV in HIV positives not on 
HAART. 
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Figure 69. Partial Regression plot for AIx(75) as the dependent variable and age as the 
independent variable in HIV HAART naive participants. 
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Figure 70. Partial Regression plot for AIx(75) as the dependent variable and Spa as the 
independent variable in HIV HAART naive participants.  
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Figure 71. Partial Regression plot for AIx(75) as the dependent variable and height as 
the independent variable in HIV HAART naive participants.  
 
 
 
 
 
 
 
 
4.5.2.3. HIV positive on HAART 
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After excluding confounding factors, height (negative correlation), age (positive correlation), 
MP (positive correlation) HDL-C (negative correlation), platelets (positive correlation) 
alcohol intake (excessive consummation associated with positive correlation) and TNFα 
(negative correlation) were identified as the independent and significant variables associated 
with increase in AIx(75) among HIV positive participants on HAART (Table 35). 
 
Table 35. Independent determinants of AIx(75) in HIV positive participants on HAART 
Variables                                    Beta                                        P-value 
Height                                      -0.676                                     <0.0001 
Age                                          0.460                                     <0.0001 
MP                                           0.480                                      <0.0001 
HDL-C                                      -0.212                                      0.015 
Platelets                                   0.319                                      <0.001 
Alcohol intake                            -0.298                                      0.005 
TNFα                                       -0.219                                      0.024 
____________________________________________________________________ 
R
2
 =68.1% (adjusted R
2
 =63.3%). Model adjusted for gender, smoking, weight, waist 
circumference, hip circumference, waist to hip ratio, neutrophils, lymphocytes, 
monocytes,CD4 count, triglycerides, total cholesterol, LDL-C IL-6, E-Selectin, and other 
haemodynamic data. 
The equation between these independent determinants and Aix(75) (dependent variables) in 
HIV positives on HAART are shown in Figures 72-78. 
212 
 
 
Figure 72. Partial Regression plot for AIx(75) as the dependent variable and age as the 
independent variable in HIV positive participants on HAART.   
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Figure 73. Partial Regression plot for AIx(75) as the dependent variable and MP as the 
independent variable in HIV positive participants on HAART. 
  
 
 
 
 
214 
 
 
Figure 74. Partial Regression plot for AIx(75) as the dependent variable and TNFα as 
the independent variable in HIV positive participants on HAART. 
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Figure 75. Partial Regression plot for AIx(75) as the dependent variable and HDL-C as 
the independent variable in HIV positive on HAART. 
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Figure 76. Partial Regression plot for AIx(75) as the dependent variable and platelets as 
the independent variable in HIV positive participants on HAART.  
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Figure 77. Partial Regression plot for AIx(75) as the dependent variable and height as 
the independent variable in HIV positive participants on HAART.  
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Figure 78. Partial Regression plot for AIx(75) as the dependent variable and alcohol as 
the independent variable in HIV participants on HAART.  
 
 
 
 
 
 
 
 
CHAPTER 5 
DISCUSSION 
219 
 
5.1. Compostion of the participants and main findings of the study 
This study evaluated the functions of the vasculature which could lead to cardiovascular risks 
in male and female HIV positive and HIV seronegative participants of African ancestry.  
Some of the HIV participants who were positive and on treatment were slightly older than 
those participants who were not on treatment. This is not unexpected  because most of the 
participants were diagnosed a long time ago and have been on treatment. Females were more 
than males in the two HIV positive groups. This may be because most attendees in our public 
hospitals were females and therefore constituted the majority of willing participants. Some of 
the participants in the study dropped out because of financial reasons, as they had to leave 
their homes to search for jobs making it difficult to contact them.  
 
The main fidings of this study are that patients with HIV had increased arterial stiffness 
compared with HIV negative groups after adjustment for conventional  cardiovascular risk 
factors. Within the HIV group, participants who are HAART naïve had increased arterial 
stiffness compared to participants exposed to HAART. Using multiple linear regresssion, 
individuals with HIV and on HAART had age, MP, HDL-C, and triglycerides as significant 
independent determinants of the variations of PWV. Using multiple linear regression with 
adjustment for gender, anthropometric data, smoking, alcohol, cytokines, adhesion 
molecules, total cholesterol, LDL-C, haematological data, CD4 count, and other 
haemodynamic parameters, only MP and waist circumference were identified as the most 
important and significant independent determinants of PWV in HIV positive participants not 
on treatment. Spa, age and triglycerides are the only independent and significant determinants 
of PWV among HIV negatives in a multivariate analysis. This study therefore demonstrates 
the importance of mean arterial pressure in the assessment of arterial stiffness as most 
previous studies focused on pulse pressure. 
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When participants were stratified by gender, there was no significant influence of gender on 
the variations in age, haemodynamic and anthropometric data, except that females were 
shorter. There were no significant differences in the levels of TNFα, IL-6, E-selectin and Crp 
in both males and females while ED % was higher in females (p<0.000). This might indicate 
that the diastolic period and coronary perfusion pressure and blood flow to the myocardium 
in the females were compromised.  On the other hand, SEVR was higher in males (p<0.000). 
This shows that females are less tolerant to physical activity and more prone to develop sub-
endocardial ischaemia. AIx(75)  was also higher in females (p<0.001). AIx(75), a measure of 
systemic arterial stiffness might have increased in these female participants because of their 
short stature as corrobated by the study of Yasmin and Brown (1999). Using PWV there was 
no difference in arterial stiffness between males and females.  
 
In HIV negatives, there was a significant positive correlation between age, number of 
cigarettes, weight and PWV. In HIV positive participants not on HAART there was a 
significant positive correlation between age, waist to hip ratio, height and PWV. Also in HIV 
positive participants on HAART there was a positive correlation between waist to hip ratio, 
height and PWV. This shows that there is a strong association of arterial stiffness with age in 
all groups and also waist to hip ratio in both HIV positive groups. 
 
5.2. Carotid pulse wave velocity as the gold standard for measuring arterial stiffness in 
HIV negative, HAART naïve HIV positive participants and HIV participants on 
treatment  
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Carotid pulse wave velocity (PWV) was used to evaluate arterial stiffness in this 
study, and is recognised as the gold standard. The patients tolerated the procedure 
as it was not invasive and not time consuming if measured by an experienced 
investigator. Carotid-femoral PWV has been used in epidemiological studies 
demonstrating the predictive value of aortic stiffness for CV events. Pulse wave 
velocity (PWV) is considered a non-invasive diagnostic test for subclinical 
atherosclerosis (SA) or arterial stiffness, and is a predictor of cardiovascular risk and 
also a surrogate marker of vascular disease (London & Cohn 2002).  Alterations in 
arterial stiffness are known to precede clinical hypertension by a substantial period 
of time (Willum-Hansen et al 2006). Increased arterial stiffness has been linked to a 
higher rate of future cardiovascular complications and death (Laurent et al. 2001). 
Premature atherosclerosis has also been reported in young adults with HIV infection 
in the pre- HAART era (Charakida et al. 2009). 
Subclinical cardiovascular disease is an accurate reflection of the real prevalence of 
atherosclerosis at a potentially reversible stage, so that detecting it makes it possible 
to implement secondary preventive measures. Until now, there have been very few 
studies using PWV to evaluate SA or arterial stiffness in HIV patients, and these 
studies involved very few subjects with conflicting results (Ho et al. 2010; Schillaci et 
al. 2005; Schillaci et al. 2008). 
 
5.3. Role of HIV infection in the development of arterial stiffness 
In this study, participants who were HIV positive and HAART naïve had significantly 
increased pulse wave velocity than those who were on treatment and those who were 
seronegative.  The  results of this study are in agreement with a previous study that found 
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increased arterial stiffness in patients with HIV infection compared with healthy controls 
(Van Wijk et al. 2006).  
 
In the study by Van Wijk et al (2006), thirty-seven HIV-infected patients underwent 
assessment of flow-mediated vasodilation (FMD), aortic pulse-wave velocity (PWV), and 
carotid intima-media thickness (IMT). Age-matched type 2 diabetic patients (n = 13) and 
healthy controls (n = 14) served as reference groups.  In the HIV infected patients there was 
an  increased cardiovascular risk. The presence of the metabolic syndrome in some of the  
HIV patients  was associated with even more advanced atherosclerotic changes. Presumably, 
HIV infection may promote atherosclerosis through mechanisms involving endothelial cells, 
either directly or indirectly via metabolic risk factors. 
Van Vonderen et al (2009) in his study on HIV patients said the  mechanism for the increase 
in pulse wave velocity with HIV patients  is not completely understood, but the implication of 
classical cardiovascular risk factors, and of systemic chronic inflammation should not be 
under-estimated  (Van Vonderen et al 2009). The study reported by Van Vonderen et al 
(2009) also did not agree with that of Monteiro (2012) in Brazil who  found lack of 
association between arterial stiffness and HIV. Monteiro‘s study comprised of 261 HIV 
infected and 82 uninfected participants. He found no association between arterial stiffness 
and HIV but found association between age, gender and arterial stiffness. 
 
A recent study compared measures of arterial stiffness using radial artery tonometry in 276 
HIV-infected and 67 HIV-uninfected Rwandan women (Lazar 2009). They reported that HIV 
infection was associated with greater arterial wave reflection in women who are HAART 
naïve without other CVD risk factors. This is not very different from this study in which the 
PWV is highest in the HAART naïve participants. This could be due to the chronic 
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inflammation of the HI virus itself.  HIV infection may lead to changes in the vascular 
endothelium by depressed immunity, sustained inflammation, and viral replication. Another 
explanation may be that treatment with HAART by reducing the inflammation due to active 
HIV infection may to some extent counteract any adverse effects of treatment. The balance 
between the beneficial effects of HAART may be essential to determine the net effect in an 
individual patient. 
 
5.4. Role of antiretroviral therapy in the development of atherosclerosis 
In this study, arterial stiffness was significantly higher in antiretroviral naïve HIV 
positive participants than in those who are on treatment and those who are 
seronegative implicating that the HIV virus causes more of arterial stiffness than 
HAART despite the older age of the participants who are on treatment. A study 
showed that endothelial dysfunction actually improved after starting HAART, despite 
the rapid onset of dyslipidemia (Torriani 2008). This might support the findings in this 
study that the arterial stiffness caused by HAART was not as much as that caused 
by that of the HIV infection. The study by Torriani (2008) included 82 treatment-naïve 
HIV-infected subjects  who participated in a prospective, multicenter study of three 
class-sparing antiretroviral therapy regimens. Flow-mediated dilation of the brachial 
artery improved after 4 weeks (+0.74%, p=0.003) and at 24 weeks (+1.48%, p< 
0.001), with similar observations in each arm (p>0.600).  The improvement of 
endothelial function with treatment might be another reason why aortic stiffness 
decreased in HIV positive participants on HAART. Wolf et al in 2002 demonstrated 
that antiretroviral therapy reduced markers of endothelial and coagulation activation 
in HIV-infected patients (Wolf et al. 2002). These markers include soluble vascular 
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cell adhesion molecule (sVCAM-1) and soluble intercellular adhesion molecule 
(sICAM-1). 
 
Another study by Torriani in 2005 also showed  that cumulative PI use is associated with 
femoral artery stiffness, whereas no such association was found for cumulative NNRTI use. 
This may suggest that effects of HAART on arterial stiffness vary between different drug 
classes. Our participants were on NNRTI and not PI. Another controversy about the impact 
that administering HAART might have on increasing the stiffness of the arterial walls in HIV 
patients is that of Hulten et al (2009). The meta-analysis involving 5456 HIV-positive and 
3600 HIV negative patients did not find an association between SA and HAART (Hulten et 
al. 2009) while other authors suggest that HAART has a possible protective effect on the 
development of early atherosclerosis (Ho et al. 2010). On the contrary, others report an 
increased rate of SA in HIV patients taking antiretroviral therapy administered over a longer 
period (Lekakis et al. 2009, Van et al. 2009).  
 
Schillacci et al (2005) in their study consisting of 32 HIV-infected patients treated with 
protease inhibitors and 32 age, sex, and blood pressure–matched HIV-uninfected control 
subjects, obtained aortic pulse wave velocity and central aortic pressure waveform, from 
which aortic augmentation was calculated. HIV patients had a higher aortic pulse wave 
velocity (7.6±1.1 versus 6.8±1.2 m×s
−1
, P=0.015) and aortic augmentation (6.8±5 versus 
4.6±4 mm Hg, p=0.037) than control subjects. In this study, the aortic pulse wave velocity 
was (6.84±1.17 vs 6.38±1.67,p=0.037)  in HIV treated positives, although  participants in this 
study were on first line antiretroviral therapy used in our public hospitals. 
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The relative contributions of conventional cardiovascular risk factors, metabolic side effects 
of antiretroviral drugs, and HIV infection itself on cardiovascular risk are difficult to identify 
(Phillips et al. 2008, El -Sadr et al. 2006). These cardiovascular risk factors include; genetic, 
smoking, lack of exercise and diet.  
5.5. Impact of cardiovascular risk factors on the arterial wall 
Smoking, lack of physical exercise, obesity were some of the factors considered in the 
questionnairres administered to the participants in this study as these are considered as 
traditional risk factors. 17.24% of the HAART naïve HIV positive participants smoked whilst 
only 2.8% of HIV participants who were on treatment smoked. This difference might be 
because the participants on treatment were always counselled not to smoke. 
 
In a review by Safar in 2003 the prognostic importance of PWV has been attributed to it 
being an integrated measure of the impact of cardiovascular risk factors on the arterial wall 
and to adverse hemodynamic effects of aortic stiffening (Safar  2003). One of the reasons of 
the increased mortality in younger HIV infected patients on antiretrovirals may be the fact 
that they developed atherosclerosis early in life which increased the risk of cardiovascular 
disease (Triant et al. 2007). The HIV or the treatment might have gradually caused some 
degree of inflammation in the endothelium of the blood vessels as they grow in age. The HIV 
or the treatment might have gradually caused some degree of inflammation in the 
endothelium of the blood vessels as they grow in age since they were infected in childhood. 
 
The study by Triant et al (2007) was performed using data from a Massachusetts 
administrative hospital database including 3851 HIV-infected patients and more than 1 
million HIV uninfected patients from 1996 to 2004. The mean MI rates were 11.13 versus 
6.98 per 1000 person-years, respectively. The MI rates were higher in HIV-infected patients 
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in all age groups, with very high rates in older patients. Haemodynamic effects of arterial 
stiffening include an increase in systolic blood pressure and pulse pressure with increased 
systolic load and decreased myocardial perfusion pressure (Najjar et al. 2008). 
 
The prevalence of some risk factors may be higher in HIV-infected populations, however, in 
the D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) study involving 23,468 
HIV-infected persons, at baseline, 11.4% had a family history of coronary disease, 1.4% had 
a prior history of coronary disease, 51.5% were current smokers, 3.5% had a body mass index 
greater than 30 kg/m2, 8.5% had hypertension, 2.5% had diabetes, 22.2% had elevated levels 
of total cholesterol, and 33.8% had elevated triglyceride levels (Friis-Moller et al. 2003). A 
recent analysis of modifiable risk factors and death in the D:A:D study showed that smoking 
(rate ratio, 1.20), hypertension (rate ratio, 1.53), and diabetes (rate ratio, 1.83) were 
independently associated with risk of death during treatment for HIV infection (Smith et al. 
2009).  
 
5.6. Arterial stiffness and Inflammation 
Inflammation refers to the complex cascade of events that happen when the immune system 
recognizes a threat and goes into action, including migration and activation of various types 
of white blood cells (leukocytes) and release of chemical messengers known as cytokines. 
The word ‗inflammation‘ often brings to mind the immune system‘s immediate response to 
acute injury or infection. Inflammation can become chronic if the trigger persists, or if 
suppressive control mechanisms do not work properly. 
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In this study, IL-6 and E-selectin in HIV positives not on HAART were significantly and 
positively correlated with PWV (P<0.05). This means that these cytokines increase with 
increase in arterial stiffness in treatment naïve HIV positives.   
 
With multiple linear regression excluding confounding factors, TNFα is one of the variables 
that was identified (negative correlation) as  independent and significantly associated with 
increase in AIx(75) among HIV positive participants on HAART. One should bear in mind 
that Tnfα is both anti and proinflammatory. These observations were corroborated with 
increases in their values compared to controls and their significant values in univariate 
analysis. Although there were no differences in the inflammatory markers between the 
genders and the ages, infection with HIV might have  resulted in dysregulation of the 
cytokine profile in vivo and in vitro. In an unpublished study by the author with over 300 
participants it was found that  E- selectin was significantly increased in HIV positive 
participants. 
 
Cytokines play an important role in controlling the homoeostasis of the immune system 
(Krishnaswamy et al. 2000).  During the course of HIV-1 infection, proinflammatory 
cytokines (IL-1, IL-6, IL-8) and tumour necrosis factor (TNF)-alpha, are increased.  As stated 
earlier, cytokines were increased in this study but not significantly in the HIV positive 
participants. This  abnormal cytokine production  may contribute to the pathogenesis of the 
HIV disease by impairing cell-mediated immunity. A number of cytokines have been shown 
to modulate in vitro HIV-1 infection and replication in both CD
4
 T lymphocytes and cells of 
macrophage lineage. HIV inductive cytokines include: TNF-alpha, and IL-6, which stimulate 
HIV-1 replication in T cells and monocyte-derived macrophages (Kedzierska et al. 2001). 
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It has also been shown that HIV infection induces increased production of TNFα by 
macrophages. The immuno-regulatory response of the host influences the 
pathogenesis of HIV-1 infection, triggering monocytes, macrophages, and natural 
killer cells to produce TNFα (Alfano & Poli 2005). In this study, the Tnfα is increased 
in HAART naïve positives compared to the other groups but there was a negative 
correlation with AIx(75). This may be because it is both antiinflammatory and 
proinflammatory. TNFα is an acute phase protein which initiates a cascade of 
cytokines and increases vascular permeability, thereby recruiting macrophage and 
neutrophils to a site of infection.  TNFα secreted by the macrophage causes blood 
clotting which serves to contain infection, but high levels of TNFα correlate with 
increased risk of mortality (Rink & Kirchner 1996).  Exogenous and endogenous 
factors from bacteria, viruses, and parasites stimulate production of Tnfα and other 
cytokines. Tnfα exhibits chronic effects as well as resulting in acute pathologies.This 
relationship suggests that reducing Tnfα levels may also reduce occurrence of HIV - 
1 viraemia. In excess, Tnfα may cause severe inflammatory damage and toxicity, 
making control of its production and secretion highly important. Regulating its 
release serves as a potential means of therapy for HIV-1 and other diseases. Tnfα 
can also induce other pro-inflammatory cytokines such as IL-6 and IL-8 (Fernandez-
Ortega et al. 2004). Studies have also shown the ability of Tnfα to stimulate 
production of anti-inflammatory cytokine IL-10, preventing further inflammation by 
causing Tnfα inhibition (Leghmari et al 2008). TNFα is secreted during the early 
phase of acute inflammatory diseases. Its pathogenic role in HIV-1 infection involves 
activation of nuclear factor ķB, stimulating apoptosis of T lymphocytes (Fernandez-
Ortega et al 2004). 
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In this study there is a depletion of lymphocytes and absolute CD4 counts in HIV participants 
who are HIV positive. Tissue and plasma samples of hosts express high levels of TNFα 
contributing to fever, anorexia, and other symptoms of HIV/AIDS. In a pilot study of patients 
with untreated HIV infection, 8 weeks of treatment with the tumor necrosis factor inhibitor 
pentoxifylline resulted in improvements in the endothelial activation marker VCAM-1 and 
brachial artery flow-mediated dilation (Gupta et al,  2008). A study of women treated for 
cervical intraepithelial lesions showed that after treatment, there were increased levels of 
genital HIV, TNF-α, IL-6, and other activation markers in cervicovaginal lavage (Spear et al 
2008). In univariate analysis, genital tract HIV RNA was significantly associated with plasma 
HIV RNA and several of the cytokines (Spear et al. 2008).  
 
Many data sustain the role of a persistent low grade inflammation in the development of large 
arteries stiffness (McEniery & Wilkinson 2005, Loscalzo & Welch 1995, Moncada 1999). 
Chronic inflammation resulting from HIV infection may therefore explain the association 
between HIV infection and increased arterial stiffness, as has been shown  in this study. In 
bivariate/univariate analysis Tnfα showed a negative association with PWV. Also in multiple 
linear regression Tnfα had a negative association with AIx(75).This could be because the 
TNFα may be proinflammatory or anti-inflammatory depending on the immune status of the 
HIV positive participants and duration of treatment. In this study none of the participants had 
detectable viral level on admission to the study. 
 
A study by (Hsue et al. 2004) suggested that chronic inflammation may be a key contributor 
to the accelerated development of atherosclerosis in HIV patients. They compared carotid 
intima media thickness and levels of C-reactive protein (a marker of systemic inflammation) 
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in HIV-positive and HIV-negative patients. The carotid intima media thickness was greater in 
all groups of HIV patients, irrespective of level of viremia or exposure to antiretroviral 
therapy, than in healthy controls. In addition, C-reactive protein levels remained elevated in 
HIV-infected participants regardless of their level of viremia. These findings suggest not only 
that HIV-associated atherosclerosis is determined by advanced immunodeficiency, high-level 
viremia, and exposure to antiretroviral drugs, but also that persistent inflammation due to 
HIV infection may play an important role in accelerated atherosclerosis.  
 
In this study, Crp level was highest in HIV participants on treatment although not significant 
than the other two groups. Crp is an acute phase reactant protein and could be 
proinflammatory. It probably helps in phagocytosis of invading organisms. Its increased level 
seen in participants on treatment might be a protective one.  Another reason might be because 
the group may have other complications due to the treatment like; abnormal fat deposit which 
in itself is a source of inflammation which might increase the level of Crp.  
 
Little is known about how different antiretroviral drugs affect Crp levels during successful 
antiretroviral therapy. Recent data from ACTG (AIDS Clinical Trials Group) study involving 
5095 subjects demonstrated that Crp levels did not improve during 96 weeks of treatment 
with efavirenz. Shikuma et al (2009) in their study comprising of mainly women found out 
that the Crp level rose (Shikuma et al. 2009). Most of my participants were women and 
probably that is why there was an increase in the level of Crp with treatment. 
 
Despite the potential association of inflammation with increased CVD risk, a number of small 
studies have not found a strong association between higher levels of high-sensitivity Crp 
(hsCRP) and IMT. In my study, there was a negative correlation with PWV. The negative 
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correlation of Crp with arterial stiffness also suggests that it could be protective.  This may 
mean that Crp may be both inflammatory and anti-inflammatory thus  decreasing arterial 
stiffness in HIV participants? Could TNFα and Crp be  modulating   HIV-1 infection? Hsue 
et al (2006) found no association of HSCRP or immune activation (CD38+, CD4+, CD8+ cell 
responses) with IMT, but they reported an association between IMT and cytomegalovirus-
specific T-cell responses, suggesting that response to latent or persistent viral infection might 
be driving a proatherosclerotic response (Hsue et al. 2006).  
 
Endothelial activation may also occur by cytokines secreted in response to leukocyte 
activation by HIV (Krishnaswamy et al. 2000). Cytokines play an important role in 
controlling the homoeostasis of the immune system. Abnormal cytokine production  may 
contribute to the pathogenesis of the HIV disease by impairing cell-mediated immunity. A 
number of cytokines have been shown to modulate in vitro HIV-1 infection and replication in 
both CD4 T lymphocytes and cells of macrophage lineage. HIV-inductive cytokines include: 
TNFα, and IL-6, which stimulate HIV-1 replication in T cells and monocyte-derived 
macrophages (Kedzierska et al. 2001). 
HIV infection per se has been attributed to have several pathways of instigating vascular 
complications. Similar to other chronic infections such as cytomegalovirus and Chlamydia 
(Zhu et al. 1999), HIV may contribute to the vascular endothelial damage and premature 
atherosclerosis via sustaining a low-degree inflammation. Secondly, both immunodeficiency 
and the immune reconstruction following the commencement of the antiretroviral therapy are 
associated with enhanced T-lymphocyte proliferation and activation that adds to the overall 
atherogenic pro-inflammatory state.  
 
5.7. Arterial stiffness and aging 
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In this study participants who were older than 35 years had a greater pulse wave velocity and 
arterial stiffness than those who are less than 35 years (p<0.001). Pulse wave velocity had a 
positive correlation with age in the HIV negative group (r =0.606, p<0.001), and with HIV 
positive participants not on treatment (r =0.647, p<0.001). 
 
Comparing participants who are over the age of 35 years and those who are older than 35 
years all the indices with the exception of the lipid profile increased in participants over 35 
years. The indices that increased are; the anthroprometric measurements, blood pressure, 
blood counts with the exception of CD4, the pulse wave velocity and the augmentation index. 
The cardiac functions such as as subendocardial viability ratio and ejection duration index 
were not affected by age.  
 
With multiple linear regression, after excluding confounding factors; age (positive 
correlation), was amongst the variables identified as an independent and significant variable 
associated with increase in AIx(75) among HIV positive participants on HAART in this 
study. Since AIx(75) is an index of arterial stiffness, age is therefore an important factor in 
the development of atherosclerosis. This implies that as one gets older one is prone to 
developing atherosclerosis. 
 
These results were not unexpected, as aging produces more collagen than elastin, hence the 
increase in PWV. An increased arterial stiffness and augmentation index (wave reflection) 
are now well accepted as the most important determinants of increasing systolic and pulse 
pressure in ageing societies, thus affording a major contribution to stroke and myocardial 
infarction (Guerin et al. 2008). 
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Vascular aging is an independent risk factor for cardiovascular disease, from atherosclerosis 
to target organ damage, including coronary artery disease, stroke and heart failure. Various 
strategies, especially controlling hypertension, show benefit in preventing, delaying or 
attenuating vascular aging (Lee 2010). In children, and in the youth, the arterial wall 
comprises an orderly arrangement of elastic laminae separated by interconnecting elastic 
fibers, smooth muscle, collagen fibers, and connective tissue. In older humans, this orderly 
structure becomes deranged, with thinning, splitting, fraying, and fracture of the elastic 
laminae and with increase in connective tissue and collagen fibers.  This also supports the 
fact that arterial stiffness increases with aging as in this study. 
 
Some other studies have also referred to arterial stiffness as being affected by age (Charadika 
et al. 2009, Avolio 1985). The present study showed positive correlations of arterial stiffness 
with age in the controls and HAART naïve participants. These findings are also in agreement 
with studies previously reported in HIV children by measuring their carotid arterial stiffness 
(Ananyeva et al. 1997 & Charadika et al. 2009). They studied  83 HIV-infected children with 
a mean age of 1.0 +/-3.1 years and 59 controls aged 12.2 +/-2.8 years. Among the HIV-
infected children, 48 were receiving HAART (23 including a protease inhibitor). HIV-
infected children had increased arterial stiffness compared with healthy children. These 
changes were more pronounced with increasing age in HIV-infected children particularly in 
those who were receiving HAART. This study differentiated between HIV positives on 
HAART and HAART naïve HIV positives. HAART naïve HIV positives had the greatest 
increase in arterial stiffness.  Mitchell et al (2007) in the Framingham study reported that with 
advancing age, arterial stiffness and wave reflections increase and elevate systolic and pulse 
pressures. 
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A study by Monteiro (2012) showed that there was no statistically significant difference in 
mean PWV values between HIV-infected and uninfected individuals who did not agree with 
the findings of this study as indicated earlier. On the other hand Monteiro‘s study concluded 
that in both HIV infected and uninfected groups, PWV was significantly higher in individuals 
aged 40 years or older particularly in males, which agreed with this study. 
  
Long-standing arterial pulsation which might be due to aging  in the central artery might 
cause elastin fiber fatigue and fracture. Increased vascular calcification and endothelial 
dysfunction are also characteristic of arterial aging. These changes lead to increased pulse 
wave velocity, especially along central elastic arteries, and increases in systolic blood 
pressure and pulse pressure (Lee 2010). Vascular aging is accelerated by co-existing 
cardiovascular risk factors, such as hypertension, metabolic syndrome and diabetes. The 
major parameters to be taken into account, when evaluating the degree of arterial stiffness, 
are; age, blood pressure, and, to a lesser extent, gender and classical CV risk factors. This is 
in agreement with this study. 
 
Aging is an important determinant of cardiovascular risk and is associated with a number of 
changes in the structure and function of the cardiovascular system including the large arteries 
(Lee 2010).  Although the aorta is often thought to be an inert conduit vessel, it plays a vital 
role in buffering and smoothing the pulsatile nature of blood flow as it travels to the 
periphery. With age, the aorta stiffens (McEniery et al. 2005;2009), dilates, and becomes 
tortuous. Such changes lead to an increase in pulse pressure, which places an additional strain 
on the aorta and limits its buffering capacity. 
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The stability, resilience, and compliance of the vascular wall are dependent on the relative 
contribution of its 2 prominent scaffolding proteins: collagen and elastin. The relative content 
of these molecules is normally held stable by a slow, but dynamic, process of production and 
degradation. Histological examination of the intima of stiffened vessels reveals abnormal and 
disarrayed endothelial cells, increased collagen, frayed and broken elastin molecules, 
infiltration of vascular smooth muscle cells, macrophages and mononuclear cells, and 
increased matrix metalloproteinases, transforming growth factor (TGF)-β, intracellular cell 
adhesion molecules, and cytokines (Lakatta 2003). In addition to vessel wall thickening, 
aging is associated with a gradual increase in central artery lumen diameter; 9% per decade 
from 20 to 60 years in the ascending aorta (Watanabe et al. 1996), although some recent 
studies have suggested this does not occur (Mitchell et al. 2003). 
 
Elderly people are predisposed to lose arterial elastic laminae and increase collagen depo.  In 
a study carried out by Guerin et al (2008) stiffness of the whole aorta was greatest in older 
subjects, and the impact of age was most marked in those older than 50 years of age, in 
keeping with previous observations (Guerin et al. 2008). This is also in keeping with the 
observation in this study. 
 
5.8. Arterial stiffness and other pathological conditions 
A large number of publications and several reviews reported the various pathophysiological 
conditions associated with increased arterial stiffness and wave reflections (Oliver 2003). 
Apart from the dominant effect of ageing, they include physiological conditions such as; low 
birth weight (Lurbe 2003), menstrual cycle (Giannattasio 1999), CV risk factors such as 
obesity (Ferreira 2005), smoking (Kool 2005). Other factors that affect arterial stiffness 
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include; hypertension (Simon 1985), hypercholesterolemia (Wilkinson et al 2002), impaired 
glucose tolerance, metabolic syndrome, types 1 and 2 diabetes (Schram et al. 2005). 
 
5.9. Blood pressure and arterial stiffness  
In this study with HIV negative participants, using univariate analysis, there was a significant 
correlation between Ppa, MP, Spa, Dbp, and PWV. In HIV positive participants not on 
HAART and HIV positive participants on HAART, Ppa, MP and Spa were significantly and 
positively correlated with PWV. In both HIV positive groups, HR and Dbp were not 
significantly correlated with PWV. With multiple linear regression and the model adjusted 
for gender, anthropometric parameters, HDL-C, TC, LDL-C, haematologic data, 
haemodynamic data, cytokines, smoking, alcohol. Spa, age and triglycerides are the only 
independent and significant determinants of PWV among HIV negative participants.This also 
shows that systolic aortic  pressure, triglycerides and age are strong determinants of PWV in 
HIV negatives. 
 
Findings from this study confirm the well-established association of PWV with blood 
pressure. The aortic pulse pressure (Ppa) correlated positively with pulse wave velocity in  all 
the three groups and so does the mean aortic pressure (MP). The systolic aortic pressure (Spa) 
correlated positively with both the HIV negative participants and HIV positive participants 
not on treatment in univariate/bivariate analysis. All the blood pressures correlated with pulse 
wave velocity in all the three groups of participants with the exception of the brachial 
diastolic blood pressure which correlated with the PWV in participants who are HIV 
negative. 
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An elevated central (aortic) pulse pressure as in the case of the HIV positive patients in this 
study is generally ascribed to increased wave reflection and portrays an unfavorable 
prognosis.   With a higher aortic systolic pressure, and higher mean arterial pressure, these 
factors might be expected to cause fracture of elastic fibers leading to increased pulse wave 
velocty. 
 
Using arterial tonometry, the Framingham study group evaluated central (carotid-femoral) 
and peripheral (carotid-brachial) pulse wave velocity, amplitudes of forward and reflected 
pressure waves, and augmentation index in 188 men and 333 women who were free of 
clinical cardiovascular disease, hypertension, diabetes, smoking within the past 12 months, 
dyslipidemia, and obesity. In their study using multivariable linear regression models, 
advancing age was the predominant correlate of higher carotid-femoral pulse wave velocity.  
 
Their study is in agreement with this study in which age, blood pressure, triglycerides, heart 
rate and augmentation index correlated with carotid -aortic pulse wave velocity. With 
multivariate linear regression, this study also showed only MP and waist circumference as the 
most important and significant independent determinants of PWV in HIV positive 
participants not on treatment.  Again the mean arterial pressure is being considered as 
significant in the determination of pulse wave velocity.   
 
Other factors which were considered in this study were the environment, economic status, 
diet, smoking, and drinking habits. All these are factors that might contribute to arterial 
stiffness. In the district of Lugalawa (Tanzania), subjects who are used to eating fish show a 
lower BP and no increase in systolic BP with increasing age in comparison with those of the 
same genetic strain living some kilometers away and eating a more complex diet (Pavan et al. 
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1997). In Europe important differences were found in the prevalence of hypertension in a 
survey representative of the general population recruited from eight countries (Kuznetsova et 
al. 2002). Therefore, environmental factors play a role in allowing full expression of the 
genetic potential of individuals to become hypertensive with age. The increase in blood 
pressure with age should be seen as a sort of adaptation to the environment. In this study the 
participants come from very poor background eating mostly carborhydrate meals. 
 
The diastolic aortic (central) blood pressure is the blood pressure when the heart is relaxed, 
measured at the level of the aorta. In normal arteries, when blood is pumped from the heart, 
the arteries expand (increase in diameter) due to elasticity, and "store" some blood and during 
diastole, the recoil of the arteries pushes the stored blood through the circulatory tree to give 
the diastolic pressure. When the compliance decreases, this capacity to "store" blood 
decreases and thus, the diastolic pressure decreases also.The diastolic brachial (peripheral ) 
blood pressure was lower in the HIV negative participants. This is probably because the 
compliance of the blood vesel is  affected by HIV and therefore the capacity of HIV 
negatives to store blood in diastole increases more than that of the HIV positive participants. 
Vessel compliance basically modulates blood pressure to keep it within a relatively narrow 
range, this is key given that the heart is an intermittent pump. Without compliance, blood 
pressure will peak and crash with every beat. Diseased aorta are less elastic/compliant, 
therefore they cannot modulate blood pressure quite well, hence systolic pressure increases 
and diastolic pressure decreases.  Pulse pressure increases and this therefore enhanced arterial 
stiffness. The positive correlation of the blood pressure parameters with PWV were marked 
in all the three groups of participants in my study. Using multivariate linear regression in HIV 
positive participants on treatment, age, MP, HDL-C, and triglycerides were identified as the 
significant independent determinants of the variations of PWV. 
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The elevation of  aortic (central) pulse pressure, aortic systolic pressure and aortic mean 
pressure in the HIV participants who are HAART naïve might be because the inflammatory 
state of the  HIV has caused some structural abnormalities to the elastin and collagen fibres of 
the blood vessels. Arterial stiffening is the principal cause of increasing systolic pressure with 
advancing years. It is associated with progressive arterial dilation and is due to degeneration 
of the arterial wall, probably as a consequence of repetitive cyclic stress. It increases systolic 
pressure directly by increasing amplitude of the pressure wave generated by a given flow 
impulse from the heart and indirectly by increasing wave velocity so that wave reflection 
from the periphery occurs earlier, augmenting pressure in late systole (O'Rourke 1990). 
 
Isolated systolic hypertension (defined as systolic blood pressure >140 and diastolic blood 
pressure <90 mm Hg) and elevated pulse pressure (PP=systolic blood pressure−diastolic 
blood pressure) are 2 clinical manifestations of decreased vascular distensibility (Dart & 
Kingwell 2001).  The prevalence of hypertension increases with age such that >60% of 
people older than age 65 years are hypertensive with systolic blood pressure >140 mm Hg 
and/or a diastolic blood pressure >90 mm Hg; older blacks have a higher prevalence of 
hypertension than do whites in all age groups (Chobanian et al. 2003), However, unlike 
younger hypertensive subjects in whom systolic blood pressure, diastolic blood pressure, and 
MP are all risks for cardiovascular events,  isolated systolic hypertension, elevated PP, and 
increased PWV pose more significance at risks for strokes, myocardial infarctions, heart 
failure, and overall mortality in older adults (Mitchell et al. 1997). This difference in risk 
implies a different pathophysiological mechanism for hypertension in younger versus older 
individuals and perhaps a different therapeutic approach (Darne et al. 1999). In fact, it is 
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reported that every 2-mm Hg increase in systolic blood pressure increases the risk of fatal 
stroke by 7% and fatal coronary heart disease event by 5% (Darne et al. 1999). 
 
Chronic elevation of mean blood pressure also leads to thickening of arterial wall, mostly in 
the intima media. Elevation of peripheral vascular resistance combined with increased arterial 
stiffness in older subjects leads to development of isolated systolic hypertension. There is 
growing evidence that response of PP to therapy may also be relevant to outcomes. In post-
hoc analysis of Systolic Hypertension in the Elderly Program (SHEP) trial data, widening of 
PP (>10 mm Hg) on active drug therapy was associated with increased risk of stroke 
(Vaccarino et al. 2001). Another analysis of the same study showed that the risk stemming 
from excessive diastolic blood pressure reduction is dose-dependent, with a threshold at ≈60 
mm Hg (Somes et al. 2009). 
 
It is important to underscore that a reduction in blood pressure and/or an increase in vascular 
compliance are associated with a reduction in cardiovascular risk. However, it is often 
difficult to separate the effects of pharmacological and lifestyle interventions on blood 
pressure reduction alone from their direct effects on the vascular wall properties. Changes in 
MP tend to correlate better with changes in arterial compliance than do changes in systolic 
blood pressure. As highlighted in these clinical and observational trials, interventions that 
lower blood pressure and that are associated with reduction in cardiovascular risk are 
associated with a decrease in measures of arterial stiffness (PWV, augmentation index, 
compliance); however, they may not necessarily have any direct effect on structural 
components of the vessel wall that contribute to stiffness.  
The simple interpretation of systolic and diastolic pressures recorded with a 
sphygmomanometer as put forth by Mackenzie in 1926 is that "As regards the relative 
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importance of systolic and diastolic pressures, it may be said that the systolic pressure 
represents the maximum force of the heart while the diastolic pressure measures the 
resistance the heart has to overcome (Fisher 1985).  
 
In this study, the diastolic blood pressures were greater in HIV positive participants on 
treatment. Diastolic blood pressure is more in keeping with arterial tone and happens  during 
relaxation and during this time they would have transferred stress to the aorta. Thus arterial 
stiffness does not manifest itself much during diastole. Hence it can be said that the systolic 
pressure is more important in arterial stiffening than the diastolic pressure, so the participants 
who are antiretroviral naïve are more prone to arterial stiffness. The treatment might have 
caused the blood vessel to be less compliant and thereby increasing diastolic blood pressure. 
The HIV participants on treatment might have had low or normal blood pressure at the 
beginning of treatment and as treatment advances the duration of treatment might affect the 
deposition on lipids on the arteries causing a decrease in the diameter of the lumen of the 
blood vessels. Thus the duration of treatment might have caused diabetes, insulin resistance 
or even the metabolic syndrome. (Awotedu et al 2010 & Awotedu et al. 2012).  
 
It could be observed from these results that the aortic blood. pressures are better in assessing 
blood pressure than the brachial blood pressure. Aortic blood pressure is higher in the 
HAART naive HIV positive participants so also is the MP. The HI virus in these HAART 
naïve HIV positives might be causing structural deformities in the arterial wall.  
 
It is inaccurate to use arterial stiffness brachial pulse pressure as a surrogate for aortic or 
carotid pulse pressure, particularly in young subjects because the amplitude of the pressure 
wave is higher in peripheral arteries than in central arteries (O‘Rourke 1990). Pulse wave 
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velocity is directly related to brachial and aortic pulse pressure, mean arterial pressure and 
systolic blood pressure. According to Wilkinson (2001), pulse pressure over-estimates central 
systolic blood pressure and pulse pressure in young subjects.  
 
One would say what matters most is the aortic or systolic blood pressure and pulse pressure 
but observations from this study has shown the mean arterial pressure is very important and 
should even take preference over the pulse pressure in the determination of arterial stiffness. 
Again, this study shows that the HI virus can cause raised systolic blood pressure.  
 
A generally accepted mechanistic view is that an increase in arterial stiffness causes a 
premature return of reflected waves in late systole, increasing central pulse pressure, thus 
systolic blood pressure. Systolic blood pressure increases the load on the left ventricle, thus 
increasing myocardial oxygen demand. In addition, arterial stiffness is associated with left 
ventricular hypertrophy (Asmaar et al. 1988). The increase in central pulse pressure and the 
decrease in diastolic BP may directly cause sub-endocardial ischemia (Boutouyrie 1994).  
 
Pressure wave reflection in the arterial system serves two beneficial purposes. When 
normally timed, the reflected wave returns to the central aorta in diastole and therefore 
enhances diastolic perfusion pressure in the coronary circulation (Mitchell et al. 2004). Partial 
wave reflection also returns a portion of the pulsatile energy content of the wave form to the 
central aorta where it is dissipated by viscous damping. Thus, wave reflection limits 
transmission of pulsatile energy into the periphery where it might otherwise damage the 
microcirculation (Woolam et al. 1962). Loss of this apparently protective function of wave 
reflection could contribute to the pathogenesis of a growing spectrum of cardiovascular and 
noncardiovascular accompaniments of aging that share a potential microvascular etiology 
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(Avolio et al. 1983) including white matter lesions of the brain and renal dysfunction (Sutton-
Tyrrell et al. 2001). 
 
In the normal arterial system, there is a steep gradient of increasing arterial stiffness moving 
outward from the heart. In a young adult, pulse wave velocity (PWV), a close correlate of 
arterial wall stiffness, is only 4 to 6 m/s in the highly compliant proximal aorta and increases 
to 8 to 10 m/s in the stiffer peripheral muscular arteries. This progressive increase in regional 
arterial stiffness, together with branching and narrowing of the lumen, creates an impedance 
mismatch and leads to a partial reflection of the advancing pressure wave (Kannel et al. 
1979). Prior studies have shown that central arterial stiffness increases to a far greater extent 
than peripheral arterial stiffness with advancing age (Kelly & Fitchett 1992). As a result, 
aortic stiffness may equal or exceed peripheral arterial stiffness in the elderly. This reversal 
of the normal arterial stiffness gradient may diminish wave reflections and therefore increase 
transmission of pulsatile energy into the periphery and microcirculation. 
 
5.10. Arterial stiffness and dyslipaedimia in HIV positive participants 
In this study, both the  means of HDL-C and  Total choleterol levels in the HIV participants 
on  treatment were significantly higher than the two other groups (p=.002 and p=.005 
respectively). Non-nucleoside reverse transcriptase inhibitors have been associated with 
elevated levels of high-density lipoprotein cholesterol (Murphy et al. 2003). NNRTI were the 
antiretrovirals used in this study as in the study by Murphy.  
 
Initiation of NNRTI-based HAART regimen has been shown to result in increases in HDL-C 
of approximately 40% depending on the agent used, with increases in total cholesterol 
(Haubrich et al. 2009). This is in agreement with this study in which NNRTI-based HAART 
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regimen was used and there was increase in HDL-C levels of participants on treatment. Use 
of NRTI is not free of dyslipidaemia. 
 
Use of the NRTI stavudine has been associated with a worse lipid profile than the nucleotide 
reverse transcriptase inhibitor (NRTI) tenofovir, with significant increases in total 
cholesterol, LDL-C and triglycerides (Gallant et al. 2004). This study was started in 2009 and 
stavudine was amongst the drugs  commonly used in the public clinics though at present 
tenofovir has been substituted for stavudine in cases of severe lipodystrophy. Although these 
data point to dyslipidaemia induced by HAART from all of the three commonly used drug 
classes, not all patients responded similarly to antiretroviral regimen. 
 
Shor-Posner et al (1993) and Grunfeld et al (1992) in their study found out that HIV-infected, 
untreated patients (particularly those with more advanced disease) are more likely to have 
low total, LDL-C and HDL-C and elevated serum triglyceride (TGs) than HIV-negative 
controls. This is in agreement with this study which showed that HDL-C and TC were lower 
in the participants even in the HIV negatives. Lower HDL-C concentrations is associated 
with higher circulating HIV RNA levels and longer duration of HIV infection (Rose et al. 
2006). These  HAART naïve HIV positive participants may have the infection for a long 
time. Effective HAART in the majority of patients suppresses HIV RNA to undetectable 
levels thus allowing immune recovery, measured by increases in CD4 cell counts. This is 
usually accompanied by some increases in total cholesterol and LDL-C (Ridler 2003) which 
some have suggested may be a return to normal. 
 
Many infections favour or are directly implicated with lipid metabolism changes and/or 
increased risk of coronary heart disease. HIV itself has been shown to increase lipogenesis in 
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the liver and to alter lipid profile (Melzi et al. 2010). HIV-1 infection causes a specific pattern 
of dyslipidemia, resulting from a combination of increased production and decreased 
clearance of lipoproteins.  
 
Molecular mechanisms responsible for the numerous lipid-related disorders in HIV-infected 
individuals are not well understood. Adipose tissue hosts multiple cell types including 
monocytes, macrophages, endothelial and vascular smooth muscle cells. These immune cells 
are functionally active in the adipose tissue and produce numerous cytokines and other 
regulatory factors that influence lipid homeostasis, regulation of steroid hormones, 
prostaglandin, and fat-soluble vitamins. These factors also control storage of excess lipids 
and triglycerides (either normal and abnormal fatty acids) present in the circulation. 
Many infectious agents including HIV-1 have profound impact on adipocytes which become 
dysfunctional and cannot store most lipids that is, triglycerides properly (Melzi et al. 2010). 
The above factors might also explain the elevated levels of triglycerides and cholesterol 
found in the HIV positive participants in this study by controlling storage of excess lipids in 
the circulation.  
 
Riddler et al (2003) evaluated changes in serum cholesterol associated with HIV infection 
and subsequent antiretroviral therapy. They tested saved blood samples from 50 of 517 male 
seroconverters from the Multicenter AIDS Cohort Study. The outcome measures were; 
changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C). These parameters were evaluated at six time points 
over a period of 12 years. After HIV seroconversion, they noted significant declines in TC, 
HDL-C, and LDL-C. Following the initiation of HAART, increases in TC and LDL-C to 
slightly above pre-seroconversion levels were seen. The authors concluded that HIV infection 
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alone results in substantial decrease in TC, HDL-C, and LDL-. They postulated that the post 
treatment elevations in TC and LDL-C probably represent a return to pre-infection lipid 
levels.  This is in agreement with our study that shows decreased level of HDL-C in HAART 
naïve HIV positive participants compared to the other two groups (p=0.002) and decreased 
level of TC also (p=0.05). The decreased level of the lipid profile with the exception of the 
LDL-C seen in HAART naive participants might be because of the HIV itself or because of 
wasting as a result of chronic inflammation. 
The triglyceride level of HIV participants  on treatment correlated positively with pulse wave 
velocity (r= 0.490; p=.002) so was the total cholesterol level (r=0.370;p=0.019).   In a study 
by  Yao et al 2012  they found that   elevated levels of circulating triglycerides and increased 
arterial stiffness are associated with cardiovascular disease. Numerous studies have reported 
an association between levels of circulating triglycerides and arterial stiffness. They 
investigated the association between circulating triglyceride levels, the apolipoprotein A-V 
(ApoA5) -1131T>C single nucleotide polymorphism and brachial-ankle pulse wave velocity 
(baPWV) by examining data from 4421 subjects aged 18-74 years who were recruited from 
the Chinese population. baPWV was significantly associated with the levels of circulating 
triglycerides after adjusting for age, sex, body mass index (BMI), systolic blood pressure, 
heart rate, waist-to-hip ratio, antihypertensive treatment and diabetes mellitus status. This is 
in agreement with this study in which with the use of  multiple linear reggression  Spa, age 
and triglycerides were the only independent and significant determinants of PWV among 
HIV negatives. My model was adjusted for gender, anthropometric parameters, HDL-C, TC, 
LDL-C, haematologic data, haemodynamic data, cytokines, smoking, alcohol.  
 
With HIV positive participants on HAART, age, MP, HDL-C, and triglycerides were 
identified as the significant independent determinants of the variations of PWV whilst 
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adjusting for gender, anthropometric data, smoking, alcohol, cytokines, adhesion molecules, 
total cholesterol, LDL-C, haematological data, CD4 count, and other haemodynamic 
parameters. Aznaouridis et al ( 2007) in their study found out that in  healthy men, serum 
triglyceride levels are associated with indices of arterial stiffness and wave reflections, which 
are important determinants of cardiovascular function and risk (Aznaouridis et al 2007). The 
importance of HDL-C as a determinant of PWV is emphasized in this study. 
 
HDL-C levels in the  HIV positive participants on treament was significantly higher than the 
other two groups. It could be that the treatment has helped in alleviating arterial stiffness in 
those on treatment. The cholesterol level in those on treatment was also the highest in the 
three groups and this is also significant. With  HDL-C there was a slight negative  correlation 
with PWV in HIV positive partiipants on treatment. This shows that with increase in HDL 
there was decrease in arterial stiffness in the HIV positives who are on treatment. This is in 
agreement with a study by Wang et al (2011) in which  HDL-C was independently inversely 
associated with aortic stiffness and peripheral stiffness (Wang et al 2011). ).  According to  
Velagaleti  et al (2009) decreased HDL-cholesterol levels are associated with increased left 
ventricular mass, decreased diastolic function, and a lower ejection fraction in individuals 
with normal and narrowed arteries, which inevitably leads to increased arterial stiffness. 
 
In my study,  triglyceride correlated with aortic stiffness in HIV participants who are on 
treatment. The result of this  study is also in agreement with that of Grunfeld at al (1999) in 
which he found that HIV infection was associated with elevated triglyceride levels that 
worsened with progression of HIV-related disease. Serum triglyceride levels are associated 
with indices of arterial stiffness and wave reflections, which are important determinants of 
cardiovascular function and risk. (Aznaouridis et al 2007). HIV has also been associated with 
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dyslipidemia independent of antiretroviral therapy (Riddler et al 2007). This is contrary to the 
result from this study in which there was no significant association of arterial stiffness with 
lipids in HAART naïve HIV positive participants.  
 
Patients with hypercholesterolaemia have a higher central pulse pressure and stiffer blood 
vessels than matched controls, despite similar peripheral blood pressures (Wilkinson et al  
2007). These haemodynamic changes may contribute to the increased risk of cardiovascular 
disease associated with hypercholesterolaemia and their assessment may improve risk 
stratification. Lipid-lowering therapy, particularly with statins, generally leads to a reduction 
in arterial stiffness, re-enforcing the concept that stiffness is a modifiable parameter and risk 
factor. There are a number of potential mechanisms linking arterial stiffness and plasma 
lipids, including atherosclerosis, changes in the elastic elements of the arterial wall, 
endothelial dysfunction and inflammation (Wilkinson et al. 2007). 
 
In this study, the group of HIV participants on antiretrovirals had the highest level of 
cholesterol. Young subjects with isolated hypercholesterolemia have normal or even 
increased arterial compliance (Lehmann 1992). With progressing age, the relationship 
between arterial compliance and low-density lipoprotein (LDL) cholesterol becomes 
negative, as a result of more pronounced endothelial dysfunction (Giannattasio 1996). 
 
Antiretroviral therapy can also contribute to dyslipidemia. Dyslipidemia has been described 
as being more common and more severe in HIV patients receiving antiretroviral therapy than 
in patients not on therapy (Aznaouridis et al. 2007). It remains unclear whether the deposition 
of lipids in the vascular wall and development of atherosclerotic lesions alone contribute to 
vessel stiffness. 
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Initial concerns of increased rates of myocardial infarction arising as a result  of 
dyslipidaemia in HIV-infected patients on antiretrovirals have been confirmed by studies 
such as the D:A:D study (Carr et al. 1998 & Holmberg et al. 2002). D:A:D study is a large, 
prospective, multi-cohort study that showed associations between exposure to antiretroviral 
therapy and an increased risk of myocardial infarction (Friis-Moller et al. 2003). In 
multivariate analyses, for every mmol/L increase in total cholesterol, the relative risk of 
myocardial infarction increased by a factor of 1.26 (Friis-Moller et al. 2007). In another 
analysis from D:A:D which included stroke, acute myocardial infarction and invasive 
cardiovascular procedures there was a similar effect of hypercholesterolemia, with every 
mmol/L increase in total cholesterol associated with a relative risk of 1.11 of the combined 
endpoint (d'Arminio et al. 2004).  
 
Although the triglyceride level in HAART naïve HIV positive participant was higher than 
those on treatment, in this study it was not significant. This is probably because  
hypertriglyceridemia in untreated HIV-infected patients may be a response to a systemic 
inflammatory response against persistent viral infection. Triglyceride concentrations, and TG 
clearance time in untreated HIV-infected patients have been shown to correlate with serum 
interferon-alpha (IFN-)  which is overproduced in HIV infection (Grunfeld 1991). In these 
untreated patients, the activity of lipoprotein lipase (LPL) and hepatic lipase, which are both 
involved in TG clearance from the circulation, are decreased compared to controls.  
 
5.11. Heart rate and arterial stiffness 
Heart rate was lower in the HIV negative participants in this study. Heart rate did not show 
any significant changes in both the genders. There was also no significant difference in the 
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heart rate between the ages below 35 years and above 35 years. Increased heart rate may be 
an indicator of increased sympathetic tone, which may increase the stiffness of large arteries 
directly (Michelle et al. 2004). Alternatively, increased large artery stiffness is associated 
with reduced baroreceptor sensitivity, which could alter sympathetic tone and heart rate 
(Michelle et al. 2004). 
 
As discussed earlier, elevated heart rate was observed in HIV positive participants compared 
to HIV negative participants. This chronically elevated heart rate may increase large artery 
stiffness by accelerating elastin breakdown in the arterial wall. In paced animal models, 
increased heart rate was shown to increase stiffness of large elastic arteries while having a 
variable effect on muscular arteries. It could also be that the HIV participants had increased 
heart rate because the inflammation has caused some arterial stiffness which could alter the 
sympathetic tone. HIV positive participants on the other hand might have increased heart rate 
because of their underlying anxiety and the increased heart rate might accelerate elastin 
breakdown leading to arterial stiffness. 
 
5.12. Augmentation index in the estimation of arterial stiffness 
Pulse wave velocity (PWV) and the augmentation index (AIx (75)) are the two major 
noninvasive methods of assessing arterial stiffness. Some studies suggest that the predictive 
value of aortic stiffness may be slightly better than carotid artery stiffness, and because of the 
ease of measurement, aortic (carotid-femoral) PWV has been proposed as the gold standard 
for arterial stiffness measurement. The fact that PWV is dependent on arterial stiffness is one 
of the reasons that the augmentation index, which has been correlated with PWV (Yasmin & 
Brown 1999), has been proposed as a marker for arterial stiffness (Wilkinson et al. 1988). 
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However, the relationship between PWV and the augmentation index may not be as clear cut 
as initially believed.  
 
Wilkinson (1998) reported that PWA is a simple and reproducible technique with which to 
measure PWV and AIx(75). Reproducibility accords with that reported by other workers 
using different methodologies. Augmentation index using PWA may, therefore, be suitable 
for large-scale population and intervention studies investigating the clinical relevance of 
vascular stiffness. The central aortic pressure within the larger arteries - including the 
brachial and femoral arteries - consists of a forward wave generated during ventricular 
systole, followed by a reflected wave from the periphery. With increasing arterial stiffness, 
this reflected wave arrives earlier, augmenting pressure during late systole (Nichols 2002). 
This can be measured as the ratio of the reflected wave to the pulse pressure (―augmentation 
index‖, or AIx(75).  
 
AIx is the most widely researched index of PWA, with several studies indicating that AIx is 
independently predictive of adverse cardiac events. Since AIx (75) varies with heart rate it is 
commonly adjusted to a ‗standard heart rate of 75 beats per minute‘ (AIx (75)). 
 
This highly reproducible technique of PWA is based on processing of the pulse wave contour 
depicting local changes in arterial pressure occurring during one cardiac cycle (Wilkinson 
1998). The stiffer the conducting vessels, the faster the pressure wave travels and the earlier it 
is reflected back. Consequently, it superimposes on the forward-travelling wave of the 
following cardiac cycle, causing an increase, or augmentation in central systolic pressure and 
a decrease in diastolic pressure. The augmentation index has also been identified as an 
independent risk marker of the severity of premature coronary artery disease among men 
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undergoing coronary angiography (Weber et al. 2004) and as a predictor of cardiovascular 
disease among healthy individuals (Nurnberger et al. 2002). 
 
In this study the augmentation index was significantly higher in HIV positive partcipants on 
treatment which also confirms that arterial stiffness is more in this group of HIV positives 
(p=0.024) but the augmentation index correllated positively with PWV in participants who 
are HIV negative and those who are HAART naïve. With the augmentation index  in HIV 
negatives the multiple linear regression model identified age (positive correlation), height 
(negative correlation), CD4 (positive correlation) and MP (positive correlation) as the 
independent and significant determinants of AIx(75), with the model adjusted for gender, 
smoking, alcohol, weight, waist circumference, hip circumference, waist to hip ratio, lipid 
profiles, cytokines, adhesion molecules, haematological data, and other haemodynamic 
parameters. 
 
In HAART naïve HIV positive participants Spa and age were independently and significantly 
associated with the variations of AIx(75) among HIV positives not on HAART and height 
was negatively and significantly associated with AIx(75). This implies that the shorter one is 
the greater the AIx(75). The model in this study was adjusted for gender, smoking, alcohol 
intake, cytokines, weight, waist circumference, hip circumference, waist to hip ratio, 
cytokines, CD4, haematological data, lipid profiles, and other haemodynamic parameters. 
 
In  HIV positive participants on HAART after excluding confounding factors, height 
(negative correlation), age (positive correlation), MP (positive correlation) HDL-C (negative 
correlation), platelets (positive correlation) alcohol intake (excessive consummation 
associated with positive correlation) and TNFα (negative correlation) were identified as the 
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independent and significant variables associated with increase in AIx(75) among HIV 
positive participants on HAART. 
 
The study found an inverse association with multiple linear regression using augmentation 
index with height in HIV negative participants. Also in women the augmentaion index was 
greater than that of men. This is probably because of the shorter height of women in the study 
as  the  augmentaion index increases as one becomes shorter. This means that shorter people 
are more prone to arterial stiffness.  
 
Yasmin & Brown (1999) investigated whether there was a correlation between the 
simultaneous assessments of augmentation index (AIx(75)) and pulse wave velocity (PWV), 
undertaken by the SphygmoCor system,  in 105 offspring (41 men, 64 women) aged 19–71 
years, of patients with familial hypertension. Arterial stiffness was measured using the 
SphygmoCor pulse wave analysis system. AIx and PWV correlated significantly and 
positively (r=0.29, p<0.005) and the strength of the correlation was greater when each gender 
was examined separately. In my study AIx(75) correlated significantly and positively with 
PWV in the participants using their status and gender.  
 
Yasmin & Brown (1999) observed several-fold higher AIx(75)   in women (22.04±12) than 
in men (8.59±13) (p<0.001); the difference could be explained only in part by an inverse 
regression correlation between AIx(75)  and height (r=−0.45; p<0.001), but not PWV. This is 
an agreement with this study. The AIx(75)  in women in this study was (21.15 ±12.81) 
compared to that of men which was (14.64± 11.78 ) (p<0.001). The finding of increased 
AIx(75) in women is also consistent with the published literature by London et al (1996). In 
the study they showed that multiple regression showed that the effect of the increased 
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augmentation index is  partly explained bydecreased height in women. 
 
The inverse correlation found between AIx(75)  and body height in the HIV negative 
participant and HAART naive HIV positive participants  have also been noted in a previous 
study by Marchais et al (1993). They concluded that it is probably due to earlier reflection of 
the aortic wave in short people. AIx(75)  was also more influenced than PWV by heart rate 
and blood pressure. It is probable that separate normal ranges should be established for men 
and women, while further studies determine what parameters other than height are 
responsible for the gender difference.  
 
Women had larger reflected waves than men in this study hence increased augmentation 
index. This is in part due to shorter height and closer physical proximity between heart and 
reflecting sites (Mitchell et al. 2004). However, height was not sufficient to fully explain 
higher reflected wave pressure in women which is consistent with findings of a prior study of 
elderly men and women who were matched for height (Gatzka et al. 2001). Thus, there are 
unexplained differences in arterial structure or function between men and women that lead to 
increased wave reflection in women hence increased augmentation index. 
 
In this study, there was also a positive correlation between PWV and AIx(75)  in both the 
HIV negative group and HIV positive group not on treatment (r=0.850, p=0.004., r=0.027, 
p=0.27 respectively). Augmentation index was also significantly higher in participants who 
are more than 35 years.  
 
Kelly et al (2001) found that the augmentation index  correlated with PWV, age and blood 
pressure in univariate analysis. However, in multivariate analysis it was related only to age. 
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The investigators suggested that the relationship between the augmentation index and PWV 
may be stronger when the aorta becomes stiffer, as PWV may not change greatly whilst the 
aorta remains elastic. In this present study with multiple linear regression, AIx(75) was 
associated with age, MP, height and excessive consumption of alcohol, and HDL  which are 
significant determinants of augmentation index in HIV positive participants  on HAART. All 
these variables which are associated with augmentation index in HIV positive participants on 
HAART might have caused increase in  the time of reflection. Thus, in an elastic aorta, the 
AIx(75) is more likely to be related to the intensity of the reflected wave rather than to its 
velocity. 
 
Overall, HIV participants had greater PWV and augmentation index than those who are HIV 
negative. This is in agreement by the study reported by Falasca, et al (2012) who compared 
HIV patients and non infected subjects. Compared with uninfected subjects, HIV-infected 
subjects in their study had higher, PWV and AIx(75)  values.  
 
Sevastianova et al (2005) reported that the duration of antiretroviral treatment affected the 
augmentation index. The increased augmentation index observed in this study might be due 
to the duration of antiretroviral therapy to which the participants were exposed.  
 
According to McEniery et al (2005), the AIx(75)  might be a more sensitive marker of arterial 
alteration and cardiovascular risk in younger individuals, whereas the aortic PWV is likely to 
be a better measure in older individuals.  
 
5.13. Relationship of some cardiac functions to arterial stiffness in HIV 
The duration of left ventricular systolic ejection (systolic time interval in milliseconds) can be 
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measured using PWA. The ratio of the duration of systolic ejection to the total duration of a 
cardiac cycle is the ejection duration index (ED %). Patients with systolic dysfunction have 
been found to have a higher ED% than those with diastolic dysfunction (Nichols 2004). The 
HIV positive participants in this study have higher ejection duration index ED%. The ED% 
was lowest in the HIV negative participants and highest in those that are not on 
treatment.(p<0.001). This might indicate that the HIV positive participants not on treatment  
are at a higher risk of developing cardiovascular problems such as systolic dysfunction. 
Sub-endocardial viability ratio (SEVR), calculated through pulse wave analysis, is an index 
of myocardial oxygen supply and demand (Tsiachris et al 2010). The SEVR% is highest in 
the HIV negative participants and lowest in HAART naïve participants. The tonometric sub-
endocardial viability ratio (SEVR) is a non-invasive estimate of myocardial perfusion relative 
to cardiac workload (Chemla et al 2008). It is impaired in the HIV positive participants. In 
HIV positive participants there was also significant arterial stiffness compared to HIV 
negative partcipants. This shows that increased aortic stiffness  and decreased subendocardial 
viability ratio predisposes to myocardial ischaemia by increasing the systolic tension–time 
index and by decreasing aortic pressure throughout diastole. Thus the HIV positive 
participants are prone to having myocardial infarction or stroke because of the impaired 
oxygen supply to the heart. From this study, there was also no significant correlation between 
ejection duration index and subendocardial viabilty ratio with arterial stiffness. 
 
5.14. Arterial stiffness and anthropometry 
There is a positive correlation of age, waist, waist to hip ratio, and weight in HIV negative 
participants with PWV. With HAART naïve participants there is a positive correlation with 
age ,waist to hip ratio and height. There is also a positive correlation of waist to hip ratio, 
height,  and PWV in participants on treatment. 
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Although, BP remains the major determinant of arterial stiffness and endothelial dysfunction, 
waist circumference independently predicts arterial stiffness (Lilitkarntakul 2012). With waist 
circumference, there was also an association with PWV using multivariate linear regression  
with the the HAART naive HIV positive groups. 
 
Results of the present study support the concept that central obesity, represented by 
anthropometric measurement, such as BMI, percentage of body fat, waist circumference, and 
waist/hip ratio, play an important role in the association between obesity and arterial 
stiffness. Interestingly, a study showed that BMI, waist circumference, and waist/hip ratio 
were significant and inverse predictors of arterial stiffness in women, (352 healthy patients, 
including 200 premenopausal women), whereas in men, only BMI  inversely predicted 
arterial stiffness. The authors suggested that the relationship of arterial stiffness and obesity 
may be sex specific; however, they indicate the need for further studies to validate their 
findings (Budimir et al. 2012).  
 
Although a definite mechanism is yet to be elucidated, several factors associated with central 
obesity may play a role, such as the increased lipolytic activity of visceral 
adipocytes,increased insulin and pro-inflammatory cytokine levels, greater sympathetic 
nervous system activity, or even an imbalance between vasodilatory and vasoconstricting 
substances, all of which have been shown to play key roles in the process of arterial stiffening 
(Eckel et al. 2002). 
 
For the genders, there was also no significant difference in other anthropometric 
measurements except for hip circumference and height (p<0.001 and p<0.001) respectively. 
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There was a correlation between the waist to hip ratio and arterial stiffness in HIV negative 
participants, HAART naïve group of participants and HIV positive participants on treatment 
(r=0.479;p=0.015,r=0.319;p=0.037,r=0.319 p=0.037 respectively). In a study by Recio-
Rodriguez et al (2012), measurement of the waist circumference correlated with arterial 
stiffness relatively to BMI. This was evaluated by PWV and C-IMT respectively. 
 
The waist circumference and the waist to hip ratio of participants on treatment were more 
than that of the other two groups of the participants. This might imply some degree of 
lipodystrophy in those particiats who are on HAART. Waist to hip ratio is positively 
associated with pulse wave velocity in all the groups.  
 
With multiple linear regression  waist circumference and MP were  identified as the most 
important and significant independent determinants of PWV in HIV positive participants not 
on treatment, whist the model was adjusted for gender, weight, height, hip circumference, 
waist to hip ratio, lipid profiles, haematological data, cytokines adhesion molecules, smoking, 
alcohol, other haemodynamic parameters and CD4 count. The significant waist 
circumference seen in this group of participants might be due to metabolic syndrome due to 
their increased waist circumference and consequently  insulin resistance. Fat distribution 
affects metabolism and cardiovascular risk. Truncal obesity is associated with insulin 
resistance, dyslipidemia, and hypertension (Awotedu et al 2010). The women generally are 
often obese in the Transkei region and this may be because of genetic reasons. A study by 
Sevastianova et al (2005)  stated that time since HIV diagnosis, severity of immunodeficiency 
or presence of HAART-associated lipodystrophy bore no relationship to  augmentation index 
which is contrary to this study. 
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Zheng et al (2011) reported that obesity was an independent risk factor of PWV, which was 
an early marker of cardiovascular and renal diseases, among community population in 
Beijing area. Arterial stiffness and wave reflections are markers of cardiovascular health and 
outcomes. Corrigan et al (2012) reported that although arterial health is influenced by weight, 
it is not known whether fat distribution differentially modulates arterial function (Corrigan et 
al 2012). 
 
5.15. Association of arterial stiffness with CD4 count, macrophages, monocytes, 
platelets, neutrophils in HIV positive participants 
The monocyte levels of the HIV positive participants on treatment correlated positively with 
pulse wave velocity even though the monocyte levels of the HAART naïve positives were 
higher and it did not correlate with PWV. Monocytes are the precursors of the lipid-laden 
foam cells within the atherosclerotic plaque and produce high levels of proinflammatory 
cytokines such as IL-6. The minor CD14+/CD16+ ‗proinflammatory‘ monocyte 
subpopulation is preferentially susceptible to HIV infection and may play a critical role in the 
pathogenesis of HIV-related CAD (Ziegler-Heitbrock, et al 2007).  
 
Monocytes play a critical role in atherogenesis and HIV disease. Monocytes develop initially 
in the bone marrow, emigrate into peripheral blood, from where they provide routine 
immunosurveillance or respond to infection/inflammation, and are subsequently delivered to 
tissues, where they differentiate into macrophages (Auffray et al 2009). In humans, peripheral 
blood monocytes may be divided into at least two major subsets: a minority subset of 
monocytes expresses CD16 and has variable expression of CD14, produces more 
inflammatory cytokines, and expresses higher levels of TLR-4 compared with the majority 
CD14+/CD16– monocytes population (Ziegler-Heitbrock, et al 2007). Monocytes are 
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precursors of the macrophages within atherosclerotic lesions, including lipid-laden foam cells 
(Ziegler-Heitbrock, et al 2009) , and lesion-associated macrophages represent a major source 
of a number of cytokines and chemokines that direct monocytes into vascular lesions, thus 
creating a positive-feedback loop, although the roles of the two monocyte subsets are poorly 
characterized. Changes that occur in monocytes and macrophages during HIV-1 infection are 
likely to impact on atherogenic processes.  
 
During HIV infection, monocytes display an activated phenotype, although correlates of 
monocyte phenotype and cardiovascular disease are poorly characterized. Additionally, HIV 
interferes with the ability of macrophages to handle excessive cholesterol by inhibiting 
cholesterol efflux (Mujawar et al. 2006); both of these mechanisms may impact on initiation 
and progression of atherosclerotic plaques. Hence the association of monocytes in 
participants who are on treatment, with PWV  in this study. The monocytes develop into 
macrophages which are the precursors of foam cells which now progress to atherosclerotic 
plaque formation.  
 
There was also a significant positive correlation between the neutrophil count and pulse wave 
velocity in this study. This could be because the inflammation produced by the HI virus 
causes increased migration of leucocytes to the site. This was more evident in those on 
treatment in this study. Consequently the migration of the leucocytes contributed to the 
arterial stiffness seen in these HIV positive participants. Monocytes are implicated as a viral 
reservoir based on the detection of infectious virus from monocytes isolated from HIV-
positive individuals on antiretroviral therapy (Naif et al. 1998). It appears that CD16- positive 
monocytes (5% of monocyte population) are both more susceptible to infection and 
preferentially harbour the virus long-term (Arfi et al. 2008). Blood monocytes and resident 
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macrophages are important in vivo cell targets for HIV infection and their role in AIDS 
pathogenesis are well documented (Alfano et al. 2005). HIV infects immune cells of the 
macrophage and T-cell lineage. It is therefore not surprising that there are increases in the 
levels of the monocytes and neutrophils in HIV positive participants. These leucocytes also 
had positive correlation with PWV in HIV positive participants. This means that the 
increased monocyte count also contributed to arterial stiffness in HIV positive participants.  
 
Kedzierska et al (2005),  in their study explained that monocytes, macrophages and dendritic 
cells play  important roles in the initial infection of HIV and contribute to its pathogenesis 
throughout the course of infection (Kedzierska et al 2005).  After excluding confounding 
factors, platelets (positive correlation) was also amongst the variables  identified as  
independent and significant variable  associated with increase in AIx(75) among HIV positive 
participants on HAART in this study.  
 
With multivariate linear regression in HIV negative participants, CD4 was a significant 
determinant of AIx (75), whist the model in this study was adjusted for gender, smoking, 
excessive alcohol intake, weight, waist circumference, hip circumference, waist to hip ratio, 
lipid profiles, cytokines, adhesion molecules, haematological data, and other haemodynamic 
parameters. 
 
To identify risk factors for augmentation index normalized for a heart rate of 75 beats/min, 
Hsue et al (2004) devised a multivariate model that weighed systolic blood pressure, diabetes 
mellitus, hyperlipidemia, family history of heart disease, injection drug use, high-sensitivity 
C-reactive protein (hsCRP), estimated glomerular filtration rate (eGFR), current CD4 count, 
duration of HIV infection, antiretroviral therapy, and PI therapy. In that model a nadir CD4 
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count below 350 was independently associated with 7.2% higher normalized augmentation 
index, and four traditional risk factors were also independently associated with a higher 
normalized augmentation index. Hsue and colleagues believe their findings ‗suggest that 
cardiovascular risk among HIV-infected individuals could be reduced through early initiation 
of antiretroviral therapy, before CD4 T-cell counts are depressed‘. They called for 
prospective studies to test this hypothesis. 
 
Kaplan et al (2011) among a cohort of HIV infected women studied the association of carotid 
artery stiffness with expression of markers of T cell activation. They suggested that activation 
of CD4+ T cells is associated with increased vascular stiffness among HIV infected women 
(Kaplan et al. 2011). Progressive depletion in numbers of circulating CD4+ T cells occurs in 
almost all cases of untreated HIV infection. The number of circulating CD4+ T cells is 
widely used as a measure of global ‗immune competence‘ and provides a predictor of the 
immediate risk for opportunistic illnesses (Masur et al. 1989). CD4 levels  are reduced in the 
HIV positive participants taking part in this study  with level being lowest in those not on 
treament. There was negative correlation of CD4 count with pulse wave velocity. This means 
that as the CD4 count decreases arterial stiffness increases. 
 
Another recent study showed that arterial stiffness was associated with a low CD4 count in  
HIV infected indivividuals concluding that an early ARV treatment may be of benefit in  
reducing arterial modifications (Ho et al. 2010). Literature data regarding the effect of  
HAART on arterial stiffness are conflicting. Several studies have reported an association 
between HAART and increased arterial stiffness in HIV infected patients (Boccara et al 
2006). Other studies found no influence of HIV specific antiretroviral therapy on arterial 
stiffness (Bonnet et al 2004), or a possible favourable interaction related to its anti-
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inflammatory effect and to the reduction of immunosupression (Ho et al 2010).  
 
Other studies showing conflicting results are those that reported an association between a 
lower nadir CD4+ T cell count and arterial stiffness (Schillaci 2005) while other reported no 
association (Sevastianova 2004). The results of a more recent trial showed that the nadir 
CD4+ T-cell count, as represented by a nadir CD4+ T-cell count below 350 cells/mm
3
, is a 
predictor of PWV (Ho et al. 2010). The association appeared to be independent of other 
factors. 
 
In a study by Omoregie et al (2009)  in Benin City, they found  a significant reduction in CD4 
count in HIV seropositive patients compared with their seronegative counterparts (p < 0.001). 
They concluded that  HIV attacks and destroys cells with the CD4 antigen and this explains 
why HIV-positive patients had lower CD4 counts than HIV-negative individuals. 
 
Like the CD4 count, the platelet count was significantly lower in HIV seropositive patients 
(p=0.001). Impaired thrombopoiesis and production of anti-platelet antibodies have been 
suggested as possible mechanisms. Impaired thrombopoiesis can result from infection of 
megakaryocytes by HI virus because megakaryocytes possess CD4 and CXCR4, which are 
known receptors for HIV, and various megakaryocyte lines are infectable with HIV. Also in  
this study, there may be endothelial activation by the cytokines in response to the leucocyte 
activation by HIV since the monocyte, neutrophils are higher in HIV positive participants 
with depletion of their correponding lymphocytes. Thus the increase in the cytokine levels in 
the HIV positives might be because of their response to leucocytes activation by HIV. 
 
5.16. Proposed mechanism of arterial stiffness in HIV positive participants 
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The mechanism of increased arterial stiffness in  HIV participants that took part in this study 
is proposed as follows. Injury to endothelial cells  by the HI virus perpetuated a local 
inflammatory response that promoted thrombosis, impaired vessel responsiveness. HIV 
replication may activate endothelial surfaces directly or via up-regulation of pro-
inflammatory cytokines (Ren et al. 2002) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79. Integrated summary of some cardiovascular risk factors affecting the 
vasculature 
 
 
Endothelial cell adhesion molecules (intercellular and vascular cell adhesion molecules; 
ICAM and VCAM respectively) such as E-selectin are expressed by endothelial cells in 
response to leukocytes and cytokines which were also elevated in HIV positive participants 
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when compared to HIV negative controls although not significantly. E-selectin was elevated 
in treatment naïve HIV positive paricipants in a yet to be published work by the author. This 
study involved over 400 participants and funded by the medical research council of South 
Africa . This is in agreement with previous work by  Leeuwenberg (1999). Endothelial cell 
activation, though a normal physiological response to inflammation, can lead to vessel 
damage and dysfunction with chronic stimulation (Blann &Taberner 2000). Studies using a 
murine AIDS model have demonstrated that vascular dysfunction was correlated to oxidative 
stress and endothelial activation (Balga et al. 2005). Hence the oxidative stress seen in the 
map. HIV has been reported to infect smooth muscle cells in vitro and in vivo and increases 
secretion of a monocytes chemoattractant (CCL2, or MCP-1), which facilitates development 
of foam cells (Eugenin et al, 2008). Macrophages, which play a pivotal role in 
atherosclerosis, are also hosts for HIV. The HIV Nef protein impairs the adenosine 
triphosphate binding cassette (ABCA-1) transporter in macrophages, which is important to 
reverse cholesterol transport. This inhibition may lead to conversion of macrophages into 
foam cells and initiate plaque formation in vessel walls (Mujawar et al. 2006). HIV may also 
directly impair HDL metabolism, thus enhancing transfer of HDL to atherogenic 
apolipoprotein B lipoproteins (Rose et al. 2008). Collectively, these findings suggest that 
untreated HIV infection could contribute to the development of dyslipidemia hence 
atherosclerosis. 
Another mechanism could be that the normal healthy endothelium regulates vascular tone and 
structure and exerts anticoagulant, antiplatelet, and fibrinolytic properties. The maintenance 
of vascular tone is accomplished by the release of numerous dilator and constrictor 
substances. A major vasodilative substance released by the endothelium is nitric oxide (NO), 
originally identified as endothelium-derived relaxing factor (EDRF).  
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Other endothelium-derived vasodilators include prostacyclin and bradykinin. Prostacyclin 
acts synergistically with NO to inhibit platelet aggregation. Bradykinin stimulates release of 
NO, prostacyclin, and endothelium-derived hyperpolarizing factor, another vasodilator, 
which contributes to inhibition of platelet aggregation. Bradykinin also stimulates production 
of tissue plasminogen activator (t-PA), and thus may play an important role in fibrinolysis.  
 
The endothelium also produces vasoconstrictor substances, such as endothelin (the most 
potent endogenous vasoconstrictor identified to date) and angiotensin II. Angiotensin II not 
only acts as a vasoconstrictor but is also pro-oxidant and stimulates production of endothelin. 
Endothelin and angiotensin II promote proliferation of smooth muscle cells and thereby 
contribute to the formation of plaque. Activated macrophages and vascular smooth muscle 
cells, characteristic cellular components of atherosclerotic plaque, produce large amounts of 
endothelin.  
Damage to the endothelium upsets the balance between vasoconstriction and vasodilation and 
initiates a number of events/processes that promote or exacerbate atherosclerosis; these 
include increased endothelial permeability, platelet aggregation, leukocyte adhesion, and 
generation of cytokines. Decreased production or activity of NO, manifested as impaired 
vasodilation, may be one of the earliest signs of atherosclerosis. Nitric oxide is a pivotal 
endothelium-derived substance. The hallmark of endothelial dysfunction is impaired 
endothelium-dependent vasodilation, which is mediated by NO. A defect in NO production or 
activity has been proposed as a major mechanism of endothelial dysfunction and a 
contributor to atherosclerosis. There might be a problem with the production of NO due to HI 
virus disrupting the endothelium as seen in concept map. Nitric oxide mediates endothelium-
dependent vasodilation by opposing the effects of endothelium-derived vasoconstrictors such 
as angiotensin II and endothelin. It also inhibits platelet adherence and aggregation, leukocyte 
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adhesion/infiltration, and proliferation of vascular smooth muscle cells. Nitric oxide prevents 
oxidative modification of low-density lipoprotein (LDL) cholesterol.  
 
Oxidation of LDL has been proposed as a major mechanism of the atherosclerotic process. 
Furthermore, plasma and macrophage content of oxidized LDL in coronary plaques correlate 
with severity of acute coronary syndrome (Rubbo et al. 2002). Conversely, impaired 
production or activity of NO such as may be the case of the HI virus leads to events or 
actions that promote atherosclerosis, such as vasoconstriction, platelet aggregation, smooth 
muscle cell proliferation and migration, leukocyte adhesion, and oxidative stress. Oxidized 
LDL cholesterol increases synthesis of caveolin-1, which inhibits production of NO by 
inactivating eNOS (Endres et al. 1998) . Oxidative stress in this case which migh be the HI 
virus can also interfere with the production and activity of NO by a number of mechanisms 
that are independent of LDL. For example, the free radical superoxide anion rapidly 
inactivates NO and destroys tetrahydrobiopterin, a cofactor required for NO synthesis.  
 
Nitric oxide expression may itself be reduced (d‘Alessio et al. 2004).  Increased expression of 
a natural nitric oxide synthase (NOS) inhibitor, asymmetrical dimethylarginine, has been 
linked to vascular stiffening (Miyazaki et al. 1999). The level of nitric oxide expression may 
be reduced in HIV positive participants.  Bioavailability of nitric oxide is also reduced by 
activation of reactive oxygen species caused by stress, hormones, and likely AGEs (Taddei et 
al. 2001) and probably by the HI virus. The formation of peroxynitrite and other highly 
reactive species results in abnormal vascular tone (Peng et al. 2003). 
 
Although many studies have established a role of endothelial dysfunction in vascular 
stiffening, recent studies have suggested the opposite holds as well  ie, that structural 
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stiffening could alter endothelial function and thereby worsen stiffening. 
 
It has been shown that HIV infection induces increased production of free radicals by 
macrophages. Free radical formation occurs as a by-product of oxidative stress. Oxidative 
stress occurs when there is a disproportion between the reactive oxygen elements in the body 
versus the ability of the body to properly eliminate these reactive species. The presence of 
free radicals has been implicated in disturbing and damaging a number of biological 
processes (Karthikeyan et al 2010). With regards to HIV infection the increase of oxidative 
stress has been seen to influence components in antioxidant defense in physiological 
antioxidants such as glutathione which are seen to decrease dramatically in HIV patients 
(Pace and Leaf, 1995).  
 
In addition to glutathione, vitamin A, C, and E in high doses while improving low levels of 
selenium were also associated with the prevention of HIV infection progression by working 
as antioxidants to remove free radicals (Garland and Fawzi, 1999). The progression of HIV is 
correlated with a decreased immunity. One way in which this decreased immunity progresses 
is by free radical overload of monocytes and granulocytes which leads to deficiency of 
antioxidant mechanisms which may lead to the loss of CD4 cells often seen in the 
progression of HIV (Dobmeyer et al 1997). The decreased immunity may also be related to 
the reactive oxygen species and free radical presence which is higher in HIV infected 
patients.  
 
With HIV infection progression there is an increased production of reactive oxygen species 
which leads to the theory of free radical mediated apoptosis of lymphocytes which reduces 
the ability for immune response to progressive HIV infections (Dobmeyer et al 1997). In this 
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study there was depletion of lymphocytes and reduced absolute counts of CD4 cells. With 
regards to CD4 cell counts the apoptosis of lymphocytes by free radicals leads to progression 
of immunodeficiency and makes for a quicker transition from HIV infection to AIDS 
(Bautisita, 2001).  
It has been published that during HIV-1 infection, haematopoietic cells are exposed to high 
amounts of free radicals. Subsequently there is a reduction of leukocytopoiesis and increase 
susceptibility to further infections (Masutani, 2000). Furthermore, there is a link between 
lipid peroxidation observed in patients with HIV or AIDS and a deficiency of antioxidants 
which leads to free radical proliferation (Favieret al 1994). There is no significant difference 
in the LDL levels in the groups of participants. This could be that some of the LDL particles 
have undergone oxidation. 
 
It has been suggested for 20 years that oxidative stress, and particularly LDL oxidation, could 
induce atherosclerosis (Toshima et al 2000),  and that markers of LDL oxidation in plasma 
(circulating oxidized LDL, autoantibodies against oxidized LDL) could be used to assess the 
development of atherosclerosis in patients. 
 
The HIV positive participants had increased levels of cholesterol, triglycerides, 
hyperlipidaemia.  Hypertension, diabetes and smoking are associated with overproduction of 
reactive oxygen species or increased oxidative stress. The HIV participants in the study had 
increased blood pressure.  
 
The body's immune system responds to the damage to the arterial wall caused by oxidized 
LDL by sending specialized white blood cells (macrophages and T-lymphocytes) to absorb 
the oxidized-LDL forming specialized foam cells (Lowe et al 2003) . These white blood cells 
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are not able to process the oxidized-LDL, and ultimately grow, and then rupture, depositing a 
greater amount of oxidized cholesterol into the artery wall. This triggers more white blood 
cells, continuing the cycle. Eventually, the artery becomes inflamed. The cholesterol plaque 
causes the muscle cells to enlarge and form a hard cover over the affected area. This hard 
cover is what causes a narrowing of the artery, reduces the blood flow and increases blood 
pressure. 
 
During the course of inflammation, E-selectin plays an important part in recruiting leukocytes 
to the site of injury. E- Selectin is increased in HIV positive partcipants in this study but not 
significantly. The local release of cytokines TNF-α by damaged cells as in this study  induces 
the over-expression of E-selectin on endothelial cells of nearby blood vessels according to 
(Collins et al 1991). Leukocytes in the blood expressing the correct ligand will bind with low 
affinity to E-selectin, also under the shear stress of blood flow, causing the leukocytes to 
"roll" along the internal surface of the blood vessel as temporary interactions are made and 
broken. As the inflammatory response progresses, chemokines released by injured tissue 
enter the blood vessels and activate the rolling leukocytes, which are now able to tightly bind 
to the endothelial surface and begin making their way into the tissue. This will now cause an 
increased expression of adhesion molecules and inflammatory cytokines, namely, of tumour 
necrosis factor-α (TNF-α), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-
1), intercellular cell adhesion molecule-1 (ICAM-1), monocyte chemo attractant protein-1 
(MCP-1) and von Willebrand factor (VWF), which  are all molecules involved in the 
recruitment and adhesion of leukocytes at sites of atheroma initiation  (Deanfield et al 2007). 
This will now initiate the formation of plaques.  
 
HIV positive patients who take combination antiretroviral therapy (cART) to combat HIV 
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infection could see the numbers of CD4 cells in their immune system rise to concentrations 
found in HIV negative individuals, if they remain on the therapy for long enough and their 
HIV viral load load is suppressed to below 50 copies per ml (Science Daily, 2007). HAART 
may also lessen the effect on endothelial dysfunction due to the cardiovascular risk factors. 
 
An increase of approximately 26% of the risk for myocardial infarction has been reported in 
patients on HAART (Fris Moller et al 2003). The detrimental effect of HAART on the 
arterial wall properties (Charadika et al 2009(b)) has been proposed as an underlying 
mechanism, while it has been documented that HIV infection per se may promote 
atherosclerosis through immunodeficiency, chronic inflammation progress, viral load, and 
endothelial cell dysfunction, and either directly or indirectly via metabolic risk factors (Coll 
et al 2007). The exact pathophysiological events underlying the development of metabolic 
changes in HIV-infected patients are still under investigation. 
 
Recently, in a study by the National Institute of Allergy and Infectious Diseases (NIAID 
2011) which is part of the National Institutes of Health, men and women infected with HIV 
reduced the risk of transmitting the virus to their sexual partners by taking oral antiretroviral 
medicines when their immune systems were relatively healthy. The results are the first from a 
major randomized clinical trial to indicate that treating an HIV-infected individual can reduce 
the risk of sexual transmission of HIV to an uninfected partner. 
 
The WHO  (July 2012) has issued its first guidance to nations considering providing ARVs 
(antiretrovirals) to HIV-negative, high risk people. WHO says its recommendations were 
based on human trials which showed that administering PrEP (pre-exposure prophylaxis) 
once daily to HIV-negative individuals who are at high risk of becoming infected, is both safe 
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and effective in helping prevent HIV infection 
 
5.17. Limitations of the study   
This study has some limitations. First, the cross-sectional design did not allow the 
investigation of some abnormalities in arterial properties. Longitudinal studies are needed to 
clarify this. Also matching for age and gender and other potential risk factors was not 
successful in all cases. The study started with 300 enrolled participants only 169 finished 
although this was anticipated. Although the duration of antiretrovirals uses were asked in the 
questionnaire because many of them were not given exact date it was not used in the study as 
some of the dates were not recorded. Exercising habit was recorded but was not included 
although all potential cofounders in the analysis were then considered.  
 
5.18. Perspectives 
The results of the present study provide evidence that aortic stiffness is increased in HIV 
treatment-naive patients free from cardiovascular disease. These findings suggest HIV 
infection as a potentially relevant contributor to arterial stiffness and provide a conceptual 
background for the increased cardiovascular risk observed among HIV-infected individuals 
regardless of antiretroviral treatment. Close, noninvasive evaluation of preclinical 
atherosclerotic disease should be considered for HIV patients, especially those with 
additional risk factors for cardiovascular diseases, with the aim of addressing intensive 
lifestyle and pharmacological interventions aimed at reducing cardiovascular risk. Statins  
and aspirin should be added to those with dylipaedimia.  
 
Liver function test and  haematological tests including blood cytokines should be evaluated to 
detect those at risk. Blood pressure, especially MP should be monitored regulaly. More 
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research should be done on the lipids and cytokines in case one can find an inhibitor to the 
cytokines which could help in modelling the endothelium.  
 
HIV may also directly impair HDL metabolism, thus enhancing transfer of HDL to 
atherogenic apolipoprotein B lipoproteins (Rose et al, 2008). Strategies to increase 
HDL cholesterol levels in HIV-infected individuals should be investigated In this study, 
multivariate analysis shows HDL-C as a determinant of arterial stiffness. This potential 
mechanism is consistent with findings in the recent SMART trial analysis indicating an 
association of total HDL particles with risk of CVD in patients  in the drug-conservation 
group (Duprez et al, 2009). In particular, risk was elevated in patients with declining HDL 
cholesterol levels after stopping non-nucleoside reverse transcriptase inhibitor (NNRTI) 
treatment. MP was also a determinant of arterial stiffness even in those who are HIV 
negative. More studies on these will be needed in confirming the fact that MP is more 
important than pulse pressure which used to be a main index of arterial stiffness. HDL-C can 
also be regarded as anti inflammatory with further research done to confirm this.   
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CHAPTER 6. 
6.1. Conclusion 
This study show that HIV infection and HAART increase arterial stiffness. The use of 
NNRTI and NRTI to treat the HIV patients may increase the risk of cardiovascular disease as 
indicated by the increases triglyceride levels and waist circumference. On the other hand, 
from these results, antiretroviral drugs might be protective as their use was associated with 
reduction of endothelial dysfunction and thereby reducing arterial stiffness. HIV infection 
increases arterial stiffness, as evident from these results that anti-retroviral naïve HIV 
positive participants had increased arterial stiffness, increase adhesion molecules, increase 
cytokine levels. Cytokines levels which were increased in HIV positive participants might 
explain the fact that cytokines are key modulators of inflammation. blood pressure, cytokine 
levels.  
 
Shorter people had increased Augmentation index (Arterial stiffness). Arterial stiffness  
decreases with increased HDL. Also using Augmentation index, arterial stiffness decreased 
with TNFα increase. This shows that TNFα is both anti inflammatory and proinflammatory. 
 
The management of cardiovascular risk factors among the HIV-1 infected participants needs 
to be improved. There is continued need for developing less harmful, better tolerated, and 
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effective treatments for HIV-1 infection. This should be with a better knowledge of 
pharmaceutical and non pharmaceutical measures directed at reducing cadiovascular risks by 
physicians involved in the management of HIV pateints. 
The sphygmocor is an accurate, non invassive  and useful tool in the evaluation of arterial 
stiffness and its use in clinical practice should be encouraged. PWV and the augmentation 
index (AIx(75) are the two major non-invasive methods of assessing arterial stiffness. 
Because some studies suggest that the predictive value of aortic stiffness may be slightly 
better than carotid artery stiffness, and because of the ease of measurement, aortic (carotid-
femoral) PWV has been proposed as the gold standard for arterial stiffness measurement.  
 
Life style modification should be incorporated into the management of HIV patients so as the 
continuous monitoring of their haematological and lipid profile. 
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                                           Questionnaire  
 
Cardiovascular risk factors in HIV positive patients and HIV naïve patients 
 
a) Name/Igama 
………………… 
 
b) Sex/Isini 
  
Female/ 
umfazi 
 
Male/indoda  
 
 
c) Date/umhla 
………….. 
 
d) Where do you live/uhlala phi? 
……………………………. 
 
e) Phone number----------------------------- 
 
f) Are you employed? Uyasebenza? 
yes  
no  
 
 
g) How old are you? mingaphi iminyaka yakho? 
 
……………………………….. 
 
h) Approximately how much do you earn? Urhola malini? 
………………………………. 
 
 
 
 
xli 
 
 
i) What is your favorite food? Kukuphi ukutya okuthandayo? 
 
Junk 
food/izint
o 
ezimnan
di 
Meat/inya
ma 
Fried 
food/ukutya 
okuqhotsiwe
yo 
Vegetables/imif
uno 
Millie-
samp/umnq
uso 
umvubo 
 
j) How many teaspoonfuls of sugar do you consume pr day/ugalela iteaspoon 
ezingaphi zeswekile? 
……………………………….. 
 
k) Do you consume alcohol? Uyabusela utywala? 
yes  
no  
 
 
l) If yes which one of the following drinks do you consume? Kokuphi utywala 
obuselayo? 
 
Whisky  Brandy/ibranti  Beer 
/ibhiya 
Seders 
/isiphuzo 
esibandayo 
Wine/iwayini Chibuku/umqomboti 
      
 
 
How many bottles or glasses/usela iglasi zibengaphi okanye ibhotile ezingaphi? 
 
m) Do you smoke? / Uyatshaya? 
Yes   
No   
 
 
n) What do you smoke? Utshaya ntoni? 
 
Cigarettes /icuba Cigar / Pipe /inqawa Boxery/iboxari  
    
 
 
xlii 
 
o) How many loose cigarettes or packets of cigarettes do you smoke a day/ utshaya 
amacuba amangaphi ngemini? 
…………….. 
 
p) Do you exercise? Uyazilolonga? 
 
yes  
no  
 
 
q) What type of exercising do you do? Uzilolonga njani? 
 
Walking 
/ukuhamba 
Running 
/ukubaleka 
Cycling 
/ibhaysekile 
Dancing 
/umdaniso 
Sport  
     
 
 
r) How often do you take exercise? Uzilolonga kangaphi? 
  
Everyday /qho ngemini Three times a 
week/kathathu ngeveki 
Once a week/kanye 
ngeveki 
   
 
 
 
s) How many hours do you sleep in a day? Ulala iyure ezingaphi ngemini? 
 
1-3 hours 4-6 hours 7-9 hours 10 and above 
    
 
 
t) What are your hobbies? Ziziphi izinto ozithandayo? 
 
Watchin
g 
TV/ukub
ukela 
umabon
akude 
Listening 
to 
music/uku
mamela 
umculo 
Reading/u
kufunda 
Traveling/uk
uhamba 
sp
ort 
Dancing/u
mdaniso  
Performing/uk
uperfoma 
       
 
xliii 
 
 
u) Are you sexually active? Uyabelana ngesondo? 
 
yes  
no  
 
 
v) How many partners do you have? Mangaphi amaqabane wakho? 
………………… 
 
w) Do you have any health problems that you know? Ingaba kukhon ukuhkathazeka 
kwempilo apha emzimbeni wakho okwaziyo? 
 
Yes   
No   
 
 
 
x) What is the health problem that you have? Ikuhlupha njani impilo? 
 
Hypert
ension/
i-
hayhay 
Diabetes
/iswekila 
Cardio
vascul
ar 
diseas
e/isifo 
sentlizi
yo 
Tubercul
osis/isifo 
sepheph
a 
Epilepsy/
ukuxhuzul
a  
Alle
rgie
s 
Asthma
/isifuba 
Chest 
infectio
ns/isifo 
sesifub
a 
Others
/eziny
e izifo 
         
 
y) Do you have any chronic infection recently/Ingaba sikhona isigulo 
esinganyangekiyo onaso? 
 
 
 
z) Do you know your HIV status? Uyasazi isimo sakho segciwane le aids? 
 
yes  
no  
 
 
i) If positive, are you on antiretroviral drugs? Uba unalo, zikhona ipilisi ozityayo? 
xliv 
 
yes  
no  
 
ii) When were you diagnosed as having HIV/ Ufamanise nini ukuba unayo 
lentsholongwane ka gawulayo? 
 
 
iii)) If yes, which type of drug(s) are you using? Ziziphi ipilisi ozityayo? 
 
……………………………………………………………………………………………………… 
 
iv) For how long have you been on antiretroviral drugs? Unexesha elingakanani 
usitye ipilisi? 
 
……………………………………………………………………………………………………………… 
 
v) When was your last menstrual period? Ugqibele nini ukuya exesheni? 
………………………………………………………………………………………………………. 
 
 
vi) Are you breast feeding? 
Uyancancisa?....................…………………………………………………………….. 
 
 
vii) Which traditional drugs do you take……………………………………………. 
 
 
viii)Anthropometric measurements? Ngawaphi amayeza esintu owasebenzisayo 
 
 
 
 
 
 
 
 
 
 
 
 
xlv 
 
 
 
